Inhibitors of the RNA helicase DHX9 for use in the treatment of DNA damage repair deficient, homologous recombination deficient, and cancers having a BRCA loss of function mutation

Abstract

The disclosure provides methods for treating a cancer, in particular, a DNA damage repair deficient (DDRD) cancer, in a subject comprising administering to the subject an inhibitor of DHX9. In particular embodiments the disclosure provides methods for treating a homologous recombination repair deficient (HRD) cancer, e.g., a BRCA loss of function cancer, in a subject comprising administering an inhibitor of DHX9.

Description

[0001]130090-01720 METHODS OF TREATING CANCER WITH INHIBITORS OF THE RNA HELICASE DHX9 RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 63 / 543,489, filed on October 10, 2023, and U.S. Provisional Application No.63 / 618,886, filed on January 8, 2024. The entire contents of each of the foregoing applications are incorporated herein by reference. BACKGROUND OF THE INVENTION Cancer is presently one of the leading causes of death in developed nations. A diagnosis of cancer traditionally involves serious health complications. Cancer can cause disfigurement, chronic or acute pain, lesions, organ failure, or even death. Traditionally, many cancers are treated with surgery, chemotherapy, radiation, or combinations thereof. Chemotherapeutic agents used in the treatment of cancer are known to produce several serious and unpleasant side effects in patients. For example, some chemotherapeutic agents cause neuropathy, nephrotoxicity (e.g., hyperlipidemia, proteinuria, hypoproteinemia, combinations thereof, or the like), stomatitis, mucositisemesis, alopecia, anorexia, esophagitis amenorrhoea, decreased immunity, anaemia, high tone hearing loss, cardiotoxicity, fatigue, neuropathy, myelosuppression, or combinations thereof. Oftentimes, chemotherapy is not effective, or loses effectiveness after a period of efficacy, either during treatment, or shortly after the treatment regimen concludes (i.e., the treatment regimen does not result in a cure). Improved methods for the treatment of cancer remain desirable. SUMMARY OF THE INVENTION DHX9, a RNA helicase, has regulatory roles in various RNA and DNA related cellular processes, such as transcription, translation, RNA splicing, editing, RNA transport and processing, microRNA genesis, and maintenance of genomic stability (Pan et al., 2021, Current Protein & Peptide Science (22), 29-40). For example, DHX9 unwinds double stranded RNA, DNA, and secondary RNA / DNA structures such as R-loops and G-quadruplexes. DHX9 interacts with a large number of proteins that function at the interface of transcription and DNA damage repair. DHX9 may be recruited to promoters of transcribed genes and then by interacting with RNA Pol II it can travel along the gene and unwind R-loops during transcription. In addition, DHX9 mediates recruitment of BRCA1 to RNA Pol II at stalled 1 ME150647165v.1 130090-01720 replication forks or double stranded breaks, functions as a complex to prevent / resolve R-loops, alleviate replication stress and mediate DNA damage repair. As a result, inhibiting DHX9 results in increased R-loops and other secondary structures, leading to unresolved replication stress, cell cycle arrest and cell death. Due to its regulatory role in processes such as transcription and maintenance of genomic stability, DHX9 has shown to be a key regulator in a variety of cancer types (Gulliver et al., 2020, Future Science OA (2), FSO650). DHX9 has been shown to be involved in the regulation of genes associated with sustained proliferative signaling, evasion of growth suppressors, evasion of apoptosis, angiogenesis, and metastasis, all of which are hallmarks of cancer. The present invention is based, at least in part, on the unexpected and surprising discovery that certain types of cancers are more sensitive to DHX9 inhibition, in particular, DNA damage repair deficient (DDRD) cancers, e.g., homologous recombination deficient (HRD) cancers, including in particular, cancers having a BRCA loss of function or alteration. The inventors of the present invention have demonstrated, both in vitro and in vivo, that breast, ovarian, colorectal, pancreatic, prostate, gastric and uterine cancers having a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., homologous recombination repair, e.g., a loss of function or alteration in the BRCA1 / 2 genes, were particularly responsive to DHX9 inhibitor treatment, with robust and significant tumor growth inhibition and / or regression observed in multiple tumor models. Accordingly, in one aspect, the present invention provides a method of treating a DNA damage repair deficient (DDRD) cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject. In some embodiments, the method further comprises selecting a subject determined as having a DDRD cancer for treatment. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes involved in a DNA damage repair pathway. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes involved in a DNA damage repair pathway selected from the group consisting of base excision repair (BER), homologous recombination (HR) repair, non-homologous end joining (NHEJ) repair, or nucleotide excision repair (NER). In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes involved in base excision repair (BER). In some embodiments, the one or more genes involved in BER is selected from the group consisting of LIG3, PARP1, PARP2, 2 ME150647165v.1 130090-01720 PNKP, PARG, FEN1, XRCC1, LIG1, PCNA, APEX2, APEX1, OGG1, NTH1, UNG, NEIL1, NEIL2, NEIL3, MYH, MPC and APTX. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes involved in homologous recombination (HR) repair. In some embodiments, the one or more genes involved in HR repair is selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes involved in non-homologous end joining (NHEJ) repair. In some embodiments, the one or more genes involved in NHEJ repair is selected from the group consisting of PRKDC, DCLRE1C, XRCC5, LIG4, XRCC4, XRCC6, WRN, APLF, and NHEJ1. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes involved in nucleotide excision repair (NER). In some embodiments, the one or more genes involved in NER is selected from the group consisting of XPC, RAD23B, ERCC5, ERCC4, ERCC2, ERCC1, CETN2, DDB1, DDB2, ERCC3 and XPA. In some embodiments, the subject is determined to have a DDRD cancer based on the presence of a loss of function or alteration in one or more genes selected from the group consisting of LIG3, PARP1, PARP2, PNKP, PARG, FEN1, XRCC1, LIG1, PCNA, APEX2, APEX1, OGG1, NTH1, UNG, NEIL1, NEIL2, NEIL3, MYH, MPC, APTX, BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, FANCG, PRKDC, DCLRE1C, XRCC5, LIG4, XRCC4, XRCC6, WRN, APLF, NHEJ1 XPC, RAD23B, ERCC5, ERCC4, ERCC2, ERCC1, CETN2, DDB1, DDB2, ERCC3 and XPA. In some embodiments, the DDRD cancer is selected from the group consisting of a DDRD breast cancer, a DDRD colorectal cancer, a DDRD gastric cancer, a DDRD uterine cancer, a DDRD ovarian cancer, a DDRD prostate cancer, and a DDRD pancreatic cancer. In some embodiments, the DDRD cancer is a DDRD breast cancer. In some embodiments, the DDRD breast cancer is triple-negative breast cancer. In some embodiments, the DDRD cancer is a DDRD colorectal cancer. In some embodiments, the DDRD cancer is a DDRD gastric cancer. In some embodiments, the DDRD cancer is a DDRD uterine cancer. In some embodiments, the DDRD cancer is a DDRD pancreatic cancer. In some embodiments, the DDRD cancer is a DDRD prostate cancer. 3 ME150647165v.1 130090-01720 In some embodiments, the DDRD cancer is a DDRD ovarian cancer. In some embodiments, the DDRD ovarian cancer is high-grade serous ovarian cancer. In some embodiments, the DDRD cancer is not a mismatch repair defective cancer. In some embodiments, the DDRD cancer is a microsatellite instable cancer. In some embodiments, the DDRD cancer is a microsatellite stable cancer In some embodiments, the DDRD cancer is not a microsatellite instable cancer and / or a mismatch repair defective cancer. In some embodiments, the DDRD colorectal cancer is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer. In some embodiments, the DDRD cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. In one aspect, the present invention provides a method of treating a homologous recombination deficient (HRD) cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject. In some embodiments, the method further comprises selecting a subject determined as having an HRD cancer for treatment. In some embodiments, the HRD cancer comprises a loss of function or alteration in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the subject is determined to have an HRD cancer based on the presence of a loss of function or alteration in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the HRD cancer is selected from the group consisting of an HRD breast cancer, an HRD DDRD colorectal cancer, an HRD gastric cancer, an HRD uterine cancer, an HRD ovarian cancer, an HRD prostate cancer, and an HRD pancreatic cancer. In some embodiments, the HRD cancer is an HRD ovarian cancer. In some embodiments, the HRD ovarian cancer is high-grade serous ovarian cancer. In some embodiments, the HRD cancer is an HRD breast cancer. In some embodiments, the HRD breast cancer is triple-negative breast cancer. In some embodiments, the HRD cancer is an HRD colorectal cancer. In some embodiments, the HRD cancer is an HRD pancreatic cancer. 4 ME150647165v.1 130090-01720 In some embodiments, the HRD cancer is an HRD prostate cancer. In some embodiments, the HRD cancer is an HRD gastric cancer. In some embodiments, the HRD cancer is an HRD uterine cancer. In some embodiments, the HRD cancer is not a mismatch repair defective cancer. In some embodiments, the HRD cancer is a microsatellite instable cancer. In some embodiments, the HRD cancer is a microsatellite stable cancer. In some embodiments, the HRD cancer is not a microsatellite instable cancer and / or a mismatch repair defective cancer. In some embodiments, the HRD colorectal cancer is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer. In some embodiments, the HRD cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. In another aspect, the present invention provides a method for treating a cancer having a BRCA loss of function or alteration in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject. In some embodiments, the method further comprises selecting a subject determined as having a cancer having a BRCA loss of function or alteration for treatment. In some embodiments, the BRCA loss of function or alteration comprises a BRCA1 and / or a BRCA2 loss-of-function mutation. In some embodiments, the cancer having a BRCA loss of function or alteration is selected from the group consisting of an ovarian cancer having a BRCA loss of function or alteration; a breast cancer having a BRCA loss of function or alteration; a colorectal cancer having a BRCA loss of function or alteration, a prostate cancer having a BRCA loss of function or alteration, and a pancreatic cancer having a BRCA loss of function or alteration. In some embodiments, the cancer is an ovarian cancer having a BRCA loss of function or alteration. In some embodiments, the ovarian cancer is high-grade serous ovarian cancer. In some embodiments, the cancer is a breast cancer having a BRCA loss of function or alteration. In some embodiments, the breast cancer is triple-negative breast cancer. In some embodiments, the cancer is a colorectal cancer having a BRCA loss of function or alteration. In some embodiments, the cancer is a pancreatic cancer having a BRCA loss of function or alteration. In some embodiments, the cancer is a prostate cancer having a BRCA loss of function or alteration. 5 ME150647165v.1 130090-01720 In some embodiments, the cancer having a BRCA loss of function or alteration is not a mismatch repair defective cancer. In some embodiments, the cancer having a BRCA loss of function or alteration is a microsatellite instable cancer. In some embodiments, the cancer having BRCA loss of function or alteration is a microsatellite stable cancer. In some embodiments, the cancer having a BRCA loss of function or alteration is not a microsatellite instable cancer and / or a mismatch repair defective cancer. In some embodiments, the colorectal cancer having a BRCA loss of function or alteration is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer. In some embodiments, the cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. In one aspect, the present invention provides a method for treating triple-negative breast cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject. In some embodiments, the method further comprises selecting a subject determined as having triple-negative breast cancer for treatment. In some embodiments, the riple-negative breast cancer is a homologous recombination deficient (HRD) cancer. In some embodiments, the triple-negative breast cancer has a loss of function or alteration in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the triple-negative breast cancer has a loss of function or alteration in BRCA1 and / or BRCA2. In some embodiments, the triple-negative breast cancer has a loss-of-function mutation in BRCA1 and / or BRCA2. In another aspect, the present invention provides a method for treating high-grade serous ovarian cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject. In some embodiments, the method further comprises selecting a subject determined as having high-grade serous ovarian cancer for treatment. In some embodiments, the high-grade serous ovarian cancer has a loss of function or alteration in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, 6 ME150647165v.1 130090-01720 ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the high-grade serous ovarian cancer is a homologous recombination deficient (HRD) cancer. In some embodiments, the high-grade serous ovarian cancer has a loss of function or alteration in BRCA1 and / or BRCA2. In some embodiments, the high-grade serous ovarian cancer has a loss-of-function mutation in BRCA1 and / or BRCA2. In some embodiments, the methods further comprise administering an additional anti- cancer therapy to the subject. In some embodiments, the subject is a human. In a first embodiment, the DHX9 inhibitor is a compound having the Formula I: or a pharmaceutically acceptable salt thereof, wherein: X is halo; Y is O or NRy; Ryis H or C1-4alkyl; R1is C1-4alkyl or C3-6cycloalkyl; wherein the C1-4alkyl or C3-6cycloalkyl are each optionally and independently substituted with 1 to 3 halo or -OH, Ring A is a C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10 membered bicyclic heterocyclyl; phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10- membered bicyclic heteroaryl; m is 0 to 3; n is 0 or 2; each R2is independently selected from C1-4alkyl, C3-6cycloalkyl, halo, OR2a, cyano, - NR2bR2c, -SO2R2a, -C(O)R2d, and –C(O)NR2bR2cwherein the C1-4alkyl and C3-6cycloalkyl are optionally substituted with 1 to 4 R2e; or 2 R2together form oxo; R2ais H, C1-4alkyl, C1-4haloalkyl or C1-4alkoxyC1-4alkyl; 7 ME150647165v.1 130090-01720 R2dis H, C1-4alkyl, C3-6cycloalkyl, OR2a, phenyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 8-membered bicyclic heterocyclyl, or 5 to 6-membered monocyclic heteroaryl, wherein the C1-4alkyl is optionally substituted with 1 to 3 halo and the 5- to 6- membered monocyclic heteroaryl is optionally substituted with 1 to 3 C1-4alkyl, C1- 4haloalkyl, or phenyl; R2band R2care each independently selected from H, C1-4alkyl, C3-6cycloalkyl, phenyl, 4 to 6-membered monocyclic heterocyclyl and 5 to 6-membered monocyclic heteroaryl, wherein the C1-4alkyl is optionally substituted with 1 to 3 substituents independently selected from halo and C1-3alkoxy; or R2band R2c, together with the nitrogen to which they are attached form a 4 to 6 membered monocyclic heterocyclyl or 6 to 10 membered bicyclic heterocyclyl; wherein the 4 to 6 membered monocyclic heterocyclyl or 6 to 10 membered bicyclic heterocyclyl are each optionally substituted with 1 to 3 R2d; each R2eis independently selected from halo, cyano, NR2bR2c, OR2a, phenyl, and 4 to 6 membered monocyclic heterocyclyl; Z is a bond, -CH2-, -O-, -O-C1-4alkylene-*, -C1-4alkylene-O-*, -C(O)-, -C(O)O-*, - OC(O)-*, -S(O)2-, -S(O)2N(Za)-*, -N(Za)S(O)2-*, -N(Za)-, -N(Za)-C1-4alkylene-*, -C1-4alkylene-N(Za)-*, -C(O)N(Za)-*, -N(Za)C(O)-*, or -C(O)N(Za)-C1-3alkylene-*, wherein * indicates the attachment point to R3; Zais H or C1-4alkyl; R3is C3-6cycloalkyl, 7 to 10-membered bicyclic carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10-membered bicyclic heteroaryl, wherein the C3-6cycloalkyl, 7 to 10-membered bicyclic carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10- membered bicyclic heterocyclyl, phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10- membered bicyclic heteroaryl are each optionally and independently substituted with 1 to 4 R4; each R4is independently selected from C1-4alkyl, C2-4alkenyl, C2-4alkynyl, halo, OR4a, cyano, -NR4bR4c, -C(O)R4a, -C(O)OR4a, -C(O)NR4bR4c, -NR4bC(O)R4a-NR4bC(O)OR4a, , - NR4bSO2R4a, -SR4a, -S(O)R4a, -SO2R4a, SO2NR4bR4c, -P(O)R4bR4c, phenyl, 5 to 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocyclyl, and 6 to 10-membered bicyclic heterocyclyl, wherein the C1-4alkyl, C2-4alkenyl, or C2-4alkynyl is optionally substituted with 1 to 4 R4d, and wherein the phenyl, 5 to 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocyclyl and 6 to 10-membered bicyclic heterocyclyl are each optionally substituted with 1 to 3 R4eand further optionally substituted with 1 or 2 oxo; or two R4together form oxo; 8 ME150647165v.1 130090-01720 R4ais H, C1-4alkyl optionally substituted with 1 to 4 R4d, -NR4bR4c, C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, phenyl, or 5 to 6-membered monocyclic heteroaryl; wherein the C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 to 3 R4e; R4band R4care each independently selected from H, phenyl, 4 to 6-membered monocyclic heterocyclyl, 5 to 6-membered monocyclic heteroaryl, and C1-4alkyl optionally substituted with 1 to 4 R4d; or R4band R4ctogether with the nitrogen atom to which they are attached to form a 4 to 6-membered monocyclic heterocyclyl; each R4dis independently selected from halo, OR4f, -C(O)C1-4alkyl, -C(O)NR4bR4c, - C(O)C1-4haloalkyl, -C(O)OR4f, -NR4bR4c, phenyl, and 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered mon ocyclic heteroaryl are each optionally substituted with 1 to 3 R4g; each R4eis independently selected from halo, C1-4alkyl, cyano, OR4f, -NR4bR4c, -C(O)H, -C(O)R4h, -SO2C1-3alkyl, and -C(O)NR4bR4c, wherein C1-4alkyl is optionally substituted with 1 to 3 substitutes independently selected from halo, -SO2C1-3alkyl and -C(O)NR4bR4c; and - C(O)NR4bR4c; or two R4etogether form oxo; R4fis H, C1-4alkyl, C1-4haloalkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with one to three halo; each R4gis independently selected from halo, OR4f, C1-4alkyl, C1-4haloalkyl, halo, cyano, -NR4bR4c, -C(O)H, and -C(O)OR4f; and each R4his independently C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy or –N(R4b)2. In a second embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, X is Cl, Br, or F; and the remaining variables are as described in the first embodiment. In a third embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, X is Cl or Br; and the remaining variables are as described in the first embodiment. In a fourth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, X is Cl; and the remaining variables are as described in the first embodiment. In a fifth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is selected from 9 ME150647165v.1 130090-01720 phenyl, thiophenyl, pyrrolyl, pyrazoyl, furanyl, isothiazoyl, thiazoyl, imidazoyl, cyclobutyl, benzofuranyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, imidazo[1,2-a]pyridin-6-yl, 1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 2-oxo-2,3-dihydro-1H-imidazolyl, indolizinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-c]pyrimidinyl, pyrrolo[1,2-a]pyraziny, 5,6-dihydro- 4H-cyclopenta[b]thiophenyl, 5-oxo-5H-thiazolo[3,2-a]pyridinyl, thieno[3,2-b]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, benzothiophenyl, thieno[3,2-d]pyrimidinyl, pyrrolo[1,2-b]pyridazinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-b] pyrimidinyl, pyrrolo[1,2-c]pyrimidinyl, 1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazinyl, pyrrolo[2,1-f][1,2,4]triazinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, 5,6-dihydro-4H- cyclopenta[b]thiophenyl, and 4,7-dihydro-5H-thieno[2,3-c]pyranyl; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a sixth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is represented by the ; each of which is substituted with 0 to 2 R2and 0 to 1 Z-R3; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a seventh embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is represented by the 10 ME150647165v.1 130090-01720 11 ME150647165v.1 130090-01720 are as described in the first, second, third, or fourth embodiment. In an eighth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazoyl, and imidazolyl; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a ninth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is ; substituted with 0 to 1 R2and 1 R3; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a tenth embodiment, for the compound of Formula (I) described in the first aspect or in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is 12 ME150647165v.1 130090-01720 the remaining variables are as described in the first, second, third, or fourth embodiment. In an eleventh embodiment, for the compound of Formula (I) described in first aspect or the first embodiment, R2is selected from –OCH3, cyclopropyl, -CH3, -CF3, -CH2CH3, - CH(CH3)2, -CH(OH)CH3, -C(CH3)2OH, -CH2OCH3, -CH2OH, -CH2CF3, -CH2CH2OH, - CH2CH2CH2OH, -CH2CN, -CH2CHF2, -CH2NH2, -N(CH3)2, -SO2CH3, cyano, halo, - the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment or any alternative embodiments described therein. In a twelfth embodiment, for the compound of Formula (I) described in the first aspect or in the first embodiment, or a pharmaceutically acceptable salt thereof, n is 1; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, eighth, or eleventh embodiment or any alternative embodiments described therein. In a thirteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, n is 1 and Z is a bond; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, eleventh, or twelfth embodiment. In a fourteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, n is 1 and Z is -CH2-, -CH(CH3)-, -O-, -N(H)-, -N(C1-4alkyl)-, or –C(O)NH-*, wherein * indicates the attachment point to R3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, eleventh or twelfth embodiment. 13 ME150647165v.1 130090-01720 In a fifteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, phenyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyrazinyl, thiophenyl, tetrahydropyranyl, tetrahydrofuranyl, oxabicyclo[3.2.1]octanyl, thiazolyl, imidazoyl, triazolyl, tetrazolyl, oxadiazolyl, 3-oxo-2,3-dihydro-1H-pyrazoly, benzamidazolyl, indazolyl, indoyl, imidazolidinyl, azetidinyl, 2,3-dihydrobenzofuranyl, imidazo[1,2-a]pyridinyl, 2,3- dihydro-1H-indenyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, spiro[3.3]heptanyl, 2- azaspiro[3.3]heptanyl, and 2-oxaspiro[3.3]heptanyl, each of which is optionally substituted with 1 to 3 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a sixteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, Z is –CH2-, R3is thiophenyl, pyrrolyl, and 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a seventeenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is represented by the following 14 ME150647165v.1 130090-01720 ; each of which is optionally substituted with 1 to 3 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment or any alternative embodiments described therein. In an eighteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is represented by the following 15 ME150647165v.1 130090-01720 in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment or any alternative embodiments described therein. In a nineteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is phenyl or 5 to 6-membered monocyclic heteroaryl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. 16 ME150647165v.1 130090-01720 In a twentieth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is phenyl, pyrazolyl, pyridyl, and pyrimidyl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a twenty-first embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is ; ; each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a twenty-second embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is represented by the following structural formula: ; variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a twenty-third embodiment, for the compound of Formula (I) described in the first embodiment or in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is selected from C1-3alkyl, C2-4alkenyl, C2-4alkynyl, -OR4a, -CN, -NH2, -NR4bR4c, halo, - C(O)R4a, -NHC(O)R4a, -NHC(O)OR4a, -NR4bSO2R4a, -SR4a, -S(O)R4a, -SO2R4a, - SO2NR4bR4c, -P(O)R4bR4c, -C(O)O-C1-4alkyl, benzyl, phenyl, 5 to 6-membered monocyclic heteroaryl, 6 to 10-membered bicyclic heterocyclyl, and 4 to 6-membered monocyclic heterocyclyl, wherein the C1-3alkyl, C2-4alkenyl, or C2-4alkynyl represented by R4is optionally substituted with 1 to 3 substituents independently selected from halo, phenyl, 5 to 17 ME150647165v.1 130090-01720 6-membered monocyclic heteroaryl optionally substituted with 1 or 2 R4g, and 4 to 6- membered monocyclic heterocyclyl optionally substituted with 1 or 2 R4g, -C(O)NR4bR4c, - C(O)R4a, and OR4f; and the benzyl, phenyl, 5 to 6-membered monocyclic heteroaryl, 6 to 10- membered bicyclic heterocyclyl, and 4 to 6-membered monocyclic heterocyclyl represented by R4are each optionally substituted with 1 to 3 R4eand further optionally substituted with one or two oxo, or two R4together form an oxo; R4ais H, C1-4alkyl optionally substituted with 1 to 4 R4d, -NR4bR4c, C3-6cycloalkyl, phenyl, 4- to 6-membered monocyclic heterocyclyl, or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl, 4- to 6-membered monocyclic heterocyclyl, and 5 to 6-membered monocyclic heteroaryl are optionally substituted with 1 to 3 R4e; each R4bis independently H or C1-4alkyl; R4cis H, C1-4alkyl optionally substituted with 1 to 4 R4d, 4 to 6-membered monocyclic heterocyclyl, or 5 to 6- membered monocyclic heteroaryl; each R4dis independently selected from halo, -OR4f, C3-6cycloalkyl, -C(O)OH, -NR4bR4c, phenyl, and 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with 1 to 3 substituents independently selected from C1-3alkyl, C1-3haloalkyl, halo, CN and OH; each R4eis independently selected from halo,-OH, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, –C(O)R4h, -SO2C1-3alkyl, -C1-3alkylSO2C1-3alkyl, -C(O)N(C1-3alkyl)2, and cyano; or two R4etogether form an oxo; R4fis H, C1-4alkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, wherein phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with 1 to 3 halo; each R4gis independently C1-3alkyl or halo; and each R4his independently C1-4alkyl, C3-6cycloalkyl, C1-3alkoxyl or –N(R4b)2; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, or twenty second embodiment or any alternative embodiments described therein. In a twenty-fourth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is represented by the following 18 ME150647165v.1 130090-01720 optionally substituted with 1 to 3 R4eand further optionally substituted with 1 or 2 oxo; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment or any alternative embodiments described therein. In a twenty-fifth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is represented by the following 19 ME150647165v.1 130090-01720 variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment or any alternative embodiments described therein. In a twenty-sixth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, each R4eis independently –F, – CH3, -CF3, -CH2CHF2, -CH2CF3, -CH2SO2CH3, -OH, -OCH3, -SO2CH3, –C(O)CH3, - C(O)cyclopropyl, -C(O)cyclobutyl, -C(O)cyclopentyl, -C(O)CH(CH3)2, -C(O)C(CH3)3– C(O)N(CH3)2, -C(O)OCH3, or cyano; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth or twenty-fifth embodiment or any alternative embodiments described therein. In a twenty-seventh embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is -OR4a; R4ais C1-3alkyl optionally substituted with 1 to 3 R4dor 4- to 6-membered monocyclic heterocyclyl optionally substituted with 1 to 3 R4e; each R4dis independently halo, C1-2alkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, provided when two or three R4dare present, one of the R4dis phenyl or 5 to 6-membered monocyclic heteroaryl, and the other R4dare each independently halo or C1-2alkyl; wherein the phenyl and 5 to 6-membered monocyclic 20 ME150647165v.1 130090-01720 heteroaryl represented by R4dare each optionally substituted with 1 to 3 substituents independently selected from C1-3alkyl, C1-3haloalkyl and halo; each R4eis independently C1-4alkyl, C1-4haloalkyl, -SO2C1-3alkyl, or -C(O)C3-6cycloalkyl; the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiment or any altenative embodiments described therein. In a twenty-eighth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is –CH3, CH2OH, -CHF2, - CF3, -CH(CF3)OH, -CH2OCH3, -CH2CN, -CH2CF3, -CH2CH2OH, -CH2C(O)N(CH3)2, - C≡CC(CH3)2OH, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH(CH3)2, -OCF3, -OCHF2, -OCH2CF3, -O-cyclopropyl, -O-cyclobutyl, -OC(CH3)3, -OC(CH3)2CH2OH, - OCH(CH3)C(O)OH, -OC(CH3)2C(O)OH, -OCH(CH3)CH2OH, -OCH2CH2N(CH3)2, -CN, - NH2, -NHCH3, halo, -C(O)H, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)O-t-butyl, - N(CH3)SO2CH3, -NHC(O)CH3, -NHC(O)cyclopropyl, -NHC(O)OC(CH3)3, -C(O)CH3, - C(O)OH, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -C(O)NC(CH3)3, -SCH3, -S(O)CH3, - SO2CH3, -SO2N(CH3)2, -P(O)(CH3)2, phenyl, or R4is represented by the following structural formula: 21 ME150647165v.1 130090-01720 22 ME150647165v.1 130090-01720 the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiment or any alternative embodiments described therein. In a twenty-ninth embodiment, the DXH9 inhibitor is a compound is represented by Formula (IIA), (IIB), or (IIC): 23 ME150647165v.1 130090-01720 or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; and the variables X, R1, R2, and R3depicted in Formula (IIA), (IIB), or (IIC) are as described in the first, second, third, fourth, eleventh, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth embodiment or any alternative embodiments described therein. In a thirtieth embodiment, the DXH9 inhibitor is a compound represented by Formula (IIIA) or (IIIB): or a pharmaceutically acceptable salt thereof; where the variables X, R1, R2, and R3depicted in Formula (IIIA) or (IIIB) are as described in the first, second, third, fourth, eleventh, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty- third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth embodiment or any alternative embodiments described therein. In a thirty-first embodiment, the DXH9 inhibitor is a compound represented by Formula (IVA), (IVB), (IVC), or (IVD): 24 ME150647165v.1 130090-01720 or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; and the variables X, R1, R2, and R3depicted in Formula (IVA), (IVB), (IVC), or (IVD) are as described in the first, second, third, fourth, eleventh, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty- seventh, or twenty-eighth embodiment or any alternative embodiments described therein. In a thirty-second embodiment, for compounds of Formula (I), (IIA), (IIB), (IIC), (IIIA), (IIIB), (IVA), (IVB), (IVC), or (IVD), or a pharmaceutically acceptable salt thereof, R1is –CH3 or –CH2CH3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty- second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty- eighth, twenty-ninth, thirtieth, or thirty-first embodiment or any alternative embodiments described therein. In a thirty-third embodiment, for compounds of Formula (I), (IIA), (IIB), (IIC), (IIIA), (IIIB), (IVA), (IVB), (IVC), or (IVD), or a pharmaceutically acceptable salt thereof, R1is – CH3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty- third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, or thirty-first embodiment or any alternative embodiments described therein. In a thirty-fourth embodiment, the DXH9 inhibitor is a compound represented by Formula (V): 25 ME150647165v.1 130090-01720 or a pharmaceutically acceptable salt thereof, wherein: X is Cl or Br; R1is -CH3or –CH2CH3; ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazolyl, and imidazolyl; m is 0 or 1; each R2is independently selected from C1-3alkyl and -C(O)R2d, wherein the C1-3alkyl is optionally substituted with R2g; R2dis 4 to 6-membered monocyclic heterocyclyl; R2gis cyano or OH; R3is phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 or 2 R4; each R4is independently selected from halo, C1-4alkyl, -O-benzyl, -O-C1-3alkyl, cyano, -NH2, and 4 to 6-membered monocyclic heterocyclyl, wherein the benzyl is optionally substituted with 1 to 3 halo or C1-3haloalkyl. In an alterntive thirty-fourth embodiment, for the compound of formula (V) or a pharmaceutically acceptable salt thereof, the definitions of variables are: X is Cl or Br; R1is -CH3or –CH2CH3; ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazolyl, and imidazolyl; m is 0 or 1; each R2is independently selected from C1-3alkyl and -C(O)R2d, wherein the C1-3alkyl is optionally substituted with R2g; R2dis 4 to 6-membered monocyclic heterocyclyl; R2gis cyano or OH; 26 ME150647165v.1 130090-01720 R3is phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 or 2 R4; each R4is independently selected from C1-4alkyl, -O-benzyl, cyano, -NH2, and 4 to 6- membered monocyclic heterocyclyl, wherein the benzyl is optionally substituted with halo. In a thirty-fifth embodiment, for compounds of Formula (V), or a pharmaceutically any alternative embodiments described therein. In a thirty-sixth embodiment, the DXH9 inhibitor is a compound represented by Formula (IIB), (IIIA), (IVA); or (IVB): or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; and the variables X, R1, R2, and R3depicted in Formula (IIIA), (IVA), or (IVB) are as described in the thirty- fourth embodiment or any alternative embodiments described therein. In a thirty-seventh embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R3is phenyl, pyrazolyl, pyridyl, and pyrimidyl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables 27 ME150647165v.1 130090-01720 are as described in the thirty-fourth, thirty-fifth, or thirty-sixth embodiment or any alternative embodiments described therein. In a thirty-eighth embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA), or (IVB) or a pharmaceutically acceptable salt thereof, R3is represented by the following R4; and the remaining variables are as described in the thirty-fourth, thirty-fifth, or thirty- sixth embodiment or any alternative embodiments described therein. In a thirty-ninth embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA); or (IVB) or a pharmaceutically acceptable salt thereof, R4is –F, -OCH(CH3)2, -OC(CH3)3, – CH3, cyano, -NH2, or R4is represented by the following structural formula: ; the remaining variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, or thirty-eighth embodiment or any alternative embodiments described therein. In a fortieth embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA),or (IVB) or a pharmaceutically acceptable salt thereof, R2is –CH3, -CH2CN, -CH2OH, the remaining variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, thirty-eighth, or thirty-ninth embodiment or any alternative embodiments described therein. In a forty-first embodiment, the present disclosure provides a compound represented by Formula (IIB) or (IVB): 28 ME150647165v.1 130090-01720 or a pharmaceutically acceptable salt thereof, wherein: m is 0 or 1; R1is -CH3; X is Cl; R2is -CH3; R3is pyrimidinyl or pyridinyl, each of which is optionally substituted with 1 or 2 R4; R4is halo, C1-3alkyl, -OC1-3alkyl, or 4- to 6-membered monocyclic heterocyclyl, wherein the 4- to 6-membered monocyclic heterocycly is optionally substituted with 1 or 2 halo or C1-3haloalkyl. In a forty-second embodiment, for compounds of Formula (IIB) or (IVB), or a pharmaceutically acceptable salt thereof, R3is represented by the following structural formula: ; and the remaining variables are as described in the forty-first embodiment. In a forty-third embodiment, for compounds of Formula (IIB) or (IVB), or a pharmaceutically acceptable salt thereof, each R4is independently –F, -CH3, -OCH(CH3)2, or -OC(CH3)3, or R4is represented by the following structural formula: remaining variables are as described in the forty-first or forty-second embodiment. In a forty-fourth embodiment, the present disclosure provides a compound selected from the group consisting of: N-(3-chloro-5-(methylsulfonamido)phenyl)-1-phenyl-1H-imidazole-4-carboxamide; 5-bromo-N-(3-fluoro-5-(methylsulfonamido)phenyl)-1H-pyrrole-3-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-1H-pyrazole-3-carboxamide; 5-bromo-N-(3-fluoro-5-(methylsulfonamido)phenyl)-1H-pyrazole-3-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; 29 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-2-phenyl-1H-imidazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenylfuran-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenyl-1H-pyrrole-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenyl-1H-imidazole-2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-methyl-3-(1H-pyrazol-1-yl)benzamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-phenylthiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-2-phenylcyclobutane-1-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3'-cyano-[1,1'-biphenyl]-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(pyridin-4-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-iodo-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyrazin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(2-hydroxy-6-methylphenyl)thiophene- 2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)-5-methylthiophene- 2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(pyrimidin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-5-methyl-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(pyrimidin-2-yl)thiophene-2- carboxamide; 30 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(pyridin-2-yl)thiophene-2- carboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)thiophene- 2-carboxamide; 4-(2-(benzyloxy)phenyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene- 2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(4-cyanopyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(pyrazin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-cyanopyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-methylpyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-cyano-6-methylphenyl)-1H- pyrazole-4-carboxamide; 31 ME150647165v.1 130090-01720 N-(3-bromo-5-(methylsulfonamido)phenyl)-5-methyl-1-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-cyanopyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(trifluoromethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-cyclohexyl-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(3-methylpyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(pyrimidin-2-yl)-1H-pyrazole-4- carboxamide; 1-(2-(benzyloxy)phenyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(3-cyanophenyl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-cyano-2-methylphenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-methylpyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(6-(difluoromethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(6-(difluoromethoxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-formylphenyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(pyrimidin-2-yl)-1H-pyrrole- 3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(1H-pyrazol-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-3-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 32 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(1-phenylethoxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-2-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-4-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-fluorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(oxazol-5-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 1-(2-(benzyloxy)-5-cyanophenyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; 1-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((4-fluorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-chlorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 4-bromo-N-(3-fluoro-5-(methylsulfonamido)phenyl)thiophene-2-carboxamide; 4-bromo-N-(3-(ethylsulfonamido)-5-fluorophenyl)thiophene-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-(ethylsulfonamido)-5-fluorophenyl)-4-phenylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-ethyl-5-phenyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-phenyl-1-(2,2,2-trifluoroethyl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; 33 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(pyrimidin-2-yl)-1H-pyrrole- 3-carboxamide; 5-bromo-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-1H-pyrrole-3- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-cyclohexyl-5-methyl-1H-pyrrole-3- carboxamide; 1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-N-(3-bromo-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; 1-(5-(4-acetylpiperazin-1-yl)-3-methylpyridin-2-yl)-N-(3-bromo-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1- yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)pyridin-3-yl)-N,N-dimethylpiperazine-1-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2-oxopyrrolidin-1-yl)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(4-morpholinopyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2-methylmorpholino)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-morpholinopyridin-2-yl)- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(4-methyl-3-oxopiperazin- 1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(cyanomethyl)-5-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-methyl-2-(3-methylpyridin-2-yl)-1H- imidazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(difluoro(phenyl)methoxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyano-1-(pyridin-2-yl)-1H-pyrrole-3- carboxamide; 34 ME150647165v.1 130090-01720 1-benzyl-N-(3-bromo-5-(methylsulfonamido)phenyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(3-cyano-1H-pyrazol-1-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-2-oxo-1-phenyl-2,3-dihydro-1H- imidazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(2-chloropyridin-4-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-(2,2,2-trifluoro-1- hydroxyethyl)phenyl)-1H-pyrazole-4-carboxamide; 4-((1H-pyrrol-2-yl)methyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene-2- carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-methoxyphenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluorophenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-phenyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2-carboxamide; 4-(2-(benzyloxy)phenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)thiophene-2- carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2-carboxamide; N-(3-(ethylsulfonamido)-5-fluorophenyl)-4-(pyridin-2-yl)thiophene-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2,6-difluorophenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(1H-pyrazol-1-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-3-(1H-pyrazol-1-yl)benzamide; 1-ethyl-N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-1H-pyrazole-3- carboxamide; 35 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(hydroxymethyl)-4-phenylthiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonoamidimidamido)phenyl)-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonoamidimidamido)phenyl)-4-(3-methylpyridin-2- yl)thiophene-2-carboxamide; N-(3-bromo-5-(methylsulfonoamidimidamido)phenyl)-5-methyl-4-(pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-phenylthiophene-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-phenylfuran-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxypropyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-hydroxyethyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-oxaspiro[3.3]heptan-6-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-phenyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-2-ethylimidazo[1,2-a]pyridine-6- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(dimethylamino)-2-ethylimidazo[1,2- a]pyridine-6-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)imidazo[1,2-a]pyridine-6-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)benzofuran-7-carboxamide; tert-butyl 4-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)piperidine-1-carboxylate; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(pyridin-2-yl)isothiazole-5- carboxamide; 5-(2-(benzyloxy)phenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-1H- pyrazole-3-carboxamide; 36 ME150647165v.1 130090-01720 3-(2-(benzyloxy)phenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-1H- pyrazole-5-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(pyridin-2-yl)-1H-pyrazole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-3-(pyridin-2-yl)-1H-pyrazole-5- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(1-phenylethyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-difluoroethyl)-5-(3-methylpyridin- 2-yl)-1H-pyrrole-3-carboxamide; tert-butyl 6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)-2-azaspiro[3.3]heptane-2-carboxylate; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(piperidin-4-yl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-azaspiro[3.3]heptan-6-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(4-(piperazin-1-yl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; 1-(4-(4-acetylpiperazin-1-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-isobutyrylpiperazin-1-yl)pyridin- 2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-hydroxycyclohexyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(4-hydroxycyclohexyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxycyclohexyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-2-phenyl-1H-imidazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-2-(3-methylpyridin-2-yl)-1H- imidazole-4-carboxamide; 37 ME150647165v.1 130090-01720 N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(2-oxopiperidin-1-yl)-1H- pyrrole-3-carboxamide; 1-(2-(benzyloxy)cyclobutyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(3-(hydroxymethyl)-1H-pyrazol-1- yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-(hydroxymethyl)phenyl)-1H- pyrazole-4-carboxamide; 1-(3-aminopyridin-2-yl)-N-(3-bromo-5-(methylsulfonamido)phenyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(hydroxymethyl)-4-(pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(phenylamino)-1H-pyrazole-5- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(piperazine-1-carbonyl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N2-(3-chloro-5-(methylsulfonamido)phenyl)-N4-phenylthiophene-2,4- dicarboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(phenoxymethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; 1-(3-(benzylamino)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(hydroxymethyl)-1-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(pyridin-2-yl)-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-ethoxypyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-methyl-5-(pyrimidin-2-yl)-1H-pyrrole-3- carboxamide; 38 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-oxopyrrolidin-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyclopropyl-4-(pyridin-2-yl)thiophene- 2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyrimidin-2-yloxy)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-hydroxybenzyl)oxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-oxomorpholino)pyridin-2-yl)-1H- pyrazole-4-carboxamide; 5-(aminomethyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1- yl)pyrimidin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1- yl)pyrazin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-(pyridin-3-ylmethoxy)pyridin-2-yl)- 1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3,5-difluorobenzyl)oxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyrimidin-5-ylmethoxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((2-fluorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(tetrahydro-2H-pyran-4-yl)pyridin- 2-yl)-1H-pyrazole-4-carboxamide; 39 ME150647165v.1 130090-01720 1-(5-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(5,6-dihydroimidazo[1,2-a]pyrazin- 7(8H)-yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1-yl)-3- (pyridin-3-ylmethoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholino-3-(pyridin-3- ylmethoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(2-hydroxy-2- methylpropoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyrimidin-2-yloxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methoxypyridin-2-yl)-1H-pyrazole- 4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(methylsulfonyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(methylsulfonyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(N,N-dimethylsulfamoyl)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(dimethylphosphoryl)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoro-3-((3- fluorobenzyl)oxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-cyanobenzyl)oxy)-5- fluoropyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-fluorobenzyl)oxy)-6- methylpyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(thiazol-2-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 1-(3-((1H-pyrazol-4-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyrimidin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; 40 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-ethoxypyrimidin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)indolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-((3-fluorobenzyl)oxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-fluoro-6-((3- fluorobenzyl)oxy)phenyl)-1H-pyrazole-4-carboxamide; 3-(3-(benzyloxy)pyridin-2-yl)-N5-(3-chloro-5-(methylsulfonamido)phenyl)-N2- methylthiophene-2,5-dicarboxamide; 3-(3-(benzyloxy)pyridin-2-yl)-N5-(3-chloro-5-(methylsulfonamido)phenyl)-N2,N2- dimethylthiophene-2,5-dicarboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-fluoro-5-(methylsulfonamido)phenyl)thiophene- 2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(oxazol-5-ylmethoxy)pyridin-2- yl)thiophene-2-carboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- (hydroxymethyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyridin-3-ylmethoxy)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(methylthio)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(methylthio)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(cyclopropanecarboxamido)pyridin- 2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(2-(dimethylamino)-2- oxoethyl)pyridin-2-yl)thiophene-2-carboxamide; 2-(5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)thiophen-3-yl)-N,N- dimethylnicotinamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(trifluoromethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; 41 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-methylpyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-hydroxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-((3,5- difluorophenoxy)methyl)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5'-fluoro-[3,3'-bipyridin]-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)thieno[2,3-c]pyridine-2-carboxamide; 1-(3-((3-bromobenzyl)oxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-ethyl-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-isopropyl-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(methoxymethyl)-4-(pyridin-2- yl)thiophene-2-carboxamide; 4-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(1-phenyl-1H-1,2,3-triazol-4- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyrimidin-2-ylamino)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(methyl(pyrimidin-2- yl)amino)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyridin-3-yloxy)pyridin-2- yl)thiophene-2-carboxamide; 4-(2-(benzyloxy)-6-fluorophenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; 4-bromo-N-(3-chloro-5-(methylsulfonamido)phenyl)thiophene-2-carboxamide; methyl (5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)thiophen-3- yl)prolinate; 42 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(piperidin-4-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(piperazin-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-morpholinothiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-(2,2,2-trifluoroethyl)piperazin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(cyclopropanesulfonamido)phenyl)-5-methyl-1-(5-morpholinopyridin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-((difluoromethyl)sulfonamido)phenyl)-5-methyl-1-(5- morpholinopyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-1-(5-morpholinopyridin-2-yl)- 1H-pyrrole-3-carboxamide; 1-(8-oxabicyclo[3.2.1]octan-3-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoro-3-(3-fluorophenethyl)pyridin- 2-yl)-1H-pyrazole-4-carboxamide; 1-(3-((1H-imidazol-2-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; 1-(3-((1H-pyrazol-5-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; 1-(3-((1H-imidazol-4-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-((3-fluorobenzyl)oxy)-6- methylphenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3,5- difluorophenoxy)methyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(5-fluoropyridin-3-yl)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3,5-difluorobenzyl)oxy)-5-(2-oxa- 6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-phenoxycyclopentyl)-1H-pyrazole- 4-carboxamide; 43 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-phenylcyclopentyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methyl-3-(oxazol-5- ylmethoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(((5-fluoropyridin-3- yl)oxy)methyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(pyrimidin-2-yloxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(pyridin-3-yloxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(3-fluorophenoxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(1-methyl-2-oxopiperidin-4- yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyridin-2-yl)-5- (trifluoromethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-(oxazol-5- ylmethoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methyl(tetrahydrofuran-3- yl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(pyrrolidin-1-yl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyridin-2-yl)-5- (trifluoromethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2,2-dimethylmorpholino)pyridin-2- yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-morpholinopyridin-2-yl)- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-ethyl-5-(5-morpholinopyridin-2-yl)- 1H-d,de; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-morpholinopyridin-2-yl)-1-(2,2,2- trifluoroethyl)-1H-pyrrole-3-carboxamide; 1-(5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; 44 ME150647165v.1 130090-01720 5-(5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1-methyl-1H-pyrrole-3-carboxamide; 5-(5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-(thiazol-2- ylmethoxy)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(3-(thiazol-2- ylmethoxy)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxypyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-cyclopentyl-5-methyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-isobutyrylpiperazin-1-yl)pyridin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2-methyl-1H-pyrrol-1- yl)pyridin-3-yl)-N,N-dimethylpiperazine-1-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(1,1-dioxidothiomorpholino)pyridin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-difluoroethyl)-5-(5-fluoropyridin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(1-hydroxyethyl)-1-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)thieno[3,2-c]pyridine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)thieno[3,2-b]pyridine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-7-methylthieno[3,2-c]pyridine-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5,6-dimethoxybenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)pyrrolo[1,2-b]pyridazine-6-carboxamide; 6-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)benzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6-fluorobenzo[b]thiophene-2- carboxamide; 45 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-fluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-fluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-7-fluorobenzo[b]thiophene-2- carboxamide; 5-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)benzo[b]thiophene-2- carboxamide; 6-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)indolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6-methylindolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazine- 7-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-8-(trifluoromethyl)indolizine-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-7-methoxybenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methylindolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-8-fluoroindolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-hydroxycyclobutyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(1-methyl-2-oxopiperidin-4-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-phenethyl-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-cyclopentyl-1H-pyrazole-4- carboxamide; 1-(6-acetamidospiro[3.3]heptan-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-methyl-2-azaspiro[3.3]heptan-6-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(2,2,2-trifluoroethyl)-2- azaspiro[3.3]heptan-6-yl)-1H-pyrazole-4-carboxamide; 1-(2-acetyl-2-azaspiro[3.3]heptan-6-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 1H-pyrazole-4-carboxamide; 46 ME150647165v.1 130090-01720 N-(3-bromo-5-(methylsulfonamido)phenyl-2,4,6-d3)-4-phenylthiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-dimethylpiperidin-4-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)- 1H-pyrazole-4-carboxamide; 1-(1-acetylpiperidin-4-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H-pyrazole-4- carboxamide; tert-butyl (6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)spiro[3.3]heptan-2-yl)carbamate; 1-(6-aminospiro[3.3]heptan-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; and 1-(3-fluoro-5-morpholinopyridin-2-yl)-5-methyl-N-(3-(methylsulfonamido)phenyl)- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-fluoro-5-morpholinopyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1-(2- hydroxyethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-methyl-3-oxopiperazin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyrimidin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5'-fluoro-[3,3'-bipyridin]-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-methyl-2-oxoimidazolidin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-methoxybenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1,3-dimethylpyrrolo[1,2-a]pyrazine-7- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(4-phenylpiperazine-1-carbonyl)-1- (pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(trifluoromethyl)benzo[b]thiophene-2- carboxamide; 47 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4,5-difluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4,7-difluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(trifluoromethyl)benzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyrimidin-5-yl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6-methoxybenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(piperidine-1-carbonyl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(morpholine-4-carbonyl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin- 1-yl)thiophene-2-carboxamide; 4-(3-(2-(azetidin-1-yl)-2-oxoethyl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-oxooxazolidin-3-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyrazin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyrimidin-2-ylmethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-5-(4-(2,2,2- trifluoroethyl)piperazine-1-carbonyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(2-oxopyrrolidin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxy-5-(2-oxa-6- azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(2-oxo-2-(pyrrolidin-1- yl)ethyl)pyridin-2-yl)thiophene-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-4-(3-methylpyridin-2- yl)thiophene-2-carboxamide; 48 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(4-methylpiperazine-1-carbonyl)-1- (pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-3-yloxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-(pyridin-3-yloxy)pyridin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(2-(dimethylamino)-2- oxoethyl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(2-hydroxypropan-2-yl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6,8-dimethylindolizine-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-5-(2,6- diazaspiro[3.3]heptane-2-carbonyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-8-methylindolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)pyrrolo[1,2-a]pyrazine-7-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-methoxypyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(trifluoromethyl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-cyanopyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methylbenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(1-(tetrahydro-2H-pyran-4- yl)-1H-1,2,3-triazol-4-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5- (trifluoromethyl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; 49 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-ethoxypyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-methoxypyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(methoxymethyl)pyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-chloropyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methoxypyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yloxy)-5,6-dihydro-4H- cyclopenta[b]thiophene-2-carboxamide; 4-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)benzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(3-fluorophenoxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-methoxy-1H-pyrazol-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(1-phenethyl-1H-imidazol-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-methoxy-1H-pyrazol-1-yl)-5- methylthiophene-2-carboxamide; 50 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(methoxymethyl)pyrimidin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-cyanopyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-chloropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-chloropyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-fluoroazetidin-1-yl)pyridin-2-yl)- 5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-fluoropyridin-2-yl)-5- (methoxymethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-ethoxypyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-ethoxy-1H-pyrazol-1-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-fluoro-1H-pyrazol-1-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-fluoro-1H-pyrazol-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methoxypyrimidin-2-yl)-5-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(methoxymethyl)pyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxypyrimidin-2-yl)thiophene-2- carboxamide; 5-(5-(azetidin-1-yl)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoropyrrolidin-1-yl)pyridin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; 51 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methyl(tetrahydrofuran-3- yl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methyl(tetrahydrofuran-3- yl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5- (trifluoromethyl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2-methoxyethoxy)pyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyrimidin-2-yl)thiophene-2- carboxamide; 1-(5-(azetidin-1-yl)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-(cyclopropylmethoxy)pyridin-2-yl)- 1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyclopropyl-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; 1-(5-(azetidin-1-yl)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-fluoroazetidin-1-yl)pyridin-2-yl)- 1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-chloropyrimidin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; 5-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyrimidin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxopyrrolidin-1- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5,5'-difluoro-[3,3'-bipyridin]-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-1'-methyl-2'-oxo-1',2'- dihydro-[3,4'-bipyridin]-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-1'-methyl-6'-oxo-1',6'- dihydro-[3,3'-bipyridin]-2-yl)-5-methylthiophene-2-carboxamide; 52 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5,5'-difluoro-[3,3'-bipyridin]-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1- yl)pyrimidin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5- (methylsulfonyl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(trifluoromethyl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(cyclopropylmethoxy)pyridin-2-yl)- 5-methyl-1H-pyrrole-3-carboxamide; tert-butyl 3-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2-(5- fluoropyrimidin-2-yl)-1H-pyrrol-1-yl)azetidine-1-carboxylate; 1-(5-(3-azabicyclo[3.1.0]hexan-3-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-cyclopropyl-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methylthio)pyrimidin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methylsulfinyl)pyrimidin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(pyrrolidin-1-yl)pyrimidin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyclopropyl-1-(5-fluoropyrimidin-2- yl)-1H-pyrrole-3-carboxamide; 5-(5-(azetidin-1-yl)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4,4-dimethyl-2,5-dioxo-3-(pyridin-2- yl)imidazolidin-1-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-2'-methyl-[3,3'-bipyridin]-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-(oxazol-5-yl)pyridin-2-yl)- 5-methylthiophene-2-carboxamide; 53 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(oxetan-3- yloxy)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-ethoxypyrimidin-2-yl)-5- (trifluoromethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(difluoromethoxy)pyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoro-3-methoxypyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3,5-difluoropyridin-2-yl)-5-methyl- 1H-pyrrole-3-carboxamide; 5-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-ethyl-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; 1-(5-(5-azaspiro[2.4]heptan-5-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-fluoroazetidin-1-yl)pyrimidin-2- yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(N- methylmethylsulfonamido)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-cyclopropyl-5-(5-fluoropyrimidin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxopyrrolidin-1- yl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2-yl)-1-isopropyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5- (methylsulfonyl)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5,5'-difluoro-[3,3'-bipyridin]-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; 54 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,4-dimethyl-2,5-dioxo-4-(pyridin-2- yl)imidazolidin-1-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-methylpyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; methyl 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1-methyl-1H- pyrrol-2-yl)pyridin-3-yl)piperazine-1-carboxylate; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1- yl)pyrimidin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-((1-methylazetidin-3- yl)oxy)pyridin-2-yl)-1H-pyrrole-3-carboxamide; methyl 4-(6-(5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2- methylthiophen-3-yl)-5-methylpyridin-3-yl)piperazine-1-carboxylate; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3,5-difluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-fluoroazetidin-1-yl)pyrimidin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-methylpyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,5-difluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-methylpyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-(3-chloro-5-fluoropyridin-2-yl)-5-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(oxetan-3-yloxy)pyridin-2- yl)-1H-pyrrole-3-carboxamide; 55 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(pyrrolidin-1-yl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(tetrahydro-2H-pyran-4- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-chloro-5-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-methylpyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-(3,5-difluoropyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; 1-(azetidin-3-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-cyano-5-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-methoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3-chloro-5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(methylamino)pyrimidin- 2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxooxazolidin-3- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(2,4,6-trifluorophenyl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(3-fluoro-5-methylpyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(2,4,6- trifluorophenyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxooxazolidin-3- yl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; 56 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(4-(cyclopropanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(1-(2,2,2- trifluoroethyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(trifluoromethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5- (trifluoromethyl)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-chloro-5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(4-pivaloylpiperazin-1- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-methoxypyrimidin-2-yl)-1-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclopentanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 1-(5-(7-azabicyclo[2.2.1]heptan-7-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-methoxyazetidin-1-yl)pyrimidin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(2-cyano-4-fluoro-6-methylphenyl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- methylpyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3-fluoro-5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(3-methyl-5- (trifluoromethyl)pyridin-2-yl)thiophene-2-carboxamide; 57 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-methoxy-5-(trifluoromethyl)pyridin- 2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclobutanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(4,4-difluoropiperidin-1-yl)-3- methylpyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(tetrahydro-1H-furo[3,4- c]pyrrol-5(3H)-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(6-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxy-3-methylpyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,5-difluoropyridin-4-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- methylpyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-cyano-5-(3,3-difluoroazetidin-1- yl)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclopropanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 1-(3-chloro-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-isopropoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4,4-difluoropiperidin-1-yl)-3- methylpyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-(difluoromethoxy)-5-fluoropyridin- 2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 58 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)pyrimidin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(4-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-chloro-5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- methoxypyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- (trifluoromethyl)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- isopropoxypyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-cyclobutoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-ethoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- methoxypyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- methoxypyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(3,4,4-trimethyl-2,5- dioxoimidazolidin-1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(difluoromethoxy)pyrimidin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)pyrimidin- 2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(trifluoromethyl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-(3-fluoroazetidin-1-yl)pyrimidin-2-yl)- 5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-ethoxy-3-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; 59 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(5-(trifluoromethyl)pyrimidin- 2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3-fluorooxetan-3-yl)pyrimidin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1- (methylsulfonyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-methoxypyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; 4-(5-(1-acetylpiperidin-4-yl)pyrimidin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(cyclopropanesulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(propylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; methyl 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1-methyl-1H- pyrrol-2-yl)-5-fluoropyridin-3-yl)piperazine-1-carboxylate; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-methoxypiperidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-cyano-5-(3,3-difluoroazetidin-1- yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3-(2,2,2- trifluoroethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3-(2,2,2- trifluoroethoxy)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-cyclobutoxy-5-(3,3-difluoroazetidin- 1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-((1-methylazetidin-3- yl)oxy)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- (difluoromethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; 4-(5-(tert-butoxy)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclopropanecarbonyl)piperazin- 1-yl)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 60 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-ethoxy-5-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-fluoro-3-methylazetidin-1- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-cyclobutoxy-5-(3,3-difluoroazetidin- 1-yl)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(3- (methylsulfonyl)azetidin-1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-methoxyazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(3-fluoroazetidin-1- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(6-azaspiro[2.5]octan-6- yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(6-azaspiro[2.5]octan-6- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(2-oxa-6- azaspiro[3.4]octan-6-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4,4-difluoropiperidin-1-yl)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4,4-dimethyl-1,4-azasilinan-1-yl)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(6,6-difluoro-2-azaspiro[3.3]heptan- 2-yl)-3-fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(4,4-difluoropiperidin-1-yl)-3- fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1- yl)pyrimidin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(3- ((methylsulfonyl)methyl)azetidin-1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(4- (trifluoromethyl)piperidin-1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(4,4-dimethyl-1,4-azasilinan-1-yl)-3- fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; 61 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(2-oxa-7- azaspiro[3.5]nonan-7-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(2-oxa-7- azaspiro[3.5]nonan-7-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(6,6-dimethyl-3- azabicyclo[3.1.0]hexan-3-yl)-3-fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- isopropoxypyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(3- (trifluoromethyl)azetidin-1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(1,1-difluoro-5-azaspiro[2.4]heptan- 5-yl)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoropyrrolidin-1-yl)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(6,6-dimethyl-3- azabicyclo[3.1.0]hexan-3-yl)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-((2-hydroxyethyl)sulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(6,6-difluoro-2-azaspiro[3.3]heptan- 2-yl)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(1,1-difluoro-6-azaspiro[2.5]octan- 6-yl)-3-fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoropyrrolidin-1- yl)pyrimidin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((1-(cyclopropanecarbonyl)azetidin- 3-yl)oxy)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(1,1-difluoro-5-azaspiro[2.4]heptan- 5-yl)-3-fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- isopropoxypyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(4- (trifluoromethyl)piperidin-1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; 62 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoropiperidin-1-yl)-3- fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(1,1-difluoro-6-azaspiro[2.5]octan- 6-yl)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoropiperidin-1-yl)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(1-(2,2,2- trifluoroethyl)azetidin-3-yl)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(1-(2,2-difluoroethyl)piperidin-4- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoropyrrolidin-1-yl)-3- fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-cyano-5-(trifluoromethyl)pyridin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoropyrrolidin-1-yl)pyridin- 2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(3- (trifluoromethyl)azetidin-1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(trifluoromethyl)pyridin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(1-(2,2,2- trifluoroethyl)piperidin-4-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-((1-methylazetidin-3- yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-cyanopyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-isopropoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxy-3-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- methylpyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-isopropoxypyrimidin-2- yl)thiophene-2-carboxamide; 63 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-isopropoxypyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(trifluoromethyl)pyrimidin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-cyano-3-methylpyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-cyanopyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(trifluoromethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-cyano-3-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1- yl)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-isopropoxypyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoropyrrolidin-1-yl)-3- fluoropyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoropyrrolidin-1- yl)pyrimidin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(3- (trifluoromethyl)azetidin-1-yl)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoropyrrolidin-1- yl)pyrimidin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoropyrrolidin-1-yl)pyridin- 2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(6,6-difluoro-2-azaspiro[3.3]heptan- 2-yl)pyrimidin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(6,6-difluoro-2-azaspiro[3.3]heptan- 2-yl)pyrimidin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; 64 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(1,1-difluoro-5-azaspiro[2.4]heptan- 5-yl)pyrimidin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(1,1-difluoro-5-azaspiro[2.4]heptan- 5-yl)-3-fluoropyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(6,6-difluoro-2-azaspiro[3.3]heptan- 2-yl)pyrimidin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-((1-hydroxy-2-methylpropan-2- yl)oxy)pyrimidin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-ethyl-4-(3-fluoropyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(trifluoromethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(3- (trifluoromethyl)azetidin-1-yl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; 4-(5-(tert-butoxy)-3-fluoropyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(dimethylphosphoryl)pyridin-2-yl)- 5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,5-difluoropyridin-2-yl)-5- ethylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(1,1-difluoro-5-azaspiro[2.4]heptan- 5-yl)pyrimidin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-((2-hydroxyethyl)sulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1- yl)-3-methoxypyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(1,1-difluoro-5-azaspiro[2.4]heptan- 5-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(3- (trifluoromethyl)azetidin-1-yl)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(3- (trifluoromethyl)azetidin-1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-ethyl-4-(5-fluoropyridin-2- yl)thiophene-2-carboxamide; 4-(5-(tert-butoxy)pyrimidin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)thiophene-2-carboxamide; 65 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(dimethylphosphoryl)pyrimidin-2- yl)-5-methylthiophene-2-carboxamide; 4-(5-(tert-butoxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(6,6-difluoro-2-azaspiro[3.3]heptan- 2-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(6,6-difluoro-2-azaspiro[3.3]heptan- 2-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(1,1-difluoro-5-azaspiro[2.4]heptan- 5-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; 1-(5-(tert-butoxy)-3-fluoropyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 5-methyl-1H-pyrrole-3-carboxamide; 1-(5-(tert-butoxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl- 1H-pyrrole-3-carboxamide; 5-(5-(tert-butoxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(propylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1H-pyrrole- 3-carboxamide; 4-(5-(tert-butoxy)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- (hydroxymethyl)thiophene-2-carboxamide; N-(3-chloro-5-((1-methylethyl)sulfonamido)phenyl)-4-(3-methylpyridin-2- yl)thiophene-2-carboxamide; 5-(5-(tert-butoxy)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-methylpyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(N-methylmethylsulfonamido)phenyl)-4-(3-methylpyridin-2- yl)thiophene-2-carboxamide; 1-(5-(tert-butoxy)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methyl-1H-pyrrole-3-carboxamide; 5-(5-(tert-butoxy)-3-fluoropyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 1-methyl-1H-pyrrole-3-carboxamide; 66 ME150647165v.1 130090-01720 5-(3,5-difluoropyridin-2-yl)-N-(3-fluoro-5-(methylsulfonamido)phenyl)-1-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-((2-hydroxyethyl)sulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-fluoro-4-(5-isopropoxypyrimidin-2-yl)- 5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-methyl-4-(3-methylpyridin-2- yl)thiophene-2-carboxamide; 4-(3-fluoro-5-(3-(trifluoromethyl)azetidin-1-yl)pyridin-2-yl)-N-(3-fluoro-5- (methylsulfonamido)phenyl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyridin-2-yl)-5- methylthiazole-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3-fluoro-5-(3-(trifluoromethyl)azetidin- 1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-((2-hydroxyethyl)sulfonamido)phenyl)-4-(3-fluoro-5-(3- (trifluoromethyl)azetidin-1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-((1-methylazetidin-3- yl)oxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; 4-(5-(azetidin-3-yloxy)-3-fluoropyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(1,1-dioxidothiomorpholino)-5- fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; 4-(3-(4-acetylpiperazin-1-yl)-5-fluoropyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-(3-methoxypyrrolidin-1- yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-((methyl)sulfonamido-1,1,1-d3)phenyl)-4-(5-isopropoxypyrimidin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-(4- (methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-(6-azaspiro[2.5]octan-6- yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(3- (trifluoromethyl)azetidin-1-yl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; 67 ME150647165v.1 130090-01720 2-(5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2-methylthiophen-3-yl)- 3,5-difluoropyridine 1-oxide; 4-(5-(azetidin-3-yloxy)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-(3-hydroxy-3-methylbut-1- yn-1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(3-hydroxy-1- methylazetidin-3-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(2-fluoro-3-(methylsulfonamido)phenyl)-4-(3-(pyridin-3-ylmethoxy)pyridin-2- yl)thiophene-2-carboxamide; 1-(2-(benzyloxy)cyclopentyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(((5-fluoropyridin-3- yl)oxy)methyl)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-fluoro-6-((5-fluoropyridin-3- yl)methoxy)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(dimethylcarbamoyl)-6-((3- fluorobenzyl)oxy)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,4-difluoro-6-(oxazol-5- ylmethoxy)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoro-3-(oxazol-5- ylmethoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)thiophene-2-carboxamide; 1-(2-(benzyloxy)phenyl)-N-(3-fluoro-5-(methylsulfonamido)phenyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-fluoro-6-(oxazol-5- ylmethoxy)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-((3-fluorobenzyl)oxy)-4-(2-oxa-6- azaspiro[3.3]heptan-6-yl)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-5-(hydroxymethyl)-1H-pyrrole-3-carboxamide; 68 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-(thiazol-2- ylmethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-((2-methylthiazol-4- yl)methoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-((3,5-dimethylisoxazol-4- yl)methoxy)-5-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-(pyrimidin-5- ylmethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(2-((5-fluoropyridin-3-yl)methoxy)-4- methylpyridin-3-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-((1-methyl-1H-1,2,3- triazol-5-yl)methoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; (E)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(2-(2-(5-fluoropyridin-3- yl)vinyl)phenyl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-((1-methyl-1H-tetrazol-5- yl)methoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-(2-(5-fluoropyridin-3- yl)ethyl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; (E)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-(2-(5-fluoropyridin-3- yl)vinyl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 4-(3-((5-fluoropyridin-3-yl)methoxy)pyridin-2-yl)-5-methyl-N-(3- (methylsulfonamido)phenyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-(1-(3-fluoro-5- (trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-((1S)-1-(3-fluoro-5- (trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-((1R)-1-(3-fluoro-5- (trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-((5-ethylpyridin-3- yl)methoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(1-(5-fluoropyridin-3- yl)ethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; (R)-N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(1-(5-fluoropyridin-3- yl)ethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; 69 ME150647165v.1 130090-01720 (S)-N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(1-(5-fluoropyridin-3- yl)ethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-((2-hydroxyethyl)sulfonamido)phenyl)-4-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-(oxazol-5- ylmethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- (oxazol-5-ylmethoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((3,5-difluorobenzyl)oxy)-2- methylpyrimidin-4-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-(pyrimidin-5- ylmethoxy)pyridin-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; 5-(3-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methoxy)pyridin-2-yl)-1-methyl-N-(3- (methylsulfonamido)phenyl)-1H-pyrrole-3-carboxamide; 5-(3-((3-hydroxybenzyl)oxy)pyridin-2-yl)-1-methyl-N-(3- (methylsulfonamido)phenyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(1-(3,5- difluorophenyl)ethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; (S)-N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(1-(3,5- difluorophenyl)ethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; (R)-N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(1-(3,5- difluorophenyl)ethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((3,5-difluorobenzyl)oxy)pyrimidin- 4-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((1-isopropylazetidin-3- yl)oxy)pyrimidin-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; (S)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((1-methylpyrrolidin-3- yl)oxy)pyrimidin-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; (R)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((1-methylpyrrolidin-3- yl)oxy)pyrimidin-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-difluoroethyl)-5-(5-((1- methylazetidin-3-yl)oxy)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((1-(methylsulfonyl)azetidin-3- yl)oxy)pyrimidin-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; 70 ME150647165v.1 130090-01720 (R)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-((1-methylpyrrolidin-3- yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; (S)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-((1-methylpyrrolidin-3- yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 2-((2-(5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2-methylthiophen-3- yl)pyrimidin-5-yl)oxy)propanoic acid; N-(3-chloro-5-((2-hydroxyethyl)sulfonamido)phenyl)-4-(5-isopropoxypyrimidin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-hydroxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; 4-(5-(tert-butoxy)pyrimidin-2-yl)-N-(3-chloro-5-(ethylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; 2-((2-(5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2-methylthiophen-3- yl)pyrimidin-5-yl)oxy)-2-methylpropanoic acid; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-((1-hydroxypropan-2- yl)oxy)pyrimidin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(2-(dimethylamino)ethoxy)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(1-hydroxy-1-(1- methylazetidin-3-yl)ethyl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-isopropoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-((1-(2,2,2- trifluoroethyl)azetidin-3-yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 2-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1-methyl-1H-pyrrol-2-yl)- 3,5-difluoropyridine 1-oxide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-((1-isopropylazetidin-3- yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-((1-(2,2-difluoroethyl)azetidin-3- yl)oxy)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-difluoroethyl)-5-(5-(3- (trifluoromethyl)azetidin-1-yl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-6-methoxypyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; 71 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoropyridin-2-yl)-1-(2,2,2- trifluoroethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-methoxypyrimidin-2-yl)-1-(2,2,2- trifluoroethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2-yl)-1-(2,2,2- trifluoroethyl)-1H-pyrrole-3-carboxamide; and N-(3-chloro-5-(methylsulfonamido)phenyl)-5- (5-((1-methylazetidin-3-yl)oxy)pyrimidin-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3- carboxamide; or a pharmaceutically acceptable salt thereof. In some embodiments, the DHX9 inhibitor is N-(3-chloro-5- (methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the DHX9 inhibitor is N-(3-chloro-5- (methylsulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1-methyl-1H-pyrrole-3- carboxamide, or a pharmaceutically acceptable salt thereof. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to BRCA1 and / or BRCA2 loss of function in colorectal cancer. FIG. 1B depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to BRCA1 and / or BRCA2 loss of function in ovarian cancer. FIG. 1C depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to BRCA1 and / or BRCA2 loss of function in breast cancer. FIG. 1D depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to BRCA1 and / or BRCA2 loss of function in triple negative breast cancer. FIG. 1E depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to BRCA1 and / or BRCA2 loss of function in pancreatic cancer. FIG.2A depicts the in vivo efficacy of DHX9 inhibitor (compound 2) with BRCA1 loss of function HCC1187 TNBC tumor model. FIG.2B depicts the in vivo efficacy of DHX9 inhibitor (compound 2) with BRCA2 loss of function CAL-148 TNBC tumor model. FIG.2C depicts the in vivo efficacy of DHX9 inhibitor (compound 2) with BRCA2 loss of function CAL-51 TNBC tumor model. 72 ME150647165v.1 130090-01720 FIG. 2D depicts the in vivo efficacy of DHX9 inhibitor (compound 2) in BRCA1 and BRCA2 loss of function OVCAR3 HGSOC tumor model FIG. 3A depicts the in vivo efficacy of DHX9 inhibitor (compound 2) in BRCA1 and BRCA2 wild type DU4475 TNBC tumor model. FIG. 3B depicts the in vivo efficacy of DHX9 inhibitor (compound 2) in BRCA1 and BRCA2 wild type HCC1806 TNBC tumor model. FIG. 4A depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to homologous recombination (HR) deficiency in colorectal cancer. FIG. 4B depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to homologous recombination (HR) deficiency in uterine cancer. FIG. 4C depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) to homologous recombination (HR) deficiency in gastric cancer. FIG. 5A depicts the in vivo efficacy of DHX9 inhibitor (compound 3) with multiple homologous recombination (HR) deficient and proficient PDX tumor models representing breast, colorectal, gastric and uterine cancers. FIG. 5B depicts the in vivo efficacy of DHX9 inhibitor (compound 3) with multiple homologous recombination (HR) deficient and proficient triple negative breast cancer (TNBC) PDX tumor models. FIG. 5C depicts the in vivo efficacy of DHX9 inhibitor (compound 3) with multiple homologous recombination (HR) deficient and proficient colorectal cancer (CRC) PDX tumor models. FIG. 5D depicts the in vivo efficacy of DHX9 inhibitor (compound 3) with multiple homologous recombination (HR) deficient and proficient gastric cancer PDX tumor models. FIG. 5E depicts the in vivo efficacy of DHX9 inhibitor (compound 3) with multiple homologous recombination (HR) deficient and proficient uterine cancer PDX tumor models. FIG. 5F depicts the in vivo efficacy of DHX9 inhibitor (compound 3) with multiple homologous recombination (HR) deficient and proficient PDX tumor models representing breast, colorectal, gastric and uterine cancers. FIG.6A depicts the genetic profiles for colorectal cancer cell lines with respect to genes involved in the mismatch repair (MMR) pathway. FIG.6B depicts the genetic profiles for colorectal cancer cell lines with respect to genes involved in the homologous recombination (HR) repair pathway. FIG.6C depicts the genetic profiles for colorectal cancer cell lines with respect to genes involved in the base excision repair (BER) pathway. 73 ME150647165v.1 130090-01720 FIG.6D depicts the genetic profiles for colorectal cancer cell lines with respect to genes involved in the nucleotide excision repair (NER) pathway. FIG.6E depicts the genetic profiles for colorectal cancer cell lines with respect to genes involved in the non-homologous end joining (NHEJ) repair pathway. FIG. 7A depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) and homologous recombination (HR) deficiency in prostate cancer. FIG. 7B depicts the correlation between DHX9 inhibitor (compound 3) sensitivity (IC50) and homologous recombination (HR) deficiency in prostate cancer. FIG. 7C depicts the correlation between DHX9 inhibitor (compound 1) sensitivity (IC50) and homologous recombination (HR) deficiency in high grade serous ovarian cancer (HGSOC). FIG. 7D depicts the correlation between DHX9 inhibitor (compound 3) sensitivity (IC50) and homologous recombination (HR) deficiency in high grade serous ovarian cancer (HGSOC). FIG. 7E depicts the correlation between DHX9 inhibitor (compound 3) sensitivity (IC50) and BRCA1 and / or BRCA2 loss of function in triple negative breast cancer (TNBC). FIG. 7F depicts the correlation between DHX9 inhibitor (compound 3) sensitivity (IC50) and homologous recombination (HR) deficiency in triple negative breast cancer (TNBC). FIG. 8A depicts the DHX9 inhibitor (compound 3)-mediated PDX tumor growth inhibition as separated by homologous recombination (HR) status in multiple ovarian PDX models. FIG. 8B depicts the DHX9 inhibitor (compound 3)-mediated PDX tumor growth inhibition as separated by homologous recombination (HR) Scar Score in multiple ovarian PDX models. DETAILED DESCRIPTION OF THE INVENTION The present invention is based, at least in part, on the unexpected and surprising discovery that certain types of cancers are more sensitive to DHX9 inhibition, in particular, DNA damage repair deficient (DDRD) cancers, e.g., homologous recombination deficient (HRD) cancers, and / or cancers having a BRCA loss of function or alteration. The inventors of the present invention have demonstrated, both in vitro and in vivo, that breast, ovarian, colorectal, pancreatic, prostate, gastric and uterine cancers having a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., homologous 74 ME150647165v.1 130090-01720 recombination repair, e.g., a loss of function or alteration in the BRCA1 / 2 genes, were particularly responsive to DHX9 inhibitor treatment, with robust and significant tumor growth inhibition and / or regression observed in multiple tumor models. Accordingly, the present invention provides methods of treating a DNA damage repair deficient (DDRD) cancer, methods of treating a homologous recombination deficient (HRD) cancer, and / or methods of treating a cancer having a BRCA loss of function or alteration in a subject by administering to the subject a DHX9 inhibitor. I. Definitions Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In this application, the use of "or" means "and / or" unless stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as "includes" and "included", is not limiting. The term "such as" is used herein to mean, and is used interchangeably, with the phrase "such as but not limited to." The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. Unless specifically stated or obvious from context, as used herein, the term "about" is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein can be modified by the term about. Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. As used herein, "one or more" is understood as each value 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and any value greater than 10. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid 75 ME150647165v.1 130090-01720 chemistry described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. The terms “cancer” or “tumor” are well known in the art and refer to the presence, e.g., in a subject, of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, decreased cell death / apoptosis, and certain characteristic morphological features. As used herein, “cancer” refers to all types of cancer or neoplasm or malignant tumors found in humans, including, but not limited to: solid tumor, blood tumor, leukemias, myeloma, lymphomas, melanomas, carcinomas and sarcomas. As used herein, the terms or language “cancer,” “neoplasm,” and “tumor,” are used interchangeably and in either the singular or plural form, refer to cells that have undergone a malignant transformation that makes them pathological to the host organism. Primary cancer cells (that is, cells obtained from near the site of malignant transformation) can be readily distinguished from non-cancerous cells by well-established techniques, particularly histological examination. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but also cancer stem cells, as well as cancer progenitor cells or any cell derived from a cancer cell ancestor. This includes metastasized cancer cells, and in vitro cultures and cell lines derived from cancer cells. A tumor may be detectable on the basis of tumor mass; e.g., by procedures such as CAT scan, MR imaging, X-ray, ultrasound or palpation, and / or which is detectable because of the expression of one or more cancer-specific antigens in a sample obtainable from a patient. The tumor does not need to have measurable dimensions. Specific criteria for the staging of cancer are dependent on the specific cancer type based on tumor size, histological characteristics, tumor markers, and other criteria known by those of skill in the art. Generally, cancer stages can be described as follows: 76 ME150647165v.1 130090-01720 Stage 0 - Carcinoma in situ Stage I, Stage II, and Stage III - Higher numbers indicate more extensive disease: Larger tumor size and / or spread of the cancer beyond the organ in which it first developed to nearby lymph nodes and / or tissues or organs adjacent to the location of the primary tumor Stage IV - The cancer has spread to distant tissues or organs RECIST criteria are clinically accepted assessment criteria used to provide a standard approach to solid tumor measurement and provide definitions for objective assessment of change in tumor size for use in clinical trials. Such criteria can also be used to monitor response of an individual undergoing treatment for a solid tumor. The RECIST 1.1 criteria are discussed in detail in Eisenhauer et al. (New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1) Eur. J. Cancer. 45:228-247, 2009), the entire contents of which are incorporated herein by reference. As used herein, the terms “DNA damage repair (DDR)” or “DNA damage repair pathway” refer to cellular mechanisms that protect the DNA by removing or reducing the deleterious consequences of DNA damage to ensure an overall survival. Cells respond to DNA damage by instigating robust DNA damage repair pathways, which allow sufficient time for specified DNA repair pathways to physically remove the damage in a substrate-dependent manner. Several major DNA repair pathways are active throughout different stages of the cell cycle, allowing the cells to repair the DNA damage, i.e., base excision repair (BER), homologous recombination (HR) repair, non-homologous end joining (NHEJ) repair, nucleotide excision repair (NER), and mismatch repair (MMR). BER, NER and MMR repair single strand DNA damage. When only one of the two strands of the DNA double helix has a defect, the other strand can be used as a template to guide the correction of the damaged strand. In order to repair damage to one of the two paired molecules of DNA, there exist a number of excision repair mechanisms that remove the damaged nucleotide(s) and replace it with an undamaged nucleotide complementary to that found in the undamaged DNA strand. BER repairs damage due to a single nucleotide caused by oxidation, alkylation, hydrolysis, or deamination. NER repairs damage affecting longer strands of 2-30 bases. This process recognizes bulky, helix-distorting changes such as thymine dimers as well as single-strand breaks. MMR corrects errors of DNA replication and recombination that result in mispaired nucleotides following DNA replication. HR and NEHJ repair double stranded DNA breaks (DSBs). Double stranded breaks are particularly hazardous to dividing cells. Homologous recombination DNA repair requires the presence of an identical or nearly identical sequence to be used as a template for repair of the 77 ME150647165v.1 130090-01720 break. The enzymatic machinery responsible for this repair process is nearly identical to the machinery responsible for chromosomal crossover during meiosis. This pathway allows a damaged chromosome to be repaired using the newly created sister chromatid as a template, i.e. an identical copy that is also linked to the damaged region via the centromere. Double- stranded breaks repaired by this mechanism are usually caused by the replication machinery attempting to synthesize across a single-strand break or unrepaired lesion, both of which result in collapse of the replication fork. The NHEJ pathway operates when the cell has not yet replicated the region of DNA on which the lesion has occurred. The process directly joins the two ends of the broken DNA strands without a template, losing sequence information in the process. NHEJ is an intrinsically error-prone mechanism because the original sequence can only be preserved when the two DNA ends can be ligated without prior resection. If the DSB is not due to a disrupted phosphodiester bond, but is the result of a disrupted pentose sugar backbone of the DNA structure, religation cannot take place before end-processing leads to the generation of a free 5′-phosphate and a 3′-hydroxyl group. The necessary modifications of the free DNA ends, such as nucleolytic cleavage and gap filling of the ends, are highly mutagenic and render NHEJ-mediated DSB repair inaccurate. As used herein, the term “DNA damage repair deficient (DDRD) cancer” refers to a group of cancers that are characterized as being deficient in one or more DNA damage repair pathways, i.e., the DDRD cancer comprises a loss of function or alteration in one or more genes involved in a DNA damage repair pathway. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in a DNA damage repair pathway selected form the group consisting of base excision repair (BER), homologous recombination (HR) repair, non- homologous end joining (NHEJ) repair, and nucleotide excision repair (NER). In some embodiments, the DDRD cancer is proficient in mismatch repair, and / or the DDRD cancer is not or does not comprise a cancer that is deficient in mismatch repair (MMR), i.e., the DDRD cancer does not comprise a loss of function or alteration in a gene involved in the MMR pathway, such as MLH1, MSH2, MSH3, MSH6, PMS1, or PMS2. In some embodiments, the DDRD cancer is a microsatellite stable (MSS) cancer and / or is not a microsatellite instable (MSI) cancer. In some embodiments, the DDRD cancer is a microsatellite instable (MSI) cancer. In some embodiments, the DDRD cancer is proficient in mismatch repair, and is characterized as microsatellite stable (MSS), i.e., the DDRD cancer does not comprise a loss of function or alteration in a gene involved in the MMR pathway, such as MLH1, MSH2, MSH3, 78 ME150647165v.1 130090-01720 MSH6, PMS1, or PMS2, and the DDRD cancer is not or does not comprise a microsatellite instable (MSI) cancer. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in homologous recombination (HR) repair. In some embodiments, the one or more genes involved in HR is selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the DDRD cancer comprises a BRCA1 / 2 loss of function or alteration, e.g., a BRCA1 and / or a BRCA2 loss-of-function mutation. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in non- homologous end joining (NHEJ) repair. In some embodiments, the one or more genes involved in NHEJ is selected from the group consisting of PRKDC, DCLRE1C, XRCC5, LIG4, XRCC4, XRCC6, WRN, APLF, and NHEJ1. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in nucleotide excision repair (NER). In some embodiments, the one or more genes involved in NER is selected from the group consisting of XPC, RAD23B, ERCC5, ERCC4, ERCC2, ERCC1, CETN2, DDB1, DDB2, ERCC3 and XPA. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in base excision repair (BER). In some embodiments, the one or more genes involved in BER is selected from the group consisting of LIG3, PARP1, PARP2, PNKP, PARG, FEN1, XRCC1, LIG1, PCNA, APEX2, APEX1, OGG1, NTH1, UNG, NEIL1, NEIL2, NEIL3, MYH, MPC and APTX. As used herein, the term “homologous recombination repair deficient (HRD) cancer” or “homologous recombination deficient (HRD) cancer” refers to a group of cancers that are characterized as being deficient in the homologous recombination DNA damage repair pathway, i.e., the HRD cancer comprises a loss of function or alteration in one or more genes involved in homologous recombination repair. Homologous recombination (HR) is an error- free double stranded break (DSB) repair pathway that is largely restricted to the S- and G2- phases of the cell cycle, when an intact sister chromatid is available as a template. Upon initiation of the HR process, the DSB is resected to create a single-stranded (ss) 3′-overhang, which becomes rapidly coated with the ssDNA-binding protein RPA. This ssDNA overhang 79 ME150647165v.1 130090-01720 ultimately invades the sister chromatid. Once an RPA-coated ssDNA filament is generated, RPA is replaced by Rad51, which mediates homology search and restores damaged DNA. The HR repair process is coordinated by many cellular responses, such as cell cycle checkpoint, transcriptional activation, epigenetic regulation, and various post-translational modifications. Many genes are known to be involved in HR repair, a loss of function or alteration of any of which may lead to altered or deficient HR repair. In some embodiments, the one or more genes involved in HR is selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the HRD cancer is proficient in mismatch repair (MMR), i.e., the HRD cancer does not comprise a loss of function or alteration in a gene involved in MMR. In some embodiments, the HRD cancer is a microsatellite stable (MSS) cancer. In some embodiments, the HRD cancer is a microsatellite instable (MSI) cancer. In some embodiments, the HRD cancer is proficient in MMR, and is characterized as microsatellite stable (MSS), i.e., the HRD cancer does not comprise a loss of function or alteration in a gene involved in the MMR pathway, such as MLH1, MSH2, MSH3, MSH6, PMS1, or PMS2, and the HRD cancer is not or does not comprise amicrosatellite instable (MSI) cancer. In some embodiments, the HRD cancer comprises a BRCA1 / 2 loss of function or alteration, e.g., a BRCA1 and / or a BRCA2 loss-of-function mutation. As used herein, a “loss of function” or “alteration”, as used interchangeably herein, in a gene refers to a change or modification or a difference in the sequence of at least one copy (either copy or both copies) of a gene relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non-cancerous cells in the subject), such as, the presence, absence, or extent / level of some physical, chemical, or genetic characteristic of a gene or its expression product(s). Such characteristics include, but are not limited to, mutations (e.g., single nucleotide variants, small insertions and deletions (indels), or large deletions and duplications), copy number variants (e.g., copy number loss, or copy number gain), and methylation (e.g., promoter methylation) in the gene. A loss of function or alteration in a gene may result in a deficiency in the gene, which may include, for example a partial or complete loss or reduction in the expression, activity or function of the gene and / or encoded protein. In some embodiments, a loss of function or alteration of a gene comprises a loss-of-function mutation, e.g., single nucleotide variants, small insertions and deletions (indels), or large 80 ME150647165v.1 130090-01720 deletions and duplications. In some embodiments, a loss of function or alteration of a gene comprises copy number variants for the gene, e.g., copy number loss, or copy number gain. In some embodiments, a loss of function or alteration of a gene comprises methylation, e.g., promoter methylation, in the gene. In some embodiments, a loss of function or alteration in a gene may not have been previously identified, described and / or characterized, i.e. may be unknown in function. In other embodiments, a loss of function or alteration in a gene may not result in a deficiency in the gene, e.g., may not result in the partial or complete loss or reduction in expression, activity or function of the gene or encoded protein. As used herein, “BRCA loss of function” or “BRCA alteration”, used interchangeably herein, refers to a change or modification or a difference in the sequence of at least one copy (either copy or both copies) of either or both of the BRCA1 or BRCA2 genes relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non-cancerous cells in the subject), such as, the presence, absence, or extent / level of some physical, chemical, or genetic characteristic of a BRCA1 or BRCA2 gene or its expression product(s). Such characteristics include, but are not limited to, mutations (e.g., single nucleotide variants, small insertions and deletions (indels), or large deletions and duplications), copy number variants (e.g., copy number loss, or copy number gain), and methylation (e.g., promoter methylation) in one or both BRCA genes. In some embodiments, a loss of function or alteration in the BRCA1 / 2 gene may result in a BRCA1 / 2 deficiency, which may include, for example a partial or complete loss or reduction in the expression, activity or function of the BRCA1 / 2 gene and / or encoded protein. In some embodiments, a BRCA loss of function or alteration comprises a BRCA1 and / or a BRCA2 loss-of-function mutation, e.g., single nucleotide variants, small insertions and deletions (indels), or large deletions and duplications. In some embodiments, a BRCA loss of function or alteration comprises copy number variants for BRCA1 and / or BRCA2, e.g., copy number loss, or copy number gain. In some embodiments, a BRCA loss of function or alteration comprises methylation, e.g., promoter methylation, in BRCA1 and / or BRCA2 genes. In some embodiments, a loss of function or alteration in the BRCA1 / 2 gene may not have been previously identified, described and / or characterized, i.e. may be unknown in function. In other embodiments, a loss of function or alteration in the BRCA1 / 2 gene may not result in a BRCA1 / 2 deficiency, e.g., may not result in the partial or complete loss or reduction in expression, activity or function of the BRCA1 / 2 gene or encoded protein. As used herein, the terms “treat,” “treating” or “treatment” refer to an action to obtain a beneficial or desired clinical result including, but not limited to, alleviation or amelioration 81 ME150647165v.1 130090-01720 of one or more signs or symptoms of a disease or condition (e.g., regression, partial or complete), diminishing the extent of disease, stability (i.e., not worsening, achieving stable disease) of the state of disease, delay in onset or slowing of condition, disorder or disease progression; amelioration or palliation of the disease state, diminishing rate of or time to progression, and remission (whether partial or total). “Treatment” of a cancer can also mean eliciting a clinically significant response without excessive levels of side effects, and / or prolonging survival as compared to expected survival in the absence of treatment. Treatment need not be curative. A “therapeutically effective amount” means the amount of a compound that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease, e.g., the amount of such a substance that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment, e.g., is sufficient to ameliorate at least one sign or symptom of the disease, e.g., to prevent and / delay progression of the disease or condition, e.g., reduce tumor volume, inhibit and / or prevent tumor growth, promote tumor regression, induce tumor cell apoptosis, reduce tumor angiogenesis, and / or prevent metastasis. When administered for preventing a disease, the amount is sufficient to avoid or delay onset of the disease. The "therapeutically effective amount" will vary depending on the compound, its therapeutic index, solubility, the disease and its severity and the age, weight, etc., of the patient to be treated, and the like. For example, certain compounds discovered by the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit / risk ratio applicable to such treatment. Administration of a therapeutically effective amount of a compound may require the administration of more than one dose of the compound. As used herein, the terms “administer”, “administering” or “administration” include any method of delivery of a pharmaceutical composition or agent into a subject's system or to a particular region in or on a subject. In certain embodiments, the agent is delivered orally. In certain embodiments, the agent is administered parenterally. In certain embodiments, the agent is delivered topically including transmucosally. In certain embodiments, the agent is delivered by inhalation. In certain embodiments of the invention, an agent is administered by parenteral delivery, including, intravenous, intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections. In one embodiment, the compositions provided herein may be administered by injecting directly to a tumor. In some embodiments, the agent is delivered by injection or infusion. In certain embodiments, administration is systemic. In certain embodiments, administration is local. In some embodiments, one or more routes of administration may be combined, such as, 82 ME150647165v.1 130090-01720 for example, intravenous and intratumoral, or intravenous and peroral, or intravenous and oral, intravenous and topical, or intravenous and transdermal or transmucosal. Administering an agent can be performed by a number of people working in concert. Administering an agent includes, for example, prescribing an agent to be administered to a subject and / or providing instructions, directly or through another, to take a specific agent, either by self-delivery, e.g., as by oral delivery, subcutaneous delivery, intravenous delivery through a central line, etc.; or for delivery by a trained professional, e.g., intravenous delivery, intramuscular delivery, intratumoral delivery, etc. As used herein, the term “subject” refers to human and non-human animals, including veterinary subjects. The term “non-human animal” includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, mice, rabbits, sheep, dog, cat, horse, cow, chickens, amphibians, and reptiles. In a preferred embodiment, the subject is a human and may be referred to as a patient. The recitation of a listing of chemical group(s) in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein including, but not limited to, combinations of dosing rates, dosing times, dosing amounts, treatment methods, monitoring methods, and selection methods. II. Methods of the Invention The present invention is based, at least in part, on the unexpected and surprising discovery that certain types of cancers are more sensitive to DHX9 inhibition, in particular, DNA damage repair deficient (DDRD) cancers, e.g., homologous recombination deficient (HRD) cancers, including cancers having a BRCA loss of function or alteration. The inventors of the present invention have demonstrated, both in vitro and in vivo, that breast, ovarian, colorectal, pancreatic, prostate, gastric and uterine cancers having a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., homologous recombination repair, e.g., a loss of function or alteration in the BRCA1 / 2 genes, were particularly responsive to DHX9 inhibitor treatment, with robust and significant tumor growth inhibition and / or regression observed in multiple tumor models. 83 ME150647165v.1 130090-01720 Accordingly, the present invention provides methods of treating a DNA damage repair deficient (DDRD) cancer, methods of treating a homologous recombination deficient (HRD) cancer, and / or methods of treating a cancer having a BRCA loss of function or alteration in a subject by administering to the subject a DHX9 inhibitor. DNA Damage Repair Deficient (DDRD) Cancer The present invention provides methods of treating a DDRD cancer in a subject, e.g., a subject in need thereof, by administering to the subject a DHX9 inhibitor. In some embodiments, the method further comprises identifying and / or selecting a subject determined as having a DDRD cancer for treatment. In some embodiments, the method comprises identifying and / or selecting a subject determined as having a DDRD cancer, and administering a DHX9 inhibitor to the subject. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes involved in a DNA damage repair pathway selected from the group consisting of base excision repair (BER), homologous recombination (HR) repair, non- homologous end joining (NHEJ) repair, or nucleotide excision repair (NER). In some embodiments, the DDRD cancer consists of a loss of function or alteration in one or more genes involved in a DNA damage repair pathway selected from the group consisting of base excision repair (BER), homologous recombination (HR) repair, non- homologous end joining (NHEJ) repair, or nucleotide excision repair (NER). Any appropriate methods or techniques can be used to determine whether or not a subject has a loss of function or alteration in one or more genes involved in a DNA damage repair pathway. As used herein, a “loss of function” or “alteration” in a gene refers to a change or modification or a difference in the sequence of at least one copy (either copy or both copies) of a gene relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non-cancerous cells in the subject), such as, the presence, absence, or extent / level of some physical, chemical, or genetic characteristic of a gene or its expression product(s) that is cancer-predictive. Such characteristics include, but are not limited to, mutations (e.g., single nucleotide variants, small insertions and deletions (indels), or large deletions and duplications), copy number variants (CNV) (e.g., copy number loss, or copy number gain), and methylation (e.g., promoter methylation) in the gene. Loss of function or alteration in a gene involved in a DNA damage repair pathway may be assayed directly (e.g., by assaying a gene's expression level) or determined indirectly (e.g., assaying the level of a gene or genes whose expression level is correlated to the expression 84 ME150647165v.1 130090-01720 level of the gene of interest). Those skilled in the art are familiar with various techniques for determining the status of a gene or protein including, but not limited to, whole genome or gene- specific sequencing, locus-specific genotyping (e.g., SNP arrays), large-rearrangement analysis, CNV analysis, microarray mRNA expression analysis, quantitative real-time PCR (qRT-PCR, e.g., TaqMan), immunoanalysis (e.g., ELISA, immunohistochemistry), etc. The methods of the invention may be practiced independent of the particular technique used. In some embodiments, multiple techniques are used to confirm the status of the genes. In some embodiments, a subject (e.g., a human) can be identified as having a loss of function or alteration in one or more genes involved in a DNA damage repair pathway using standard diagnostic techniques. Genetic tests are available, and known by those of skill in the art. Single nucleotide variants and small insertions and deletions (indels) may be identified by polymerase chain reaction (PCR) and nucleotide sequencing. Large deletions and duplications in the genes may be detected using multiplex PCR. In some embodiments, gene mutations can be detected using next generation sequencing methods, e.g., the Foundation One Liquid CDx test approved for detecting gene alterations. In some embodiments, a loss of function or alteration in one or more genes involved in a DNA damage repair pathway comprises a loss-of-function mutation. In some embodiments, a loss-of-function mutation can be a germline mutation, which indicates it was inherited from one or both parents. Germline mutations affect every cell in an organism and are passed on to offspring. In some embodiments, a loss-of-function mutation can also be acquired during one's lifetime, i.e. spontaneously arising in any cell in the body at any time during the patient's life, (i.e., non-inherited), which is referred to herein as a sporadic mutation or a somatic mutation. A subject is identified to have a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., a loss-of-function mutation, if, at least in some cases, a mutation is present in at least one copy of a gene. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., a loss-of-function mutation, if the subject has been determined to contain a mutation in the gene. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., a loss-of-function mutation, if the subject has a germline mutation and / or a somatic mutation. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., a loss-of-function mutation, if the subject has been determined to have a reduced expression of the gene. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in 85 ME150647165v.1 130090-01720 a DNA damage repair pathway if the mRNA expression level, methylation level or other epigenetic modification of the gene is altered relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non-cancerous cells in the subject). In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a blood sample of a subject. In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a saliva sample of a subject. In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a cell sample inside the cheek of a subject. In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a tumor sample of a subject. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in homologous recombination (HR) repair. In some embodiments, the one or more genes involved in HR repair is selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the DDRD cancer comprises a BRCA1 / 2 loss of function or alteration, e.g., a BRCA1 and / or a BRCA2 loss-of-function mutation. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in non- homologous end joining (NHEJ) repair. In some embodiments, the one or more genes involved in NHEJ is selected from the group consisting of PRKDC, DCLRE1C, XRCC5, LIG4, XRCC4, XRCC6, WRN, APLF, and NHEJ1. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in nucleotide excision repair (NER). In some embodiments, the one or more genes involved in NER is selected from the group consisting of XPC, RAD23B, ERCC5, ERCC4, ERCC2, ERCC1, CETN2, DDB1, DDB2, ERCC3 and XPA. In some embodiments, the DDRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in base excision repair (BER). In some embodiments, the one or more genes involved in BER is selected from 86 ME150647165v.1 130090-01720 the group consisting of LIG3, PARP1, PARP2, PNKP, PARG, FEN1, XRCC1, LIG1, PCNA, APEX2, APEX1, OGG1, NTH1, UNG, NEIL1, NEIL2, NEIL3, MYH, MPC and APTX. In some embodiments, the subject is determined to have a DDRD cancer based on the presence of a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, selected from the group consisting of LIG3, PARP1, PARP2, PNKP, PARG, FEN1, XRCC1, LIG1, PCNA, APEX2, APEX1, OGG1, NTH1, UNG, NEIL1, NEIL2, NEIL3, MYH, MPC, APTX, BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, FANCG, PRKDC, DCLRE1C, XRCC5, LIG4, XRCC4, XRCC6, WRN, APLF, NHEJ1 XPC, RAD23B, ERCC5, ERCC4, ERCC2, ERCC1, CETN2, DDB1, DDB2, ERCC3 and XPA. In some embodiments, the DDRD cancer is selected from the group consisting of a DDRD breast cancer, a DDRD colorectal cancer, a DDRD gastric cancer, a DDRD uterine cancer, a DDRD ovarian cancer, a DDRD prostate cancer, and a DDRD pancreatic cancer. In some embodiments, the DDRD cancer is a DDRD breast cancer. In some embodiments, the DDRD breast cancer is triple-negative breast cancer. In some embodiments, the DDRD cancer is a DDRD colorectal cancer. In some embodiments, the DDRD cancer is a DDRD gastric cancer. In some embodiments, the DDRD cancer is a DDRD uterine cancer. In some embodiments, the DDRD cancer is a DDRD ovarian cancer. In some embodiments, the DDRD ovarian cancer is high-grade serous ovarian cancer. In some embodiments, the DDRD cancer is a DDRD pancreatic cancer. In some embodiments, the DDRD cancer is a DDRD prostate cancer. In some embodiments, the DDRD cancer is a microsatellite stable (MSS) cancer. In some embodiments, the DDRD cancer is not a microsatellite instable (MSI) cancer. In some embodiments, the DDRD cancer is a microsatellite instable (MSI) cancer. In some embodiments, the DDRD cancer is mismatch repair proficient and / or does not comprise a cancer defective in mismatch repair. In some embodiments, the DDRD cancer is not a microsatellite instable cancer and is not a mismatch repair defective cancer. In some embodiments, the DDRD cancer is a microsatellite stable cancer and is a mismatch repair proficient cancer. In some embodiments, the DDRD colorectal cancer is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer. In some embodiments, the DDRD colorectal cancer is a microsatellite stable colorectal cancer and is a mismatch repair 87 ME150647165v.1 130090-01720 proficient colorectal cancer. In some embodiments, the DDRD colorectal cancer comprises a loss of function or alteration in one or more genes involved in a repair pathway selected from the group consisting of base excision repair (BER), nucleotide excision repair (NER), non- homologous end joining (NHEJ) repair, and homologous recombination (HR) repair. Microsatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy. In some embodiments, microsatellite instability is determined by PCR analysis of 5 different nucleotide repeats, which is dependent on the cancer type. (G. Yang, et al. J. Cancer Res. Clin. Oncol., 2019, 145(12): 2891-2899). In other embodiments, microsatellite instability is determined by next-generation sequencing (S.E. Trabucco, et al. J. Mol. Diagn. 2019, 21(6): 1053-1066). In some embodiments, microsatellite instable cancer is additionally characterized by defective mismatch repair (dMMR) (M. Lorenzi, et al. Journal of Oncology, Volume 2020, Article ID 1897929). For example, dMMR in colorectal cancer can be determined based on the level of promoter hypermethylation. Alternatively, dMMR can be determined by immunohistochemistry mutation status of MLH1, MSH2, MSH6, MSH3, PMS1 and / or PMS2 mismatch repair proteins. In some embodiments, the DDRD cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. Homologous Recombination Deficient (HRD) Cancer The present invention provides methods of treating a homologous recombination deficient (HRD) cancer in a subject, e.g., a subject in need thereof, by administering to the subject a DHX9 inhibitor. In some embodiments, the method further comprises identifying and / or selecting a subject determined as having an HRD cancer for treatment. In some embodiments, the method comprises identifying and / or selecting a subject determined as having an HRD cancer, and administering a DHX9 inhibitor to the subject. In some embodiments, the HRD cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the HRD cancer comprises a BRCA1 loss of function or alteration, e.g., a BRCA1 loss-of-function mutation. 88 ME150647165v.1 130090-01720 In some embodiments, the HRD cancer comprises a BRCA2 loss of function or alteration, e.g., a BRCA2 loss-of-function mutation. In one embodiment, the HRD cancer comprises a PALB2 loss of function or alteration. In one embodiment, the HRD cancer comprises an ATM loss of function or alteration In one embodiment, the HRD cancer comprises an ATR loss of function or alteration. In one embodiment, the HRD cancer comprises an MRE11 loss of function or alteration. In one embodiment, the HRD cancer comprises an NBN1 loss of function or alteration. In one embodiment, the HRD cancer comprises a BAP1 loss of function or alteration. In one embodiment, the HRD cancer comprises a BRIP1 loss of function or alteration. In one embodiment, the HRD cancer comprises an ARID1A loss of function or alteration. In one embodiment, the HRD cancer comprises a BLM loss of function or alteration. In one embodiment, the HRD cancer comprises a BARD1 loss of function or alteration. In one embodiment, the HRD cancer comprises a RAD50 loss of function or alteration. In one embodiment, the HRD cancer comprises a RAD51B loss of function or alteration. In one embodiment, the HRD cancer comprises a RAD51C loss of function or alteration. In one embodiment, the HRD cancer comprises a RAD54L loss of function or alteration. In one embodiment, the HRD cancer comprises a CDK12 loss of function or alteration. In one embodiment, the HRD cancer comprises a CHEK1 loss of function or alteration. In one embodiment, the HRD cancer comprises a CHEK2 loss of function or alteration. In one embodiment, the HRD cancer comprises a 53BP1 loss of function or alteration. In one embodiment, the HRD cancer comprises a FANCA loss of function or alteration. In one embodiment, the HRD cancer comprises a FANCD2 loss of function or alteration. In one embodiment, the HRD cancer comprises a FANCC loss of function or alteration. In one embodiment, the HRD cancer comprises a FANCE loss of function or alteration. In one embodiment, the HRD cancer comprises a FANCF loss of function or alteration. In one embodiment, the HRD cancer comprises a FANCG loss of function or alteration. Any appropriate methods or techniques can be used to determine whether or not a subject has a loss of function or alteration in one or more genes involved in a homologous recombination repair pathway. As used herein, a “loss of function” or “alteration” in a gene refers to a change or modification or a difference in the sequence of at least one copy (either copy or both copies) of a gene relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non-cancerous cells in the subject), such as, the 89 ME150647165v.1 130090-01720 presence, absence, or extent / level of some physical, chemical, or genetic characteristic of a gene or its expression product(s). Such characteristics include, but are not limited to, mutations (e.g., single nucleotide variants, small insertions and deletions (indels), or large deletions and duplications), copy number variants (CNV) (e.g., copy number loss, or copy number gain), and methylation (e.g., promoter methylation) in the gene. These may be assayed directly (e.g., by assaying a gene's expression level) or determined indirectly (e.g., assaying the level of a gene or genes whose expression level is correlated to the expression level of the gene of interest). Those skilled in the art are familiar with various techniques for determining the status of a gene or protein including, but not limited to, whole genome or gene-specific sequencing, locus-specific genotyping (e.g., SNP arrays), large-rearrangement analysis, CNV analysis, microarray mRNA expression analysis, quantitative real-time PCR (qRT-PCR, e.g., TaqMan), immunoanalysis (e.g., ELISA, immunohistochemistry), etc. The methods of the invention may be practiced independent of the particular technique used. In some embodiments, multiple techniques are used to confirm the status of the genes. In some embodiments, a subject (e.g., a human) can be identified as having a loss of function or alteration in one or more genes involved in homologous recombination repair using standard diagnostic techniques. Genetic tests are available, and known by those of skill in the art. Single nucleotide variants and small insertions and deletions (indels) may be identified by polymerase chain reaction (PCR) and nucleotide sequencing. Large deletions and duplications in the genes may be detected using multiplex PCR. In some embodiments, gene mutations can be detected using next generation sequencing methods, e.g., the Foundation One Liquid CDx test approved for detecting gene alterations. In some embodiments, a loss of function or alteration in one or more genes involved in homologous recombination repair comprises a loss-of-function mutation. In some embodiments, a loss-of-function mutation can be a germline mutation, which indicates it was inherited from one or both parents. Germline mutations affect every cell in an organism and are passed on to offspring. In some embodiments, a loss-of-function mutation can also be acquired during one's lifetime, i.e. spontaneously arising in any cell in the body at any time during the patient's life, (i.e., non-inherited), which is referred to herein as a sporadic mutation or a somatic mutation. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in homologous recombination repair, e.g., a loss-of-function mutation, if, at least in some cases, a mutation is present in at least one copy of a gene. In some 90 ME150647165v.1 130090-01720 embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in homologous recombination repair, e.g., a loss-of-function mutation, if the subject has been determined to contain a mutation in the gene. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in homologous recombination repair, e.g., a loss-of-function mutation, if the subject has a germline mutation and / or a somatic mutation. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in homologous recombination repair, e.g., a loss-of-function mutation, if the subject has been determined to have a reduced expression of the gene. In some embodiments, a subject is identified to have a loss of function or alteration in one or more genes involved in homologous recombination repair if the mRNA expression level, methylation level or other epigenetic modification of the gene is altered relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non-cancerous cells in the subject). In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a blood sample of a subject. In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a saliva sample of a subject. In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a cell sample inside the cheek of a subject. In some embodiments, the presence of a loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a tumor sample of a subject. In some embodiments, the HRD cancer is selected from the group consisting of an HRD breast cancer, an HRD DDRD colorectal cancer, an HRD gastric cancer, an HRD uterine cancer, an HRD ovarian cancer, an HRD prostate cancer, and an HRD pancreatic cancer. In some embodiments, the HRD cancer is an HRD breast cancer. In some embodiments, the HRD breast cancer is triple-negative breast cancer. In some embodiments, the HRD cancer is an HRD colorectal cancer. In some embodiments, the HRD cancer is an HRD gastric cancer. In some embodiments, the HRD cancer is an HRD uterine cancer. In some embodiments, the HRD cancer is an HRD prostate cancer. In some embodiments, the HRD cancer is an HRD pancreatic cancer. In some embodiments, the HRD cancer is an HRD ovarian cancer. In some embodiments, the HRD ovarian cancer is high-grade serous ovarian cancer. 91 ME150647165v.1 130090-01720 In some embodiments, an HRD cancer is proficient in MMR, i.e., the HRD cancer does not comprise a loss of function or alteration in a gene involved in MMR. In some embodiments, the HRD cancer is a microsatellite stable (MSS) cancer. In some embodiments, the HRD cancer is not a microsatellite instable (MSI) cancer. In some embodiments, the HRD cancer is a microsatellite instable (MSI) cancer. In some embodiments, the HRD cancer is not or does not comprise a microsatellite instable cancer and is not or does not comprise a mismatch repair defective cancer. In some embodiments, the HRD cancer is a microsatellite stable cancer and is a mismatch repair proficient cancer. In some embodiments, the HRD colorectal cancer is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer. In some embodiments, the HRD colorectal cancer is a microsatellite stable colorectal cancer and is a mismatch repair proficient colorectal cancer. Microsatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy. In some embodiments, microsatellite instability is determined by PCR analysis of 5 different nucleotide repeats, which is dependent on the cancer type. (G. Yang et al. J. Cancer Res. Clin. Oncol., 2019, 145(12): 2891-2899). In other embodiments, microsatellite instability is determined by next-generation sequencing (S.E. Trabucco et al. J. Mol. Diagn. 2019, 21(6): 1053-1066). In some embodiments, microsatellite instable cancer is additionally characterized by defective mismatch repair (dMMR) (M. Lorenzi, et al. Journal of Oncology, Volume 2020, Article ID 1897929). For example, dMMR in colorectal cancer can be determined based on the level of promoter hypermethylation. Alternatively, dMMR can be determined by immunohistochemistry mutation status of MLH1, MSH2, MSH6, MSH3, PMS1 and / or PMS2 mismatch repair proteins. In some embodiments, the HRD cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. BRCA Loss-of-Function Cancer The present invention also provides a method of treating a cancer having a BRCA loss of function or alteration in a subject, e.g., a subject in need thereof, by administering to the subject a DHX9 inhibitor. In some embodiments, the method further comprises identifying and / or selecting a subject determined as having a cancer having a BRCA loss of function or alteration for treatment. In some embodiments, the method comprises identifying and / or selecting a subject 92 ME150647165v.1 130090-01720 determined as having a cancer having a BRCA loss of function or alteration, and administering a DHX9 inhibitor to the subject. Any appropriate methods or techniques can be used to determine whether or not a subject has a BRCA loss of function. As used herein, “BRCA loss of function” or “BRCA alteration” refers to a change or modification or difference in the sequence of at least one copy (either copy or both copies) of either or both of the BRCA1 or BRCA2 genes relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non-cancerous cells in the subject), such as, the presence, absence, or extent / level of some physical, chemical, or genetic characteristic of a gene or its expression product(s) that is cancer- predictive. Such characteristics include, but are not limited to, mutations (e.g., single nucleotide variants, small insertions and deletions (indels), or large deletions and duplications), copy number variants (CNV) (e.g., copy number loss, or copy number gain), methylation (e.g., promoter methylation) in one or both BRCA genes, expression levels, or activity levels. These may be assayed directly (e.g., by assaying a gene's expression level) or determined indirectly (e.g., assaying the level of a gene or genes whose expression level is correlated to the expression level of the gene of interest). Those skilled in the art are familiar with various techniques for determining the status of a gene or protein including, but not limited to, whole genome or gene-specific sequencing, locus-specific genotyping (e.g., SNP arrays), large- rearrangement analysis, CNV analysis, microarray mRNA expression analysis, quantitative real-time PCR (qRT-PCR, e.g., TaqMan), immunoanalysis (e.g., ELISA, immunohistochemistry), etc. The methods of the invention may be practiced independent of the particular technique used. In some embodiments, multiple techniques are used to confirm the status of BRCA genes. In some embodiments, a subject (e.g., a human) can be identified as having a BRCA loss of function or alteration using standard diagnostic techniques. Genetic tests are available, and known by those of skill in the art. For example, the BRACAnalysis CDx® kit is an in vitro diagnostic for detection and classification of BRCA1 / 2 variants. Using isolated genomic DNA, the BRACAnalysis CDx identifies mutations in the protein coding regions and intron / exon boundaries of the BRCA1 and BRCA2 genes. Single nucleotide variants and small insertions and deletions (indels) may be identified by polymerase chain reaction (PCR) and nucleotide sequencing. Large deletions and duplications in BRCA1 and BRCA2 may be detected using multiplex PCR. In some embodiments, the BRCA1 and BRCA2 mutations can be detected using next generation sequencing methods, e.g., the Foundation One Liquid CDx test approved for detecting BRCA1 and BRCA2 alterations. 93 ME150647165v.1 130090-01720 In some embodiments, a BRCA loss of function or alteration comprises a BRCA1 / 2 loss- of-function mutation. In some embodiments, a BRCA loss-of-function mutation can be a germline BRCA mutation, which indicates it was inherited from one or both parents. Germline mutations affect every cell in an organism and are passed on to offspring. In some embodiments, a BRCA loss-of-function mutation can also be acquired during one's lifetime, i.e. spontaneously arising in any cell in the body at any time during the patient's life, (i.e., non- inherited), which is referred to herein as a sporadic BRCA mutation or a somatic BRCA mutation. A subject is identified to have a BRCA loss of function or alteration, e.g., a BRCA loss- of-function mutation, if, at least in some cases, a mutation is present in at least one copy of either BRCA1 or BRCA2. In some embodiments, a subject is identified to have a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation, if the subject has been determined to contain a mutation in BRCA1 and / or BRCA2. In some embodiments, a subject is identified to have a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation, if the subject has a germline BRCA mutation and / or a somatic BRCA mutation. In some embodiments, a subject is identified to have a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation, if the subject has been determined to have a reduced expression of BRCA1 and / or BRCA2. In some embodiments, a subject is identified to have a BRCA loss of function or alteration if the mRNA expression level, methylation level or other epigenetic modification of either or both of BRCA1 and BRCA2 is altered relative to an appropriate reference sequence (e.g., a wild type reference and / or a sequence that is present in non- cancerous cells in the subject). In some embodiments, the presence of a BRCA loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a blood sample of a subject. In some embodiments, the presence of a BRCA loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a saliva sample of a subject. In some embodiments, the presence of a BRCA loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a cell sample inside the cheek of a subject. In some embodiments, the presence of a BRCA loss-of-function mutation (e.g., a germline mutation and / or a somatic mutation) is determined based on a tumor sample of a subject. In some embodiments, the cancer having a BRCA loss of function or alteration is selected from the group consisting of an ovarian cancer having a BRCA loss of function or alteration; a breast cancer having a BRCA loss of function or alteration; a colorectal cancer 94 ME150647165v.1 130090-01720 having a BRCA loss of function or alteration, a prostate cancer having a BRCA loss of function or alteration, and a pancreatic cancer having a BRCA loss of function or alteration. In some embodiments, the cancer is an ovarian cancer having a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation. In some embodiments, the ovarian cancer having a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation, is high- grade serous ovarian cancer. In some embodiments, the cancer is a breast cancer having a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation. In some embodiments, the breast cancer having a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation, is triple- negative breast cancer. In some embodiments, the cancer is a colorectal cancer having a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation. In some embodiments, the cancer is a pancreatic cancer having a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation. In some embodiments, the cancer is a prostate cancer having a BRCA loss of function or alteration, e.g., a BRCA loss-of-function mutation. In some embodiments, the cancer having a BRCA loss of function or alteration is a microsatellite stable cancer. In some embodiments, the cancer having a BRCA loss of function or alteration is not or does not comprise a microsatellite instable cancer. In some embodiments, the cancer having a BRCA loss of function or alteration is a microsatellite instable cancer. In some embodiments, the cancer having a BRCA loss of function or alteration is mismatch repair proficient and / or does not comprise a cancer defective in mismatch repair. In some embodiments, the cancer having a BRCA loss of function or alteration is not a microsatellite instable cancer and is not a mismatch repair defective cancer. In some embodiments, the cancer having a BRCA loss of function or alteration is a microsatellite stable cancer and is a mismatch repair proficient cancer. In some embodiments, the colorectal cancer having a BRCA loss of function or alteration is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer. In some embodiments, the colorectal cancer having a BRCA loss of function or alteration is a microsatellite stable colorectal cancer and is a mismatch repair proficient colorectal cancer. In some embodiments, the cancer having a BRCA loss of function or alteration is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. 95 ME150647165v.1 130090-01720 Triple negative breast cancer In one aspect, the present invention provides methods of treating triple negative breast cancer (TNBC) in a subject, e.g., a subject in need thereof, by administering to the subject a DHX9 inhibitor. In some embodiments, the method further comprises identifying and / or selecting a subject determined as having TNBC for treatment. In some embodiments, the method comprises identifying and / or selecting a subject determined as having TNBC, and administering a DHX9 inhibitor to the subject. As used herein, the term “breast cancer” refers those types of cancer that originate in breast tissue. Breast cancer can begin with tumor growth in the milk duct (ductal carcinoma) or milk gland (lubular carcinoma). Invasive breast cancer can spread to the surrounding normal tissue and metastasize to a distant site. Patients with breast cancer have a much higher survival rate if the cancer is diagnosed at an earlier stage. About 70-80% of patients with early-stage, non-metastatic disease are curable, while advanced breast cancer with distant organ metastases is considered incurable with currently available therapies. Breast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors (ER and PR, respectively) and human epidermal growth factor 2 (ERBB2, formerly HER2). The subtypes determine which systemic therapy a patient receives (endocrine therapy, chemotherapy, antibody therapy, small-molecule therapy, or a combination) in addition to surgical resection and radiation options (Waks and Winer (2019) JAMA. 321(3):288-300). As used herein, the term “triple negative breast cancer (TNBC)” refers to a breast cancer characterized as estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and human epidermal growth factor receptor-2-negative (Herr2 / Neu-negative). The determination of negative status of the estrogen receptor, progesterone receptor, and Her2 / neu expression is readily determined by one of skill in the art, e.g., in accordance with the current accepted guidelines. For example, guidelines set forth by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) are widely accepted. The ASCO / CAP recommends testing by immunohistochemistry (IHC) or in situ hybridization (ISH) techniques. Further, a cancer is Her2 negative if a single test (or all tests) performed on a tumor specimen show: (a) IHC negative, IHC 1+ or IHC 0, or (b) ISH negative using single- probe ISH or dual-probe ISH. One of skill in the art would recognize that the triple negative 96 ME150647165v.1 130090-01720 cancer described herein does not include any cancer having an apparent histopathologic discordance as observed by the pathologist. (Wolff, A C et al. J Clin Oncol. 2013 Nov. 1:31(31):3997-4013). Cancer is ER-negative or PR-negative if <1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PR (positive intrinsic controls are seen). In some embodiments, the TNBC cancer comprises a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., a loss-of-function mutation, in one or more genes involved in a DNA damage repair pathway selected from the group consisting of base excision repair (BER), homologous recombination (HR) repair, non- homologous end joining (NHEJ) repair, and nucleotide excision repair (NER). In some embodiments, the TNBC cancer comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, involved in HR repair. In some embodiments, the TNBC comprises a loss of function or alteration in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the TNBC cancer comprises a BRCA loss of function or alteration, e.g., a BRCA1 / 2 loss-of-function mutation. Any appropriate method can be used to determine whether or not a subject has TNBC. For example, a subject (e.g., a human) can be identified as having TNBC using standard diagnostic techniques, e.g., breast exam, imaging tests (e.g., mammogram, ultrasound, MRI scans), blood tests, biopsy, or genetic testing. In some cases, a tissue biopsy can be collected and analyzed for the amount of estrogen receptor, epidermal growth factor receptor 2, and progesterone receptor expressed by cancer cells by immunohistochemistry or in situ hybridization to determine whether or not a subject has TNBC. In some embodiments, the TNBC is a microsatellite stable cancer. In some embodiments, the TNBC is not a microsatellite instable cancer. In some embodiments, the TNBC is a microsatellite instable cancer. In some embodiments, the TNBC is mismatch repair proficient and / or does not comprise a cancer defective in mismatch repair. In some embodiments, the TNBC is not a microsatellite instable cancer and is not a mismatch repair defective cancer. In some embodiments, the TNBC is a microsatellite stable cancer and is a mismatch repair proficient cancer. 97 ME150647165v.1 130090-01720 In some embodiments, the TNBC is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. High-grade serous ovarian cancer In one aspect, the present invention provides methods of treating a high-grade serous ovarian cancer (HGSOC) in a subject, e.g., a subject in need thereof, by administering to the subject a DHX9 inhibitor. In some embodiments, the method further comprises identifying and / or selecting a subject determined as having HGSOC for treatment. In some embodiments, the method comprises identifying and / or selecting a subject determined as having HGSOC, and administering a DHX9 inhibitor to the subject. As used herein, the term “ovarian cancer” refers to those types of cancers that originate in tissues of the ovary (one of a pair of female reproductive glands in which the ova, or eggs, are formed). Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells). Among the ovarian cancers, high-grade serous ovarian cancer (HGSOC), also known as high- grade serous carcinoma (HGSC), or high-grade pelvic (nonuterine) serous carcinoma, is the most common and deadliest ovarian cancer type, and accounts for over 70% of ovarian cancer cases and deaths. In some embodiments, the HGSOC cancer comprises a loss of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., a loss-of-function mutation, in one or more genes involved in a DNA damage repair pathway selected form the group consisting of base excision repair (BER), homologous recombination (HR) repair, non- homologous end joining (NHEJ) repair, or nucleotide excision repair (NER). In some embodiments, the HGSOC cancer comprises a loss of function or alteration in one or more genes involved in HR repair. In some embodiments, the HGSOC comprises a loss of function or alteration in one or more genes, e.g., two or more genes, or three or more genes, selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG. In some embodiments, the HGSOC cancer comprises a BRCA loss of function or alteration, e.g., a BRCA1 / 2 loss-of-function mutation. 98 ME150647165v.1 130090-01720 Any appropriate method can be used to determine whether or not a subject has HGSOC. For example, a subject (e.g., a human) can be identified as having HGSOC using standard diagnostic techniques, e.g., pelvic exam, imaging tests (e.g., ultrasound, CT scans, MRI scans, or PET scan), blood tests, colonoscopy, biopsy, or genetic testing. In some embodiments, the HGSOC is a microsatellite stable cancer. In some embodiments, the HGSOC is not a microsatellite instable cancer. In some embodiments, the HGSOC is a microsatellite instable cancer. In some embodiments, the HGSOC is mismatch repair proficient and / or does not comprise a cancer defective in mismatch repair. In some embodiments, the HGSOC is not a microsatellite instable cancer and is not a mismatch repair defective cancer. In some embodiments, the HGSOC is a microsatellite stable cancer and is a mismatch repair proficient cancer. In some embodiments, the HGSOC is not a cancer having mutations or defects in RNA splicing and the kinetochore complex. The DHX9 inhibitors can be administered to a subject in any appropriate amount, at any appropriate frequency, and for any appropriate duration effective to achieve a desired outcome. In some embodiments, administration of the DHX9 inhibitor results in one or more of, reducing tumor size, weight or volume, reducing progression grade, increasing time to progression or delaying progression, inhibiting tumor growth, inducing tumor regression, and / or prolonging the survival time of a subject in need thereof. In certain embodiments, administration of the DHX9 inhibitor reduces tumor size, weight or volume, reduces progression grade, increases time to progression or delays progression, inhibits tumor growth, induces tumor regression, and / or prolongs the survival time of the subject by at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400% or 500% relative to a corresponding control subject that is not administered the DHX9 inhibitor. For example, the progression rate can be reduced such that no additional cancer progression is detected and / or tumor size and / or volume is reduced following treatment. Any appropriate method can be used to determine whether or not the progression rate of a cancer is reduced. For example, the progression rate of a cancer can be assessed by imaging tissue at different time points and determining the amount of cancer cells present. The amounts of cancer cells determined within tissue at different times can be compared to determine the progression rate. After treatment as described herein, the 99 ME150647165v.1 130090-01720 progression rate can be determined again over another time interval. In some cases, the stage of cancer (e.g., triple-negative breast cancer, or high-grade serous ovarian cancer) after treatment can be determined and compared to the stage before treatment to determine whether or not the progression rate was reduced. In some cases the overall survival of the subjects is improved. Efficaciousness of treatment is determined in association with any known method for diagnosing or treating the particular disorder. In some embodiments, administration of a DHX9 inhibitor to a patient may be considered successful if any of a variety of laboratory or clinical objectives is achieved. For example, administration of a DHX9 inhibitor to a patient suffering from cancer may be considered successful if one or more of the symptoms associated with the disease or disorder is alleviated, reduced, inhibited or does not progress to a further, i.e., worse, state. Administration of a DHX9 inhibitor to a patient suffering from cancer may be considered successful if the disease or disorder enters remission or does not progress to a further, i.e., worse, state. In some embodiments, the DHX9 inhibitor is administered to a subject in an amount effective to inhibit the expression and / or activity of DHX9 in a cell within the subject. In some embodiments, the DHX9 inhitor is administered to a subject in a therapeutically effective amount. A “therapeutically effective amount” means the amount of a compound that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease, e.g., the amount of such a substance that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment, e.g., is sufficient to ameliorate at least one sign or symptom of the disease, e.g., to prevent and / delay progression of the disease or condition, e.g., reduce tumor volume, weight or size, inhibit and / or prevent tumor growth, promote or induce tumor regression, induce tumor cell apoptosis, reduce tumor angiogenesis, or prevent metastasis. When administered for preventing a disease, the amount is sufficient to avoid or delay onset of the disease. The "therapeutically effective amount" of a DHX9 inhibitor will vary depending on the compound, its therapeutic index, solubility, the disease and its severity state, the age, weight, sex, etc., of the patient to be treated, and the like. For example, certain compounds discovered by the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit / risk ratio applicable to such treatment. Administration of a therapeutically effective amount of a compound may require the administration of more than one dose of the compound. In some embodiments, the therapeutically effective amount can be between 10 μg and 500 mg. 100 ME150647165v.1 130090-01720 One skilled in the art would be able, by routine experimentation with the guidance provided herein, to determine what an effective, non-toxic amount of a DHX9 inhibitor would be for the purpose of treating cancer. For example, a therapeutically active amount of DHX9 inhibitor may vary according to factors such as the disease stage (e.g., stage I versus stage IV), age, sex, medical complications (e.g., immunosuppressed conditions or diseases, coagulopathies) and weight of the subject, and the ability of the DHX9 inhibitor to elicit a desired response in the subject. The dosage regimen may be adjusted to provide the optimum therapeutic response. III. DHX9 Inhibitors for Use in the Methods of the Invention The present invention further provides DHX9 inhibitors for use in the methods of the present invention, e.g., methods of treating a DNA damage repair deficient (DDRD) cancer, e.g., a homologous recombination repair deficient (HRD) cancer, including in particular a cancer having a BRCA loss of function or alteration, e.g., having a BRCA loss-of-function mutation. DHX9, also known as RNA Helicase A (RHA) or Nuclear DNA Helicase II (NDH II), is a DExH-box RNA helicase, which shuttles between nucleus and cytoplasm, and can use all four NTPs to power cycles of directional movement from 3’ to 5’. Functionally, DHX9 can bind to and unwind or resolve dsDNA / RNA, ssDNA / RNA, DNA:RNA hybrids (such as R- loops), circular RNA, and DNA / RNA G quadruplexes. As such, DHX9 has regulatory roles in various RNA and DNA related cellular processes, such as transcription, translation, RNA splicing, editing, RNA transport and processing, microRNA genesis, and maintenance of genomic stability (Pan et al., 2021, Current Protein & Peptide Science (22), 29-40). Due to its regulatory role in processes such as transcription and maintenance of genomic stability, DHX9 has shown to be a key regulator in a variety of cancer types (Gulliver et al., 2020, Future Science OA (2), FSO650). DHX9 has been shown to be involved in the regulation of genes associated with sustained proliferative signaling, evasion of growth suppressors, evasion of apoptosis, angiogenesis, and metastasis, all of which are hallmarks of cancer. Specifically, as demonstrated in the present disclosure, certain types of cancer are particularly sensitive to DHX9 inhibition, e.g., DNA damage repair deficient (DDRD) cancers, e.g., homologous recombination repair deficient (HRD) cancers, including in particular cancers having a BRCA loss of function or alteration, e.g., a BRCA1 / 2 loss-of-function mutation. The inventors of the present invention have unexpectedly demonstrated, both in vitro and in vivo, that breast, ovarian, colorectal, pancreatic, prostate, gastric and uterine cancers having a loss 101 ME150647165v.1 130090-01720 of function or alteration in one or more genes involved in a DNA damage repair pathway, e.g., homologous recombination repair, e.g., a loss of function or alteration in the BRCA1 / 2 genes, were particularly responsive to DHX9 inhibitor treatment, with robust and significant tumor growth inhibition and regression observed in multiple tumor models. In some embodiments, the DHX9 inhibitor is a DHX9 inhibitor known in the art. In some embodiment, the DHX9 inhibitor is a compound as disclosed in WO2023 / 154519 or WO2023 / 158795, the entire contents of both of which are incorporated herein by reference. In a first embodiment, the DHX9 inhibitor is a compound having the Formula I: or a pharmaceutically acceptable salt thereof, wherein: X is halo; Y is O or NRy; Ryis H or C1-4alkyl; R1is C1-4alkyl or C3-6cycloalkyl; wherein the C1-4alkyl or C3-6cycloalkyl are each optionally and independently substituted with 1 to 3 halo or -OH, Ring A is a C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10 membered bicyclic heterocyclyl; phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10- membered bicyclic heteroaryl; m is 0 to 3; n is 0 or 2; each R2is independently selected from C1-4alkyl, C3-6cycloalkyl, halo, OR2a, cyano, - NR2bR2c, -SO2R2a, -C(O)R2d, and –C(O)NR2bR2cwherein the C1-4alkyl and C3-6cycloalkyl are optionally substituted with 1 to 4 R2e; or 2 R2together form oxo; R2ais H, C1-4alkyl, C1-4haloalkyl or C1-4alkoxyC1-4alkyl; R2dis H, C1-4alkyl, C3-6cycloalkyl, OR2a, phenyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 8-membered bicyclic heterocyclyl, or 5 to 6-membered monocyclic heteroaryl, wherein the C1-4alkyl is optionally substituted with 1 to 3 halo and the 5- to 6- membered monocyclic heteroaryl is optionally substituted with 1 to 3 C1-4alkyl, C1-4haloalkyl, or phenyl; 102 ME150647165v.1 130090-01720 R2band R2care each independently selected from H, C1-4alkyl, C3-6cycloalkyl, phenyl, 4 to 6-membered monocyclic heterocyclyl and 5 to 6-membered monocyclic heteroaryl, wherein the C1-4alkyl is optionally substituted with 1 to 3 substituents independently selected from halo and C1-3alkoxy; or R2band R2c, together with the nitrogen to which they are attached form a 4 to 6 membered monocyclic heterocyclyl or 6 to 10 membered bicyclic heterocyclyl; wherein the 4 to 6 membered monocyclic heterocyclyl or 6 to 10 membered bicyclic heterocyclyl are each optionally substituted with 1 to 3 R2d; each R2eis independently selected from halo, cyano, NR2bR2c, OR2a, phenyl, and 4 to 6 membered monocyclic heterocyclyl; Z is a bond, -CH2-, -O-, -O-C1-4alkylene-*, -C1-4alkylene-O-*, -C(O)-, -C(O)O-*, - OC(O)-*, -S(O)2-, -S(O)2N(Za)-*, -N(Za)S(O)2-*, -N(Za)-, -N(Za)-C1-4alkylene-*, -C1- 4alkylene-N(Za)-*, -C(O)N(Za)-*, -N(Za)C(O)-*, or -C(O)N(Za)-C1-3alkylene-*, wherein * indicates the attachment point to R3; Zais H or C1-4alkyl; R3is C3-6cycloalkyl, 7 to 10-membered bicyclic carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10-membered bicyclic heteroaryl, wherein the C3-6cycloalkyl, 7 to 10-membered bicyclic carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10- membered bicyclic heterocyclyl, phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10- membered bicyclic heteroaryl are each optionally and independently substituted with 1 to 4 R4; each R4is independently selected from C1-4alkyl, C2-4alkenyl, C2-4alkynyl, halo, OR4a, cyano, -NR4bR4c, -C(O)R4a, -C(O)OR4a, -C(O)NR4bR4c, -NR4bC(O)R4a-NR4bC(O)OR4a, , - NR4bSO2R4a, -SR4a, -S(O)R4a, -SO2R4a, SO2NR4bR4c, -P(O)R4bR4c, phenyl, 5 to 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocyclyl, and 6 to 10-membered bicyclic heterocyclyl, wherein the C1-4alkyl, C2-4alkenyl, or C2-4alkynyl is optionally substituted with 1 to 4 R4d, and wherein the phenyl, 5 to 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocyclyl and 6 to 10-membered bicyclic heterocyclyl are each optionally substituted with 1 to 3 R4eand further optionally substituted with 1 or 2 oxo; or two R4together form oxo; R4ais H, C1-4alkyl optionally substituted with 1 to 4 R4d, -NR4bR4c, C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, phenyl, or 5 to 6-membered monocyclic heteroaryl; wherein the C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 to 3 R4e; 103 ME150647165v.1 130090-01720 R4band R4care each independently selected from H, phenyl, 4 to 6-membered monocyclic heterocyclyl, 5 to 6-membered monocyclic heteroaryl, and C1-4alkyl optionally substituted with 1 to 4 R4d; or R4band R4ctogether with the nitrogen atom to which they are attached to form a 4 to 6-membered monocyclic heterocyclyl; each R4dis independently selected from halo, OR4f, -C(O)C1-4alkyl, -C(O)NR4bR4c, - C(O)C1-4haloalkyl, -C(O)OR4f, -NR4bR4c, phenyl, and 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered mon ocyclic heteroaryl are each optionally substituted with 1 to 3 R4g; each R4eis independently selected from halo, C1-4alkyl, cyano, OR4f, -NR4bR4c, -C(O)H, -C(O)R4h, -SO2C1-3alkyl, and -C(O)NR4bR4c, wherein C1-4alkyl is optionally substituted with 1 to 3 substitutes independently selected from halo, -SO2C1-3alkyl and -C(O)NR4bR4c; and - C(O)NR4bR4c; or two R4etogether form oxo; R4fis H, C1-4alkyl, C1-4haloalkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with one to three halo; each R4gis independently selected from halo, OR4f, C1-4alkyl, C1-4haloalkyl, halo, cyano, -NR4bR4c, -C(O)H, and -C(O)OR4f; and each R4his independently C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy or –N(R4b)2. In a second embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, X is Cl, Br, or F; and the remaining variables are as described in the first embodiment. In a third embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, X is Cl or Br; and the remaining variables are as described in the first embodiment. In a fourth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, X is Cl; and the remaining variables are as described in the first embodiment. In a fifth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazoyl, furanyl, isothiazoyl, thiazoyl, imidazoyl, cyclobutyl, benzofuranyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, imidazo[1,2-a]pyridin-6-yl, 1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 2-oxo-2,3-dihydro-1H-imidazolyl, indolizinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-c]pyrimidinyl, pyrrolo[1,2-a]pyraziny, 5,6-dihydro- 4H-cyclopenta[b]thiophenyl, 5-oxo-5H-thiazolo[3,2-a]pyridinyl, thieno[3,2-b]pyridinyl, 104 ME150647165v.1 130090-01720 thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, benzothiophenyl, thieno[3,2-d]pyrimidinyl, pyrrolo[1,2-b]pyridazinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-b] pyrimidinyl, pyrrolo[1,2-c]pyrimidinyl, 1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazinyl, pyrrolo[2,1-f][1,2,4]triazinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, 5,6-dihydro-4H- cyclopenta[b]thiophenyl, and 4,7-dihydro-5H-thieno[2,3-c]pyranyl; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a sixth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is represented by the ; each of which is substituted with 0 to 2 R2and 0 to 1 Z-R3; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a seventh embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is represented by the 105 ME150647165v.1 130090-01720 106 ME150647165v.1 130090-01720 are as described in the first, second, third, or fourth embodiment. In an eighth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazoyl, and imidazolyl; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a ninth embodiment, for the compound of Formula (I) described in the first substituted with 0 to 1 R2and 1 R3; and the remaining variables are as described in the first, second, third, or fourth embodiment. In a tenth embodiment, for the compound of Formula (I) described in the first aspect or in the first embodiment, or a pharmaceutically acceptable salt thereof, ring A is described in the first, second, third, or fourth embodiment. In an eleventh embodiment, for the compound of Formula (I) described in first aspect or the first embodiment, R2is selected from –OCH3, cyclopropyl, -CH3, -CF3, -CH2CH3, - CH(CH3)2, -CH(OH)CH3, -C(CH3)2OH, -CH2OCH3, -CH2OH, -CH2CF3, -CH2CH2OH, - CH2CH2CH2OH, -CH2CN, -CH2CHF2, -CH2NH2, -N(CH3)2, -SO2CH3, cyano, halo, - C(O)OH, -C(O)N(CH3)2, and –C(O)NHCH3, or the following structural formula: 107 ME150647165v.1 130090-01720 variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment or any alternative embodiments described therein. In a twelfth embodiment, for the compound of Formula (I) described in the first aspect or in the first embodiment, or a pharmaceutically acceptable salt thereof, n is 1; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, eighth, or eleventh embodiment or any alternative embodiments described therein. In a thirteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, n is 1 and Z is a bond; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, eleventh, or twelfth embodiment. In a fourteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, n is 1 and Z is -CH2-, -CH(CH3)-, -O-, -N(H)-, -N(C1-4alkyl)-, or –C(O)NH-*, wherein * indicates the attachment point to R3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, eleventh or twelfth embodiment. In a fifteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, phenyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyrazinyl, thiophenyl, tetrahydropyranyl, tetrahydrofuranyl, oxabicyclo[3.2.1]octanyl, thiazolyl, imidazoyl, triazolyl, tetrazolyl, oxadiazolyl, 3-oxo-2,3-dihydro-1H-pyrazoly, benzamidazolyl, indazolyl, indoyl, imidazolidinyl, azetidinyl, 2,3-dihydrobenzofuranyl, imidazo[1,2-a]pyridinyl, 2,3- dihydro-1H-indenyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, spiro[3.3]heptanyl, 2- azaspiro[3.3]heptanyl, and 2-oxaspiro[3.3]heptanyl, each of which is optionally substituted with 1 to 3 R4; and the remaining variables are as described in the first, second, third, fourth, 108 ME150647165v.1 130090-01720 fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a sixteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, Z is –CH2-, R3is thiophenyl, pyrrolyl, and 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a seventeenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is represented by the following ; each of which is optionally substituted with 1 to 3 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment or any alternative embodiments described therein. 109 ME150647165v.1 130090-01720 In an eighteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is represented by the following 110 ME150647165v.1 130090-01720 the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment or any alternative embodiments described therein. In a nineteenth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is phenyl or 5 to 6-membered monocyclic heteroaryl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a twentieth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is phenyl, pyrazolyl, pyridyl, and pyrimidyl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a twenty-first embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is ; 111 ME150647165v.1 130090-01720 ; each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a twenty-second embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R3is represented by the following structural formula: ; variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment or any alternative embodiments described therein. In a twenty-third embodiment, for the compound of Formula (I) described in the first embodiment or in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is selected from C1-3alkyl, C2-4alkenyl, C2-4alkynyl, -OR4a, -CN, -NH2, -NR4bR4c, halo, - C(O)R4a, -NHC(O)R4a, -NHC(O)OR4a, -NR4bSO2R4a, -SR4a, -S(O)R4a, -SO2R4a, - SO2NR4bR4c, -P(O)R4bR4c, -C(O)O-C1-4alkyl, benzyl, phenyl, 5 to 6-membered monocyclic heteroaryl, 6 to 10-membered bicyclic heterocyclyl, and 4 to 6-membered monocyclic heterocyclyl, wherein the C1-3alkyl, C2-4alkenyl, or C2-4alkynyl represented by R4is optionally substituted with 1 to 3 substituents independently selected from halo, phenyl, 5 to 6-membered monocyclic heteroaryl optionally substituted with 1 or 2 R4g, and 4 to 6- membered monocyclic heterocyclyl optionally substituted with 1 or 2 R4g, -C(O)NR4bR4c, - C(O)R4a, and OR4f; and the benzyl, phenyl, 5 to 6-membered monocyclic heteroaryl, 6 to 10- membered bicyclic heterocyclyl, and 4 to 6-membered monocyclic heterocyclyl represented by R4are each optionally substituted with 1 to 3 R4eand further optionally substituted with one or two oxo, or two R4together form an oxo; R4ais H, C1-4alkyl optionally substituted with 1 to 4 R4d, -NR4bR4c, C3-6cycloalkyl, phenyl, 4- to 6-membered monocyclic heterocyclyl, or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl, 4- to 6-membered monocyclic heterocyclyl, and 5 to 6-membered monocyclic heteroaryl are optionally 112 ME150647165v.1 130090-01720 substituted with 1 to 3 R4e; each R4bis independently H or C1-4alkyl; R4cis H, C1-4alkyl optionally substituted with 1 to 4 R4d, 4 to 6-membered monocyclic heterocyclyl, or 5 to 6- membered monocyclic heteroaryl; each R4dis independently selected from halo, -OR4f, C3-6cycloalkyl, -C(O)OH, -NR4bR4c, phenyl, and 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with 1 to 3 substituents independently selected from C1-3alkyl, C1-3haloalkyl, halo, CN and OH; each R4eis independently selected from halo,-OH, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, –C(O)R4h, -SO2C1-3alkyl, -C1-3alkylSO2C1-3alkyl, -C(O)N(C1-3alkyl)2, and cyano; or two R4etogether form an oxo; R4fis H, C1-4alkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, wherein phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with 1 to 3 halo; each R4gis independently C1-3alkyl or halo; and each R4his independently C1-4alkyl, C3-6cycloalkyl, C1-3alkoxyl or –N(R4b)2; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, or twenty second embodiment or any alternative embodiments described therein. In a twenty-fourth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is represented by the following optionally substituted with 1 to 3 R4eand further optionally substituted with 1 or 2 oxo; and 113 ME150647165v.1 130090-01720 the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment or any alternative embodiments described therein. In a twenty-fifth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is represented by the following 114 ME150647165v.1 130090-01720 the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment or any alternative embodiments described therein. In a twenty-sixth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, each R4eis independently –F, – CH3, -CF3, -CH2CHF2, -CH2CF3, -CH2SO2CH3, -OH, -OCH3, -SO2CH3, –C(O)CH3, - C(O)cyclopropyl, -C(O)cyclobutyl, -C(O)cyclopentyl, -C(O)CH(CH3)2, -C(O)C(CH3)3– C(O)N(CH3)2, -C(O)OCH3, or cyano; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth or twenty-fifth embodiment or any alternative embodiments described therein. In a twenty-seventh embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is -OR4a; R4ais C1-3alkyl optionally substituted with 1 to 3 R4dor 4- to 6-membered monocyclic heterocyclyl optionally substituted with 1 to 3 R4e; each R4dis independently halo, C1-2alkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, provided when two or three R4dare present, one of the R4dis phenyl or 5 to 6-membered monocyclic heteroaryl, and the other R4dare each independently halo or C1-2alkyl; wherein the phenyl and 5 to 6-membered monocyclic heteroaryl represented by R4dare each optionally substituted with 1 to 3 substituents independently selected from C1-3alkyl, C1-3haloalkyl and halo; each R4eis independently C1-4alkyl, C1-4haloalkyl, -SO2C1-3alkyl, or -C(O)C3-6cycloalkyl; the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiment or any altenative embodiments described therein. In a twenty-eighth embodiment, for the compound of Formula (I) described in the first embodiment, or a pharmaceutically acceptable salt thereof, R4is –CH3, CH2OH, -CHF2, - CF3, -CH(CF3)OH, -CH2OCH3, -CH2CN, -CH2CF3, -CH2CH2OH, -CH2C(O)N(CH3)2, - 115 ME150647165v.1 130090-01720 C≡CC(CH3)2OH, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH(CH3)2, -OCF3, -OCHF2, -OCH2CF3, -O-cyclopropyl, -O-cyclobutyl, -OC(CH3)3, -OC(CH3)2CH2OH, - OCH(CH3)C(O)OH, -OC(CH3)2C(O)OH, -OCH(CH3)CH2OH, -OCH2CH2N(CH3)2, -CN, - NH2, -NHCH3, halo, -C(O)H, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)O-t-butyl, - N(CH3)SO2CH3, -NHC(O)CH3, -NHC(O)cyclopropyl, -NHC(O)OC(CH3)3, -C(O)CH3, - C(O)OH, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -C(O)NC(CH3)3, -SCH3, -S(O)CH3, - SO2CH3, -SO2N(CH3)2, -P(O)(CH3)2, phenyl, or R4is represented by the following structural formula: 116 ME150647165v.1 130090-01720 117 ME150647165v.1 130090-01720 the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third embodiment or any alternative embodiments described therein. In a twenty-ninth embodiment, the DXH9 inhibitor is a compound is represented by Formula (IIA), (IIB), or (IIC): or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; and the variables X, R1, R2, and R3depicted in Formula (IIA), (IIB), or (IIC) are as described in the first, second, third, fourth, eleventh, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth embodiment or any alternative embodiments described therein. 118 ME150647165v.1 130090-01720 In a thirtieth embodiment, the DXH9 inhibitor is a compound represented by Formula (IIIA) or (IIIB): or a pharmaceutically acceptable salt thereof; where the variables X, R1, R2, and R3depicted in Formula (IIIA) or (IIIB) are as described in the first, second, third, fourth, eleventh, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty- third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth embodiment or any alternative embodiments described therein. In a thirty-first embodiment, the DXH9 inhibitor is a compound represented by Formula (IVA), (IVB), (IVC), or (IVD): or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; and the variables X, R1, R2, and R3depicted in Formula (IVA), (IVB), (IVC), or (IVD) are as described in the first, second, third, fourth, eleventh, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty- seventh, or twenty-eighth embodiment or any alternative embodiments described therein. In a thirty-second embodiment, for compounds of Formula (I), (IIA), (IIB), (IIC), (IIIA), (IIIB), (IVA), (IVB), (IVC), or (IVD), or a pharmaceutically acceptable salt thereof, R1is –CH3 or –CH2CH3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, 119 ME150647165v.1 130090-01720 fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty- second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty- eighth, twenty-ninth, thirtieth, or thirty-first embodiment or any alternative embodiments described therein. In a thirty-third embodiment, for compounds of Formula (I), (IIA), (IIB), (IIC), (IIIA), (IIIB), (IVA), (IVB), (IVC), or (IVD), or a pharmaceutically acceptable salt thereof, R1is – CH3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty- third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, or thirty-first embodiment or any alternative embodiments described therein. In a thirty-fourth embodiment, the DXH9 inhibitor is a compound represented by Formula (V): or a pharmaceutically acceptable salt thereof, wherein: X is Cl or Br; R1is -CH3or –CH2CH3; ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazolyl, and imidazolyl; m is 0 or 1; each R2is independently selected from C1-3alkyl and -C(O)R2d, wherein the C1-3alkyl is optionally substituted with R2g; R2dis 4 to 6-membered monocyclic heterocyclyl; R2gis cyano or OH; R3is phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 or 2 R4; 120 ME150647165v.1 130090-01720 each R4is independently selected from halo, C1-4alkyl, -O-benzyl, -O-C1-3alkyl, cyano, -NH2, and 4 to 6-membered monocyclic heterocyclyl, wherein the benzyl is optionally substituted with 1 to 3 halo or C1-3haloalkyl. In an alterntive thirty-fourth embodiment, for the compound of formula (V) or a pharmaceutically acceptable salt thereof, the definitions of variables are: X is Cl or Br; R1is -CH3or –CH2CH3; ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazolyl, and imidazolyl; m is 0 or 1; each R2is independently selected from C1-3alkyl and -C(O)R2d, wherein the C1-3alkyl is optionally substituted with R2g; R2dis 4 to 6-membered monocyclic heterocyclyl; R2gis cyano or OH; R3is phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 or 2 R4; each R4is independently selected from C1-4alkyl, -O-benzyl, cyano, -NH2, and 4 to 6- membered monocyclic heterocyclyl, wherein the benzyl is optionally substituted with halo. In a thirty-fifth embodiment, for compounds of Formula (V), or a pharmaceutically any alternative embodiments described therein. In a thirty-sixth embodiment, the DXH9 inhibitor is a compound represented by Formula (IIB), (IIIA), (IVA); or (IVB): 121 ME150647165v.1 130090-01720 or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; and the variables X, R1, R2, and R3depicted in Formula (IIIA), (IVA), or (IVB) are as described in the thirty- fourth embodiment or any alternative embodiments described therein. In a thirty-seventh embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R3is phenyl, pyrazolyl, pyridyl, and pyrimidyl, each of which is optionally substituted with 1 to 2 R4; and the remaining variables are as described in the thirty-fourth, thirty-fifth, or thirty-sixth embodiment or any alternative embodiments described therein. In a thirty-eighth embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA), or (IVB) or a pharmaceutically acceptable salt thereof, R3is represented by the following R4; and the remaining variables are as described in the thirty-fourth, thirty-fifth, or thirty- sixth embodiment or any alternative embodiments described therein. In a thirty-ninth embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA); or (IVB) or a pharmaceutically acceptable salt thereof, R4is –F, -OCH(CH3)2, -OC(CH3)3, – CH3, cyano, -NH2, or R4is represented by the following structural 122 ME150647165v.1 130090-01720 the remaining variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, or thirty-eighth embodiment or any alternative embodiments described therein. In a fortieth embodiment, for compounds of Formula (V), (IIB), (IIIA), (IVA),or (IVB) or a pharmaceutically acceptable salt thereof, R2is –CH3, -CH2CN, -CH2OH, the remaining variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, thirty-eighth, or thirty-ninth embodiment or any alternative embodiments described therein. In a forty-first embodiment, the present disclosure provides a compound represented by Formula (IIB) or (IVB): or a pharmaceutically acceptable salt thereof, wherein: m is 0 or 1; R1is -CH3; X is Cl; R2is -CH3; R3is pyrimidinyl or pyridinyl, each of which is optionally substituted with 1 or 2 R4; R4is halo, C1-3alkyl, -OC1-3alkyl, or 4- to 6-membered monocyclic heterocyclyl, wherein the 4- to 6-membered monocyclic heterocycly is optionally substituted with 1 or 2 halo or C1-3haloalkyl. In a forty-second embodiment, for compounds of Formula (IIB) or (IVB), or a pharmaceutically acceptable salt thereof, R3is represented by the following structural 123 ME150647165v.1 130090-01720 formula: ; and the remaining variables are as described in the forty-first embodiment. In a forty-third embodiment, for compounds of Formula (IIB) or (IVB), or a pharmaceutically acceptable salt thereof, each R4is independently –F, -CH3, -OCH(CH3)2, or -OC(CH3)3, or R4is represented by the following structural formula: remaining variables are as described in the forty-first or forty-second embodiment. In a forty-fourth embodiment, the present disclosure provides a compound selected from the group consisting of: N-(3-chloro-5-(methylsulfonamido)phenyl)-1-phenyl-1H-imidazole-4-carboxamide; 5-bromo-N-(3-fluoro-5-(methylsulfonamido)phenyl)-1H-pyrrole-3-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-1H-pyrazole-3-carboxamide; 5-bromo-N-(3-fluoro-5-(methylsulfonamido)phenyl)-1H-pyrazole-3-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-2-phenyl-1H-imidazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenylfuran-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenyl-1H-pyrrole-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenyl-1H-imidazole-2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-methyl-3-(1H-pyrazol-1-yl)benzamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-phenylthiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-2-phenylcyclobutane-1-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3'-cyano-[1,1'-biphenyl]-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(pyridin-4-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-iodo-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyrazin-2-yl)thiophene-2- carboxamide; 124 ME150647165v.1 130090-01720 N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(2-hydroxy-6-methylphenyl)thiophene- 2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)-5-methylthiophene- 2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(pyrimidin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-5-methyl-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(pyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(pyridin-2-yl)thiophene-2- carboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)thiophene- 2-carboxamide; 4-(2-(benzyloxy)phenyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene- 2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; 125 ME150647165v.1 130090-01720 N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(4-cyanopyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(pyrazin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-cyanopyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-methylpyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-cyano-6-methylphenyl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-5-methyl-1-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-cyanopyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(trifluoromethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-cyclohexyl-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(3-methylpyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(pyrimidin-2-yl)-1H-pyrazole-4- carboxamide; 1-(2-(benzyloxy)phenyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(3-cyanophenyl)-1H-pyrazole-4- carboxamide; 126 ME150647165v.1 130090-01720 N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-cyano-2-methylphenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-methylpyridin-2-yl)-1H-pyrazole-4- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(6-(difluoromethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(6-(difluoromethoxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-formylphenyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(pyrimidin-2-yl)-1H-pyrrole- 3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(1H-pyrazol-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-3-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(1-phenylethoxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-2-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-4-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-fluorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(oxazol-5-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 1-(2-(benzyloxy)-5-cyanophenyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; 1-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((4-fluorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 127 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-chlorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 4-bromo-N-(3-fluoro-5-(methylsulfonamido)phenyl)thiophene-2-carboxamide; 4-bromo-N-(3-(ethylsulfonamido)-5-fluorophenyl)thiophene-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-(ethylsulfonamido)-5-fluorophenyl)-4-phenylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-phenylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-ethyl-5-phenyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-phenyl-1-(2,2,2-trifluoroethyl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(pyrimidin-2-yl)-1H-pyrrole- 3-carboxamide; 5-bromo-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-1H-pyrrole-3- carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-cyclohexyl-5-methyl-1H-pyrrole-3- carboxamide; 1-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-N-(3-bromo-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; 1-(5-(4-acetylpiperazin-1-yl)-3-methylpyridin-2-yl)-N-(3-bromo-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1- yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)pyridin-3-yl)-N,N-dimethylpiperazine-1-carboxamide; 128 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2-oxopyrrolidin-1-yl)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(4-morpholinopyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2-methylmorpholino)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-morpholinopyridin-2-yl)- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(4-methyl-3-oxopiperazin- 1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(cyanomethyl)-5-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-methyl-2-(3-methylpyridin-2-yl)-1H- imidazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(difluoro(phenyl)methoxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyano-1-(pyridin-2-yl)-1H-pyrrole-3- carboxamide; 1-benzyl-N-(3-bromo-5-(methylsulfonamido)phenyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazole-5-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(3-cyano-1H-pyrazol-1-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-2-oxo-1-phenyl-2,3-dihydro-1H- imidazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(2-chloropyridin-4-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-(2,2,2-trifluoro-1- hydroxyethyl)phenyl)-1H-pyrazole-4-carboxamide; 4-((1H-pyrrol-2-yl)methyl)-N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene-2- carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-methoxyphenyl)thiophene-2- carboxamide; 129 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluorophenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-phenyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2-carboxamide; 4-(2-(benzyloxy)phenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)thiophene-2- carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(pyridin-2-yl)thiophene-2-carboxamide; N-(3-(ethylsulfonamido)-5-fluorophenyl)-4-(pyridin-2-yl)thiophene-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(2-hydroxyphenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2,6-difluorophenyl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(1H-pyrazol-1-yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-3-(1H-pyrazol-1-yl)benzamide; 1-ethyl-N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-1H-pyrazole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(hydroxymethyl)-4-phenylthiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonoamidimidamido)phenyl)-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-bromo-5-(methylsulfonoamidimidamido)phenyl)-4-(3-methylpyridin-2- yl)thiophene-2-carboxamide; N-(3-bromo-5-(methylsulfonoamidimidamido)phenyl)-5-methyl-4-(pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-phenylthiophene-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-phenylfuran-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxypropyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-hydroxyethyl)-1H-pyrazole-4- carboxamide; 130 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-oxaspiro[3.3]heptan-6-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-phenyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(3-methylpyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-2-ethylimidazo[1,2-a]pyridine-6- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(dimethylamino)-2-ethylimidazo[1,2- a]pyridine-6-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)imidazo[1,2-a]pyridine-6-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)benzofuran-7-carboxamide; tert-butyl 4-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)piperidine-1-carboxylate; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(pyridin-2-yl)isothiazole-5- carboxamide; 5-(2-(benzyloxy)phenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-1H- pyrazole-3-carboxamide; 3-(2-(benzyloxy)phenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-1H- pyrazole-5-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(pyridin-2-yl)-1H-pyrazole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-3-(pyridin-2-yl)-1H-pyrazole-5- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(1-phenylethyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-difluoroethyl)-5-(3-methylpyridin- 2-yl)-1H-pyrrole-3-carboxamide; tert-butyl 6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)-2-azaspiro[3.3]heptane-2-carboxylate; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(piperidin-4-yl)-1H-pyrazole-4- carboxamide; 131 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-azaspiro[3.3]heptan-6-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(4-(piperazin-1-yl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; 1-(4-(4-acetylpiperazin-1-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-isobutyrylpiperazin-1-yl)pyridin- 2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-hydroxycyclohexyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(4-hydroxycyclohexyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxycyclohexyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-2-phenyl-1H-imidazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-2-(3-methylpyridin-2-yl)-1H- imidazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(2-oxopiperidin-1-yl)-1H- pyrrole-3-carboxamide; 1-(2-(benzyloxy)cyclobutyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(3-(hydroxymethyl)-1H-pyrazol-1- yl)benzamide; N-(3-bromo-5-(methylsulfonamido)phenyl)-1-(2-(hydroxymethyl)phenyl)-1H- pyrazole-4-carboxamide; 1-(3-aminopyridin-2-yl)-N-(3-bromo-5-(methylsulfonamido)phenyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(hydroxymethyl)-4-(pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-3-(phenylamino)-1H-pyrazole-5- carboxamide; 132 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(piperazine-1-carbonyl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N2-(3-chloro-5-(methylsulfonamido)phenyl)-N4-phenylthiophene-2,4- dicarboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(phenoxymethyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; 1-(3-(benzylamino)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(hydroxymethyl)-1-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(pyridin-2-yl)-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-ethoxypyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-methyl-5-(pyrimidin-2-yl)-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-oxopyrrolidin-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyclopropyl-4-(pyridin-2-yl)thiophene- 2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyrimidin-2-yloxy)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-hydroxybenzyl)oxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-oxomorpholino)pyridin-2-yl)-1H- pyrazole-4-carboxamide; 5-(aminomethyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; 133 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1- yl)pyrimidin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1- yl)pyrazin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-(pyridin-3-ylmethoxy)pyridin-2-yl)- 1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3,5-difluorobenzyl)oxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyrimidin-5-ylmethoxy)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((2-fluorobenzyl)oxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(tetrahydro-2H-pyran-4-yl)pyridin- 2-yl)-1H-pyrazole-4-carboxamide; 1-(5-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(5,6-dihydroimidazo[1,2-a]pyrazin- 7(8H)-yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-methyl-3-oxopiperazin-1-yl)-3- (pyridin-3-ylmethoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholino-3-(pyridin-3- ylmethoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(2-hydroxy-2- methylpropoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyrimidin-2-yloxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methoxypyridin-2-yl)-1H-pyrazole- 4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(methylsulfonyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; 134 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(methylsulfonyl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(N,N-dimethylsulfamoyl)pyridin-2- yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(dimethylphosphoryl)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoro-3-((3- fluorobenzyl)oxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-cyanobenzyl)oxy)-5- fluoropyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3-fluorobenzyl)oxy)-6- methylpyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(thiazol-2-ylmethoxy)pyridin-2-yl)- 1H-pyrazole-4-carboxamide; 1-(3-((1H-pyrazol-4-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyrimidin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-ethoxypyrimidin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)indolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-((3-fluorobenzyl)oxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-fluoro-6-((3- fluorobenzyl)oxy)phenyl)-1H-pyrazole-4-carboxamide; 3-(3-(benzyloxy)pyridin-2-yl)-N5-(3-chloro-5-(methylsulfonamido)phenyl)-N2- methylthiophene-2,5-dicarboxamide; 3-(3-(benzyloxy)pyridin-2-yl)-N5-(3-chloro-5-(methylsulfonamido)phenyl)-N2,N2- dimethylthiophene-2,5-dicarboxamide; 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-fluoro-5-(methylsulfonamido)phenyl)thiophene- 2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(oxazol-5-ylmethoxy)pyridin-2- yl)thiophene-2-carboxamide; 135 ME150647165v.1 130090-01720 4-(3-(benzyloxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- (hydroxymethyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyridin-3-ylmethoxy)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(methylthio)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(methylthio)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(cyclopropanecarboxamido)pyridin- 2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(2-(dimethylamino)-2- oxoethyl)pyridin-2-yl)thiophene-2-carboxamide; 2-(5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)thiophen-3-yl)-N,N- dimethylnicotinamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(trifluoromethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-((5-fluoropyridin-3- yl)methoxy)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-methylpyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-hydroxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-((3,5- difluorophenoxy)methyl)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5'-fluoro-[3,3'-bipyridin]-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)thieno[2,3-c]pyridine-2-carboxamide; 1-(3-((3-bromobenzyl)oxy)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-ethyl-4-(pyridin-2-yl)thiophene-2- carboxamide; 136 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-isopropyl-4-(pyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(methoxymethyl)-4-(pyridin-2- yl)thiophene-2-carboxamide; 4-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(1-phenyl-1H-1,2,3-triazol-4- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyrimidin-2-ylamino)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(methyl(pyrimidin-2- yl)amino)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyridin-3-yloxy)pyridin-2- yl)thiophene-2-carboxamide; 4-(2-(benzyloxy)-6-fluorophenyl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; 4-bromo-N-(3-chloro-5-(methylsulfonamido)phenyl)thiophene-2-carboxamide; methyl (5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)thiophen-3- yl)prolinate; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(piperidin-4-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(piperazin-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-morpholinothiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-(2,2,2-trifluoroethyl)piperazin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(cyclopropanesulfonamido)phenyl)-5-methyl-1-(5-morpholinopyridin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-((difluoromethyl)sulfonamido)phenyl)-5-methyl-1-(5- morpholinopyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-1-(5-morpholinopyridin-2-yl)- 1H-pyrrole-3-carboxamide; 1-(8-oxabicyclo[3.2.1]octan-3-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; 137 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoro-3-(3-fluorophenethyl)pyridin- 2-yl)-1H-pyrazole-4-carboxamide; 1-(3-((1H-imidazol-2-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; 1-(3-((1H-pyrazol-5-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; 1-(3-((1H-imidazol-4-yl)methoxy)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-((3-fluorobenzyl)oxy)-6- methylphenyl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3,5- difluorophenoxy)methyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(5-fluoropyridin-3-yl)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-((3,5-difluorobenzyl)oxy)-5-(2-oxa- 6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-phenoxycyclopentyl)-1H-pyrazole- 4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-phenylcyclopentyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methyl-3-(oxazol-5- ylmethoxy)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(((5-fluoropyridin-3- yl)oxy)methyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(pyrimidin-2-yloxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(pyridin-3-yloxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(3-fluorophenoxy)phenyl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(1-methyl-2-oxopiperidin-4- yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyridin-2-yl)-5- (trifluoromethyl)-1H-pyrrole-3-carboxamide; 138 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-(oxazol-5- ylmethoxy)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methyl(tetrahydrofuran-3- yl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(pyrrolidin-1-yl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyridin-2-yl)-5- (trifluoromethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2,2-dimethylmorpholino)pyridin-2- yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-morpholinopyridin-2-yl)- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-ethyl-5-(5-morpholinopyridin-2-yl)- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-morpholinopyridin-2-yl)-1-(2,2,2- trifluoroethyl)-1H-pyrrole-3-carboxamide; 1-(5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; 5-(5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1-methyl-1H-pyrrole-3-carboxamide; 5-(5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-1-(2,2,2-trifluoroethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-(thiazol-2- ylmethoxy)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(3-(thiazol-2- ylmethoxy)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxypyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-cyclopentyl-5-methyl-1H-pyrrole-3- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(4-isobutyrylpiperazin-1-yl)pyridin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2-methyl-1H-pyrrol-1- yl)pyridin-3-yl)-N,N-dimethylpiperazine-1-carboxamide; 139 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(1,1-dioxidothiomorpholino)pyridin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-difluoroethyl)-5-(5-fluoropyridin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(1-hydroxyethyl)-1-(pyridin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)thieno[3,2-c]pyridine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)thieno[3,2-b]pyridine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-7-methylthieno[3,2-c]pyridine-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5,6-dimethoxybenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)pyrrolo[1,2-b]pyridazine-6-carboxamide; 6-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)benzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6-fluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-fluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-fluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-7-fluorobenzo[b]thiophene-2- carboxamide; 5-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)benzo[b]thiophene-2- carboxamide; 6-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)indolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6-methylindolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazine- 7-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-8-(trifluoromethyl)indolizine-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-7-methoxybenzo[b]thiophene-2- carboxamide; 140 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methylindolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-8-fluoroindolizine-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-hydroxycyclobutyl)-1H-pyrazole-4- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(1-methyl-2-oxopiperidin-4-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-phenethyl-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-cyclopentyl-1H-pyrazole-4- carboxamide; 1-(6-acetamidospiro[3.3]heptan-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-methyl-2-azaspiro[3.3]heptan-6-yl)- 1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2-(2,2,2-trifluoroethyl)-2- azaspiro[3.3]heptan-6-yl)-1H-pyrazole-4-carboxamide; 1-(2-acetyl-2-azaspiro[3.3]heptan-6-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)- 1H-pyrazole-4-carboxamide; N-(3-bromo-5-(methylsulfonamido)phenyl-2,4,6-d3)-4-phenylthiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(2,2-dimethylpiperidin-4-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)- 1H-pyrazole-4-carboxamide; 1-(1-acetylpiperidin-4-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H-pyrazole-4- carboxamide; tert-butyl (6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1H-pyrazol-1- yl)spiro[3.3]heptan-2-yl)carbamate; 1-(6-aminospiro[3.3]heptan-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1H- pyrazole-4-carboxamide; and 1-(3-fluoro-5-morpholinopyridin-2-yl)-5-methyl-N-(3-(methylsulfonamido)phenyl)- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-fluoro-5-morpholinopyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; 141 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1-(2- hydroxyethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-methyl-3-oxopiperazin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyrimidin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5'-fluoro-[3,3'-bipyridin]-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-methyl-2-oxoimidazolidin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-methoxybenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1,3-dimethylpyrrolo[1,2-a]pyrazine-7- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(4-phenylpiperazine-1-carbonyl)-1- (pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(trifluoromethyl)benzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4,5-difluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4,7-difluorobenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(trifluoromethyl)benzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyrimidin-5-yl)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6-methoxybenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(piperidine-1-carbonyl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(morpholine-4-carbonyl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin- 1-yl)thiophene-2-carboxamide; 142 ME150647165v.1 130090-01720 4-(3-(2-(azetidin-1-yl)-2-oxoethyl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(2-oxooxazolidin-3-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-morpholinopyrazin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(pyrimidin-2-ylmethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-5-(4-(2,2,2- trifluoroethyl)piperazine-1-carbonyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(2-oxopyrrolidin-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-hydroxy-5-(2-oxa-6- azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(2-oxo-2-(pyrrolidin-1- yl)ethyl)pyridin-2-yl)thiophene-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-5-methyl-4-(3-methylpyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(4-methylpiperazine-1-carbonyl)-1- (pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(pyridin-3-yloxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(3-(pyridin-3-yloxy)pyridin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-(2-(dimethylamino)-2- oxoethyl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(2-hydroxypropan-2-yl)-1-(pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-6,8-dimethylindolizine-2-carboxamide; N-(3-fluoro-5-(methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(pyridin-2-yl)-5-(2,6- diazaspiro[3.3]heptane-2-carbonyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-8-methylindolizine-2-carboxamide; 143 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)pyrrolo[1,2-a]pyrazine-7-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-methoxypyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(trifluoromethyl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-cyanopyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methylbenzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(1-(tetrahydro-2H-pyran-4- yl)-1H-1,2,3-triazol-4-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5- (trifluoromethyl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-ethoxypyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-methoxypyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(methoxymethyl)pyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyridin-2-yl)thiophene-2- carboxamide; 144 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-chloropyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methoxypyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(pyridin-3-yloxy)-5,6-dihydro-4H- cyclopenta[b]thiophene-2-carboxamide; 4-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)benzo[b]thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(3-fluorophenoxy)pyridin-2-yl)-1H- pyrazole-4-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-methoxy-1H-pyrazol-1- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(1-phenethyl-1H-imidazol-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-methoxy-1H-pyrazol-1-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(methoxymethyl)pyrimidin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-cyanopyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-chloropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-chloropyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-fluoroazetidin-1-yl)pyridin-2-yl)- 5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-fluoropyridin-2-yl)-5- (methoxymethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-ethoxypyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-ethoxy-1H-pyrazol-1-yl)-5- methylthiophene-2-carboxamide; 145 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-fluoro-1H-pyrazol-1-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4-fluoro-1H-pyrazol-1-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-methoxypyrimidin-2-yl)-5-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(methoxymethyl)pyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxypyrimidin-2-yl)thiophene-2- carboxamide; 5-(5-(azetidin-1-yl)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoropyrrolidin-1-yl)pyridin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methyl(tetrahydrofuran-3- yl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methyl(tetrahydrofuran-3- yl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5- (trifluoromethyl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(2-methoxyethoxy)pyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-ethoxypyrimidin-2-yl)thiophene-2- carboxamide; 1-(5-(azetidin-1-yl)pyridin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-(cyclopropylmethoxy)pyridin-2-yl)- 1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyclopropyl-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; 146 ME150647165v.1 130090-01720 1-(5-(azetidin-1-yl)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-fluoroazetidin-1-yl)pyridin-2-yl)- 1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)thiophene-2- carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-chloropyrimidin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; 5-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoropyrimidin-2-yl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxopyrrolidin-1- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5,5'-difluoro-[3,3'-bipyridin]-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-1'-methyl-2'-oxo-1',2'- dihydro-[3,4'-bipyridin]-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-1'-methyl-6'-oxo-1',6'- dihydro-[3,3'-bipyridin]-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5,5'-difluoro-[3,3'-bipyridin]-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1- yl)pyrimidin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5- (methylsulfonyl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(trifluoromethyl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-(cyclopropylmethoxy)pyridin-2-yl)- 5-methyl-1H-pyrrole-3-carboxamide; tert-butyl 3-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2-(5- fluoropyrimidin-2-yl)-1H-pyrrol-1-yl)azetidine-1-carboxylate; 1-(5-(3-azabicyclo[3.1.0]hexan-3-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2-yl)-5- methylthiophene-2-carboxamide; 147 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-cyclopropyl-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methylthio)pyrimidin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(methylsulfinyl)pyrimidin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(pyrrolidin-1-yl)pyrimidin- 2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-cyclopropyl-1-(5-fluoropyrimidin-2- yl)-1H-pyrrole-3-carboxamide; 5-(5-(azetidin-1-yl)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(4,4-dimethyl-2,5-dioxo-3-(pyridin-2- yl)imidazolidin-1-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-2'-methyl-[3,3'-bipyridin]-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-(oxazol-5-yl)pyridin-2-yl)- 5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(oxetan-3- yloxy)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-ethoxypyrimidin-2-yl)-5- (trifluoromethyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(difluoromethoxy)pyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-fluoro-3-methoxypyridin-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3,5-difluoropyridin-2-yl)-5-methyl- 1H-pyrrole-3-carboxamide; 5-chloro-N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; 148 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-ethyl-4-(5-fluoropyrimidin-2- yl)thiophene-2-carboxamide; 1-(5-(5-azaspiro[2.4]heptan-5-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-fluoroazetidin-1-yl)pyrimidin-2- yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(N- methylmethylsulfonamido)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-cyclopropyl-5-(5-fluoropyrimidin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxopyrrolidin-1- yl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2-yl)-1-isopropyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5- (methylsulfonyl)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5,5'-difluoro-[3,3'-bipyridin]-2-yl)-5- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,4-dimethyl-2,5-dioxo-4-(pyridin-2- yl)imidazolidin-1-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-methylpyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; methyl 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1-methyl-1H- pyrrol-2-yl)pyridin-3-yl)piperazine-1-carboxylate; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1- yl)pyrimidin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-((1-methylazetidin-3- yl)oxy)pyridin-2-yl)-1H-pyrrole-3-carboxamide; methyl 4-(6-(5-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-2- methylthiophen-3-yl)-5-methylpyridin-3-yl)piperazine-1-carboxylate; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3,5-difluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; 149 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-fluoroazetidin-1-yl)pyrimidin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-methylpyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,5-difluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-methylpyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-fluoro-3-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-(3-chloro-5-fluoropyridin-2-yl)-5-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(oxetan-3-yloxy)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1-methyl-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(pyrrolidin-1-yl)pyridin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(tetrahydro-2H-pyran-4- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-chloro-5-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoro-3-methylpyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-(3,5-difluoropyridin-2-yl)-5-methyl-1H- pyrrole-3-carboxamide; 1-(azetidin-3-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyrimidin-2- yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-cyano-5-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; 150 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-methoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-fluoro-3-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3-chloro-5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(methylamino)pyrimidin- 2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxooxazolidin-3- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(2,4,6-trifluorophenyl)-1H- pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(3-fluoro-5-methylpyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(2,4,6- trifluorophenyl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(2-oxooxazolidin-3- yl)pyrimidin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(4-(cyclopropanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(1-(2,2,2- trifluoroethyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(trifluoromethyl)pyridin-2- yl)thiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5- (trifluoromethyl)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-chloro-5-fluoropyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(4-pivaloylpiperazin-1- yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; 151 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-methoxypyrimidin-2-yl)-1-methyl- 1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclopentanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 1-(5-(7-azabicyclo[2.2.1]heptan-7-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3-methoxyazetidin-1-yl)pyrimidin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(2-cyano-4-fluoro-6-methylphenyl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- methylpyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(3-fluoro-5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(3-methyl-5- (trifluoromethyl)pyridin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-methoxy-5-(trifluoromethyl)pyridin- 2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclobutanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(4,4-difluoropiperidin-1-yl)-3- methylpyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-1-(5-(tetrahydro-1H-furo[3,4- c]pyrrol-5(3H)-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(6-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-methoxy-3-methylpyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3,5-difluoropyridin-4-yl)-5- methylthiophene-2-carboxamide; 152 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- methylpyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-cyano-5-(3,3-difluoroazetidin-1- yl)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclopropanecarbonyl)piperazin- 1-yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; 1-(3-chloro-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-isopropoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4,4-difluoropiperidin-1-yl)-3- methylpyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamidos)phenyl)-5-(3-(difluoromethoxy)-5-fluoropyridin- 2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)pyrimidin- 2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(4-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-chloro-5-methoxypyridin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- methoxypyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-(2,2,2- trifluoroethoxy)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3- (trifluoromethyl)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- isopropoxypyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-cyclobutoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; 153 ME150647165v.1 130090-01720 N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-ethoxypyrimidin-2-yl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- methoxypyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)-3- methoxypyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(3,4,4-trimethyl-2,5- dioxoimidazolidin-1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(difluoromethoxy)pyrimidin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)pyrimidin- 2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(trifluoromethyl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-4-(5-(3-fluoroazetidin-1-yl)pyrimidin-2-yl)- 5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-ethoxy-3-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(ethylsulfonamido)phenyl)-5-methyl-4-(5-(trifluoromethyl)pyrimidin- 2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3-fluorooxetan-3-yl)pyrimidin-2- yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-fluoropyridin-2-yl)-1- (methylsulfonyl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-methoxypyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; 4-(5-(1-acetylpiperidin-4-yl)pyrimidin-2-yl)-N-(3-chloro-5- (methylsulfonamido)phenyl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(cyclopropanesulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(propylsulfonamido)phenyl)-5-(5-(3,3-difluoroazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; methyl 4-(6-(4-((3-chloro-5-(methylsulfonamido)phenyl)carbamoyl)-1-methyl-1H- pyrrol-2-yl)-5-fluoropyridin-3-yl)piperazine-1-carboxylate; 154 ME150647165v.1 130090-01720 N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-methoxypiperidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-cyano-5-(3,3-difluoroazetidin-1- yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3-(2,2,2- trifluoroethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(5-(3,3-difluoroazetidin-1-yl)-3-(2,2,2- trifluoroethoxy)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-cyclobutoxy-5-(3,3-difluoroazetidin- 1-yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-methyl-4-(5-((1-methylazetidin-3- yl)oxy)pyrimidin-2-yl)thiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(5-(3,3-difluoroazetidin-1-yl)-3- (difluoromethoxy)pyridin-2-yl)-5-methylthiophene-2-carboxamide; 4-(5-(tert-butoxy)pyrimidin-2-yl)-N-(3-chloro-5-(methylsulfonamido)phenyl)-5- methylthiophene-2-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(4-(cyclopropanecarbonyl)piperazin- 1-yl)-3-fluoropyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-ethoxy-5-fluoropyridin-2-yl)-1- methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-fluoro-3-methylazetidin-1- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-(3-cyclobutoxy-5-(3,3-difluoroazetidin- 1-yl)pyridin-2-yl)-5-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-1-methyl-5-(5-(3- (methylsulfonyl)azetidin-1-yl)pyridin-2-yl)-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(5-(3-methoxyazetidin-1-yl)pyridin-2- yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3-fluoro-5-(3-fluoroazetidin-1- yl)pyridin-2-yl)-1-methyl-1H-pyrrole-3-carboxamide; N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-fluoro-5-(6-azaspiro[2.5]octan-6- yl)pyridin-2-yl)-5-methylthiophene-2-carboxamide; N-(3-chl...

Claims

130090-01720 CLAIMS 1. A method for treating a DNA damage repair deficient (DDRD) cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject.

2. The method of claim 1, further comprising selecting a subject determined as having a DDRD cancer for treatment.

3. The method of claim 1 or 2, wherein the DDRD cancer comprises a loss of function in one or more genes involved in a DNA damage repair pathway.

4. The method of any one of claims 1-3, wherein the DDRD cancer comprises a loss of function in one or more genes involved in base excision repair (BER).

5. The method of any one of claims 1-4, wherein the one or more genes involved in BER is selected from the group consisting of LIG3, PARP1, PARP2, PNKP, PARG, FEN1, XRCC1, LIG1, PCNA, APEX2, APEX1, OGG1, NTH1, UNG, NEIL1, NEIL2, NEIL3, MYH, MPC and APTX.

6. The method of any one of claims 1-3, wherein the DDRD cancer comprises a loss of function in one or more genes involved in homologous recombination (HR) repair.

7. The method of any one of claims 1-3 and 6, wherein the one or more genes involved in HR repair is selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG.

8. The method of any one of claims 1-3, wherein the DDRD cancer comprises a loss of function in one or more genes involved in non-homologous end joining (NHEJ) repair.

9. The method of any one of claims 1-3 and 8, wherein the one or more genes involved in NHEJ repair is selected from the group consisting of PRKDC, DCLRE1C, XRCC5, LIG4, XRCC4, XRCC6, WRN, APLF, and NHEJ1.

10. The method of any one of claims 1-3, wherein the DDRD cancer comprises a loss of function in one or more genes involved in nucleotide excision repair (NER). 204 ME150647165v.1130090-01720 11. The method of any one of claims 1-3 and 10, wherein the one or more genes involved in NER is selected from the group consisting of XPC, RAD23B, ERCC5, ERCC4, ERCC2, ERCC1, CETN2, DDB1, DDB2, ERCC3 and XPA.

12. The method of any one of claims 1-11, wherein the subject is determined to have a DDRD cancer based on the presence of a loss of function in one or more genes selected from the group consisting of LIG3, PARP1, PARP2, PNKP, PARG, FEN1, XRCC1, LIG1, PCNA, APEX2, APEX1, OGG1, NTH1, UNG, NEIL1, NEIL2, NEIL3, MYH, MPC, APTX, BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, FANCG, PRKDC, DCLRE1C, XRCC5, LIG4, XRCC4, XRCC6, WRN, APLF, NHEJ1 XPC, RAD23B, ERCC5, ERCC4, ERCC2, ERCC1, CETN2, DDB1, DDB2, ERCC3 and XPA.

13. The method of any one of claims 1-12, wherein the DDRD cancer is a DDRD breast cancer.

14. The method of claim 13, wherein the DDRD breast cancer is triple-negative breast cancer.

15. The method of any one of claims 1-12, wherein the DDRD cancer is a DDRD colorectal cancer.

16. The method of any one of claims 1-12, wherein the DDRD cancer is a DDRD gastric cancer.

17. The method of any one of claims 1-12, wherein the DDRD cancer is a DDRD uterine cancer.

18. The method of any one of claims 1-12, wherein the DDRD cancer is a DDRD pancreatic cancer.

19. The method of any one of claims 1-12, wherein the DDRD cancer is a DDRD ovarian cancer.

20. The method of claim 19, wherein the DDRD ovarian cancer is high-grade serous ovarian cancer. 205 ME150647165v.1130090-01720 21. The method of any one of claims 1-12, wherein the DDRD cancer is a DDRD prostate cancer.

22. The method of any one of claims 1-20, wherein the DDRD cancer is not a microsatellite instable cancer and / or a mismatch repair defective cancer.

23. The method of claim 15, wherein the DDRD colorectal cancer is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer.

24. The method of any one of claims 1-23, wherein the DDRD cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex.

25. A method for treating a homologous recombination deficient (HRD) cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject.

26. The method of claim 25, further comprising selecting a subject determined as having an HRD cancer for treatment.

27. The method of claim 25 or 26, wherein the HRD cancer comprises a loss of function in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG.

28. The method of claim 26, wherein the subject is determined to have an HRD cancer based on the presence of a loss of function in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG.

29. The method of any one of claims 25-28, wherein the HRD cancer is an HRD ovarian cancer.

30. The method of claim 29, wherein the HRD ovarian cancer is high-grade serous ovarian cancer. 206 ME150647165v.1130090-01720 31. The method of any one of claims 25-28, wherein the HRD cancer is an HRD breast cancer.

32. The method of claim 31, wherein the HRD breast cancer is triple-negative breast cancer.

33. The method of any one of claims 25-28, wherein the HRD cancer is an HRD colorectal cancer.

34. The method of any one of claims 25-28, wherein the HRD cancer is an HRD pancreatic cancer.

35. The method of any one of claims 25-28, wherein the HRD cancer is an HRD gastric cancer.

36. The method of any one of claims 25-28, wherein the HRD cancer is an HRD uterine cancer.

37. The method of any one of claims 25-28, wherein the HRD cancer is an HRD prostate cancer.

38. The method of any one of claims 24-37, wherein the HRD cancer is not a microsatellite instable cancer and / or a mismatch repair defective cancer.

39. The method of claim 33, wherein the HRD colorectal cancer is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer.

40. The method of any one of claims 25-39, wherein the HRD cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex.

41. A method for treating a cancer having a BRCA loss of function in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject.

42. The method of claim 41, further comprising selecting a subject determined as having a cancer having a BRCA loss of function for treatment.

43. The method of claim 41 or 42, wherein the BRCA loss of function comprises a BRCA1 and / or a BRCA2 loss-of-function mutation. 207 ME150647165v.1130090-01720 44. The method of any one of claims 41-43, wherein the cancer is an ovarian cancer having a BRCA loss of function.

45. The method of any one of claim 44, wherein the ovarian cancer is high-grade serous ovarian cancer.

46. The method of any one of claims 41-43, wherein the cancer is a breast cancer having a BRCA loss of function.

47. The method of any one of claim 46, wherein the breast cancer is triple-negative breast cancer.

48. The method of any one of claims 41-43, wherein the cancer is a colorectal cancer having a BRCA loss of function.

49. The method of any one of claims 41-43, wherein the cancer is a pancreatic cancer having a BRCA loss of function.

50. The method of any one of claims 41-43, wherein the cancer is a prostate cancer having a BRCA loss of function.

51. The method of any one of claims 41-50, wherein the cancer is not a microsatellite instable cancer and / or a mismatch repair defective cancer.

52. The method of claim 48, wherein the colorectal cancer is not a microsatellite instable colorectal cancer and / or a mismatch repair defective colorectal cancer.

53. The method of any one of claims 41-52, wherein the cancer is not a cancer having mutations or defects in RNA splicing and the kinetochore complex.

54. A method for treating triple-negative breast cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject.

55. The method of claim 54, further comprising selecting a subject determined as having triple-negative breast cancer for treatment.

56. The method of claim 54 or 55, wherein the triple-negative breast cancer is a homologous recombination deficient (HRD) cancer. 208 ME150647165v.1130090-01720 57. The method of any one of claims 54-56, wherein the triple-negative breast cancer has a loss of function in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG.

58. The method of any one of claims 54-57, wherein the triple-negative breast cancer has a loss of function in BRCA1 and / or BRCA2.

59. The method of claim 58, wherein the triple-negative breast cancer has a loss-of- function mutation in BRCA1 and / or BRCA2.

60. A method for treating high-grade serous ovarian cancer in a subject, comprising administering to the subject a therapeutically effective amount of a DHX9 inhibitor, thereby treating the subject.

61. The method of claim 60, further comprising selecting a subject determined as having high-grade serous ovarian cancer for treatment.

62. The method of claim 60 or 61, wherein the high-grade serous ovarian cancer is a homologous recombination deficient (HRD) cancer.

63. The method of any one of claims 60-62, wherein the high-grade serous ovarian cancer has a loss of function in one or more genes selected from the group consisting of BRCA1, BRCA2, PALB2, ATM, ATR, MRE11, NBN1, BAP1, BRIP1, ARID1A, BLM, BARD1, RAD50, RAD51B, RAD51C, RAD54L, CDK12, CHEK1, CHEK2, 53BP1, FANCA, FANCD2, FANCC, FANCE, FANCF, and FANCG.

64. The method of any one of claims 60-63, wherein the high-grade serous ovarian cancer has a loss of function in BRCA1 and / or BRCA2.

65. The method of any one of claims 60-64, wherein the high-grade serous ovarian cancer has a loss-of-function mutation in BRCA1 and / or BRCA2.

66. The method of any one of claims 1-65, further comprising administering an additional anti-cancer therapy to the subject. 209 ME150647165v.1130090-01720 67. The method of any one of claims 1-66, wherein the subject is a human.

68. The method of any one of claims 1-67, wherein the DHX9 inhibitor is a compound having the Formula I:or a pharmaceutically acceptable salt thereof, wherein: X is halo; Y is O or NRy; Ryis H or C1-4alkyl; R1is C1-4alkyl or C3-6cycloalkyl; wherein the C1-4alkyl or C3-6cycloalkyl are each optionally and independently substituted with 1 to 3 halo or -OH, Ring A is a C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10 membered bicyclic heterocyclyl; phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10- membered bicyclic heteroaryl; m is 0 to 3; n is 0 or 2; each R2is independently selected from C1-4alkyl, C3-6cycloalkyl, halo, OR2a, cyano, - NR2bR2c, -SO2R2a, -C(O)R2d, and –C(O)NR2bR2cwherein the C1-4alkyl and C3-6cycloalkyl are optionally substituted with 1 to 4 R2e; or 2 R2together form oxo; R2ais H, C1-4alkyl, C1-4haloalkyl or C1-4alkoxyC1-4alkyl; R2dis H, C1-4alkyl, C3-6cycloalkyl, OR2a, phenyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 8-membered bicyclic heterocyclyl, or 5 to 6-membered monocyclic heteroaryl, wherein the C1-4alkyl is optionally substituted with 1 to 3 halo and the 5- to 6- membered monocyclic heteroaryl is optionally substituted with 1 to 3 C1-4alkyl, C1-4haloalkyl, or phenyl; R2band R2care each independently selected from H, C1-4alkyl, C3-6cycloalkyl, phenyl, 4 to 6-membered monocyclic heterocyclyl and 5 to 6-membered monocyclic heteroaryl, wherein the C1-4alkyl is optionally substituted with 1 to 3 substituents independently selected from halo and C1-3alkoxy; or R2band R2c, together with the nitrogen to which they are attached form a 4 to 6 membered monocyclic heterocyclyl or 6 to 10 membered bicyclic heterocyclyl; 210 ME150647165v.1130090-01720 wherein the 4 to 6 membered monocyclic heterocyclyl or 6 to 10 membered bicyclic heterocyclyl are each optionally substituted with 1 to 3 R2d; each R2eis independently selected from halo, cyano, NR2bR2c, OR2a, phenyl, and 4 to 6 membered monocyclic heterocyclyl; Z is a bond, -CH2-, -O-, -O-C1-4alkylene-*, -C1-4alkylene-O-*, -C(O)-, -C(O)O-*, - OC(O)-*, -S(O)2-, -S(O)2N(Za)-*, -N(Za)S(O)2-*, -N(Za)-, -N(Za)-C1-4alkylene-*, -C1-4alkylene-N(Za)-*, -C(O)N(Za)-*, -N(Za)C(O)-*, or -C(O)N(Za)-C1-3alkylene-*, wherein * indicates the attachment point to R3; Zais H or C1-4alkyl; R3is C3-6cycloalkyl, 7 to 10-membered bicyclic carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10-membered bicyclic heterocyclyl, phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10-membered bicyclic heteroaryl, wherein the C3-6cycloalkyl, 7 to 10-membered bicyclic carbocyclyl, 4 to 6-membered monocyclic heterocyclyl, 6 to 10- membered bicyclic heterocyclyl, phenyl, 5 to 6-membered monocyclic heteroaryl, or 8 to 10- membered bicyclic heteroaryl are each optionally and independently substituted with 1 to 4 R4; each R4is independently selected from C1-4alkyl, C2-4alkenyl, C2-4alkynyl, halo, OR4a, cyano, -NR4bR4c, -C(O)R4a, -C(O)OR4a, -C(O)NR4bR4c, -NR4bC(O)R4a-NR4bC(O)OR4a, , - NR4bSO2R4a, -SR4a, -S(O)R4a, -SO2R4a, SO2NR4bR4c, -P(O)R4bR4c, phenyl, 5 to 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocyclyl, and 6 to 10-membered bicyclic heterocyclyl, wherein the C1-4alkyl, C2-4alkenyl, or C2-4alkynyl is optionally substituted with 1 to 4 R4d, and wherein the phenyl, 5 to 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocyclyl and 6 to 10-membered bicyclic heterocyclyl are each optionally substituted with 1 to 3 R4eand further optionally substituted with 1 or 2 oxo; or two R4together form oxo; R4ais H, C1-4alkyl optionally substituted with 1 to 4 R4d, -NR4bR4c, C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, phenyl, or 5 to 6-membered monocyclic heteroaryl; wherein the C3-6cycloalkyl, 4 to 6-membered monocyclic heterocyclyl, phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 to 3 R4e; R4band R4care each independently selected from H, phenyl, 4 to 6-membered monocyclic heterocyclyl, 5 to 6-membered monocyclic heteroaryl, and C1-4alkyl optionally substituted with 1 to 4 R4d; or R4band R4ctogether with the nitrogen atom to which they are attached to form a 4 to 6-membered monocyclic heterocyclyl; 211 ME150647165v.1130090-01720 each R4dis independently selected from halo, OR4f, -C(O)C1-4alkyl, -C(O)NR4bR4c, - C(O)C1-4haloalkyl, -C(O)OR4f, -NR4bR4c, phenyl, and 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered mon ocyclic heteroaryl are each optionally substituted with 1 to 3 R4g; each R4eis independently selected from halo, C1-4alkyl, cyano, OR4f, -NR4bR4c, -C(O)H, -C(O)R4h, -SO2C1-3alkyl, and -C(O)NR4bR4c, wherein C1-4alkyl is optionally substituted with 1 to 3 substitutes independently selected from halo, -SO2C1-3alkyl and -C(O)NR4bR4c; and - C(O)NR4bR4c; or two R4etogether form oxo; R4fis H, C1-4alkyl, C1-4haloalkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with one to three halo; each R4gis independently selected from halo, OR4f, C1-4alkyl, C1-4haloalkyl, halo, cyano, -NR4bR4c, -C(O)H, and -C(O)OR4f; and each R4his independently C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy or –N(R4b)2.

69. The method of claim 68, wherein X is Cl, Br, or F.

70. The method of claim 68, wherein X is Cl or Br.

71. The method of claim 68, wherein X is Cl.

72. The method of any one of claims 68-71, wherein ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazoyl, furanyl, isothiazoyl, thiazoyl, imidazoyl, cyclobutyl, benzofuranyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, imidazo[1,2-a]pyridin-6-yl, 1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 2-oxo-2,3-dihydro-1H-imidazolyl, indolizinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-c]pyrimidinyl, pyrrolo[1,2-a]pyraziny, 5,6-dihydro- 4H-cyclopenta[b]thiophenyl, 5-oxo-5H-thiazolo[3,2-a]pyridinyl, thieno[3,2-b]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, benzothiophenyl, thieno[3,2-d]pyrimidinyl, pyrrolo[1,2-b]pyridazinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-b] pyrimidinyl, pyrrolo[1,2-c]pyrimidinyl, 1-oxo-1,2-dihydropyrrolo[1,2-a]pyrazinyl, pyrrolo[2,1-f][1,2,4]triazinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, 5,6-dihydro-4H- cyclopenta[b]thiophenyl, and 4,7-dihydro-5H-thieno[2,3-c]pyranyl. 212 ME150647165v.1130090-01720 73. The method of any one of claims 68-71, wherein ring A is represented by the; each of which is substituted with 0 to 2 R2and 0 to 1 Z-R3.

74. The method of claim 73, wherein ring A is represented by the following213 ME150647165v.1130090-0172075. The method of claim 72, wherein ring A is phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazoyl, and imidazolyl. 214 ME150647165v.1130090-0172079. The method of any one of claims 68-73, 75, 76, and 78, wherein n is 1. 215 ME150647165v.1130090-01720 80. The method of any one of claims 68-73, 75, 76, and 78, wherein n is 1 and Z is a bond.

81. The method of any one of claims 68-73, 75, 76, and 78, wherein n is 1 and Z is -CH2-, -CH(CH3)-, -O-, -N(H)-, -N(C1-4alkyl)-, or –C(O)NH-*, wherein * indicates the attachment point to R3.

82. The method of any one of claims 68-81, wherein R3is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, phenyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyrazinyl, thiophenyl, tetrahydropyranyl, tetrahydrofuranyl, oxabicyclo[3.2.1]octanyl, thiazolyl, imidazoyl, triazolyl, tetrazolyl, oxadiazolyl, 3-oxo-2,3-dihydro-1H-pyrazoly, benzamidazolyl, indazolyl, indoyl, imidazolidinyl, azetidinyl, 2,3-dihydrobenzofuranyl, imidazo[1,2-a]pyridinyl, 2,3- dihydro-1H-indenyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, spiro[3.3]heptanyl, 2- azaspiro[3.3]heptanyl, and 2-oxaspiro[3.3]heptanyl, each of which is optionally substituted with 1 to 3 R4.

83. The method of claim 81, wherein Z is –CH2-, R3is thiophenyl, pyrrolyl, and 2- oxo-2,3-dihydro-1H-benzo[d]imidazolyl, each of which is optionally substituted with 1 to 2 R4.

84. The method of any one of claims 68-83, wherein R3is represented by the following structural formula:;216 ME150647165v.1130090-0172085. The method of claim 84, wherein R3is represented by the following structural217 ME150647165v.1130090-0172086. The method of any one of claims 68-81, wherein R3is phenyl or 5 to 6- membered monocyclic heteroaryl, each of which is optionally substituted with 1 to 2 R4.

87. The method of claim 86, wherein R3is phenyl, pyrazolyl, pyridyl, and pyrimidyl, each of which is optionally substituted with 1 to 2 R4. 218 ME150647165v.1130090-01720 88. The method of claim 87, wherein R3is; each of which is optionally substituted with 1 to 2 R4.

89. The method of claim 87, wherein R3is represented by the following structural90. The method of any one of claims 68-89, wherein R4is selected from C1-3alkyl, C2-4alkenyl, C2-4alkynyl, -OR4a, -CN, -NH2, -NR4bR4c, halo, -C(O)R4a, -NHC(O)R4a, -NHC(O)OR4a, -NR4bSO2R4a, -SR4a, -S(O)R4a, -SO2R4a, - SO2NR4bR4c, -P(O)R4bR4c, -C(O)O-C1-4alkyl, benzyl, phenyl, 5 to 6-membered monocyclic heteroaryl, 6 to 10-membered bicyclic heterocyclyl, and 4 to 6-membered monocyclic heterocyclyl, wherein the C1-3alkyl, C2-4alkenyl, or C2-4alkynyl represented by R4is optionally substituted with 1 to 3 substituents independently selected from halo, phenyl, 5 to 6-membered monocyclic heteroaryl optionally substituted with 1 or 2 R4g, and 4 to 6- membered monocyclic heterocyclyl optionally substituted with 1 or 2 R4g, -C(O)NR4bR4c, - C(O)R4a, and OR4f; and the benzyl, phenyl, 5 to 6-membered monocyclic heteroaryl, 6 to 10- membered bicyclic heterocyclyl, and 4 to 6-membered monocyclic heterocyclyl represented by R4are each optionally substituted with 1 to 3 R4eand further optionally substituted with one or two oxo, or two R4together form an oxo; R4ais H, C1-4alkyl optionally substituted with 1 to 4 R4d, -NR4bR4c, C3-6cycloalkyl, phenyl, 4- to 6-membered monocyclic heterocyclyl, or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl, 4- to 6-membered monocyclic heterocyclyl, and 5 to 6- membered monocyclic heteroaryl are optionally substituted with 1 to 3 R4e; each R4bis independently H or C1-4alkyl; R4cis H, C1-4alkyl optionally substituted with 1 to 4 R4d, 4 to 6-membered monocyclic heterocyclyl, or 5 to 6-membered monocyclic heteroaryl; 219 ME150647165v.1130090-01720 each R4dis independently selected from halo, -OR4f, C3-6cycloalkyl, -C(O)OH, - NR4bR4c, phenyl, and 5 to 6-membered monocyclic heteroaryl, wherein the phenyl and 5 to 6- membered monocyclic heteroaryl are each optionally substituted with 1 to 3 substituents independently selected from C1-3alkyl, C1-3haloalkyl, halo, CN and OH; each R4eis independently selected from halo,-OH, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, –C(O)R4h, -SO2C1-3alkyl, -C1-3alkylSO2C1-3alkyl, -C(O)N(C1-3alkyl)2, and cyano; or two R4etogether form an oxo; R4fis H, C1-4alkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, wherein phenyl and 5 to 6-membered monocyclic heteroaryl are each optionally substituted with 1 to 3 halo; each R4gis independently C1-3alkyl or halo; and each R4his independently C1-4alkyl, C3-6cycloalkyl, C1-3alkoxyl or –N(R4b)2.

91. The method of any one of claims 68-89, wherein R4is represented by the following structural formula:;which is optionally substituted with 1 to 3 R4eand further optionally substituted with 1 or 2 oxo. 220 ME150647165v.1130090-01720 92. The method of claim 91, wherein R4is represented by the following structural93. The method of any one of claims 68-92, wherein each R4eis independently –F, –CH3, -CF3, -CH2CHF2, -CH2CF3, -CH2SO2CH3, -OH, -OCH3, -SO2CH3, –C(O)CH3, - 221 ME150647165v.1130090-01720 C(O)cyclopropyl, -C(O)cyclobutyl, -C(O)cyclopentyl, -C(O)CH(CH3)2, -C(O)C(CH3)3 – C(O)N(CH3)2, -C(O)OCH3, or cyano.

94. The method of any one of claims 68-90, wherein R4is -OR4a; R4ais C1-3alkyl optionally substituted with 1 to 3 R4dor 4- to 6-membered monocyclic heterocyclyl optionally substituted with 1 to 3 R4e; each R4dis independently halo, C1-2alkyl, phenyl or 5 to 6-membered monocyclic heteroaryl, provided when two or three R4dare present, one of the R4dis phenyl or 5 to 6- membered monocyclic heteroaryl, and the other R4dare each independently halo or C1-2alkyl; wherein the phenyl and 5 to 6-membered monocyclic heteroaryl represented by R4dare each optionally substituted with 1 to 3 substituents independently selected from C1-3alkyl, C1-3haloalkyl and halo; each R4eis independently C1-4alkyl, C1-4haloalkyl, -SO2C1-3alkyl, or -C(O)C3- 6cycloalkyl.

95. The method of any one of claims 68-90, wherein R4is –CH3, CH2OH, -CHF2, -CF3, -CH(CF3)OH, -CH2OCH3, -CH2CN, -CH2CF3, -CH2CH2OH, -CH2C(O)N(CH3)2, - C≡CC(CH3)2OH, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH(CH3)2, -OCF3, -OCHF2, -OCH2CF3, -O-cyclopropyl, -O-cyclobutyl, -OC(CH3)3, -OC(CH3)2CH2OH, - OCH(CH3)C(O)OH, -OC(CH3)2C(O)OH, -OCH(CH3)CH2OH, -OCH2CH2N(CH3)2, -CN, - NH2, -NHCH3, halo, -C(O)H, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)O-t-butyl, - N(CH3)SO2CH3, -NHC(O)CH3, -NHC(O)cyclopropyl, -NHC(O)OC(CH3)3, -C(O)CH3, - C(O)OH, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -C(O)NC(CH3)3, -SCH3, -S(O)CH3, - SO2CH3, -SO2N(CH3)2, -P(O)(CH3)2, phenyl, or R4is represented by the following structural formula:222 ME150647165v.1130090-01720223 ME150647165v.1130090-0172096. The method of any one of claims 68-71, 78, 82, and 84-95, wherein the DXH9 inhibitor is a compound represented by Formula (IIA), (IIB), or (IIC): 224 ME150647165v.1130090-01720or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.

97. The method of any one of claims 68-71, 78, 82, and 84-95, wherein the DXH9 inhibitor is a compound represented by Formula (IIIA) or (IIIB):or a pharmaceutically acceptable salt thereof.

98. The method of any one of claims 68-71, 78, 82, and 84-95, wherein the DXH9 inhibitor is a compound represented by Formula (IVA), (IVB), (IVC), or (IVD):or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1. 225 ME150647165v.1130090-01720 99. The method of any one of claims 68-98, wherein R1is –CH3 or –CH2CH3.

100. The method of any one of claims 68-99, wherein R1is –CH3.

101. The method of claim 68, wherein the DXH9 inhibitor is a compound represented by Formula (V):or a pharmaceutically acceptable salt thereof, wherein: X is Cl or Br; R1is -CH3or –CH2CH3; ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazolyl, and imidazolyl; m is 0 or 1; each R2is independently selected from C1-3alkyl and -C(O)R2d, wherein the C1-3alkyl is optionally substituted with R2g; R2dis 4 to 6-membered monocyclic heterocyclyl; R2gis cyano or OH; R3is phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 or 2 R4; each R4is independently selected from halo, C1-4alkyl, -O-benzyl, -O-C1-3alkyl, cyano, -NH2, and 4 to 6-membered monocyclic heterocyclyl, wherein the benzyl is optionally substituted with 1 to 3 halo or C1-3haloalkyl.

102. The method of claim 68, wherein the DXH9 inhibitor is a compound represented by Formula (V): 226 ME150647165v.1130090-01720or a pharmaceutically acceptable salt thereof, wherein: X is Cl or Br; R1is -CH3or –CH2CH3; ring A is selected from phenyl, thiophenyl, pyrrolyl, pyrazolyl, furanyl, isothiazolyl, and imidazolyl; m is 0 or 1; each R2is independently selected from C1-3alkyl and -C(O)R2d, wherein the C1-3alkyl is optionally substituted with R2g; R2dis 4 to 6-membered monocyclic heterocyclyl; R2gis cyano or OH; R3is phenyl or 5 to 6-membered monocyclic heteroaryl, wherein the phenyl or 5 to 6- membered monocyclic heteroaryl are each optionally and independently substituted with 1 or 2 R4; each R4is independently selected from C1-4alkyl, -O-benzyl, cyano, -NH2, and 4 to 6- membered monocyclic heterocyclyl, wherein the benzyl is optionally substituted with halo.227 ME150647165v.1130090-01720 104. The method of claim 101 or 102, wherein the DXH9 inhibitor is a compound represented by Formula (IIB), (IIIA), (IVA); or (IVB):or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.

105. The method of any one of claims 101-104, wherein R3is phenyl, pyrazolyl, pyridyl, and pyrimidyl, each of which is optionally substituted with 1 to 2 R4.

106. The method of any one of claims 101-104, wherein R3is represented by the following structural formula:;107. The method of any one of claims 101-106, wherein R4is –F, -OCH(CH3)2, - OC(CH3)3, –CH3, cyano, -NH2, or R4is represented by the following structural formula:228 ME150647165v.1130090-01720 108. The method of any one of claims 101-107, wherein R2is –CH3, -CH2CN, -109. The method of claim 101, wherein the DHX9 inhibitor is a compound represented by Formula (IIB) or (IVB):or a pharmaceutically acceptable salt thereof, wherein: m is 0 or 1; R1is -CH3; X is Cl; R2is -CH3; R3is pyrimidinyl or pyridinyl, each of which is optionally substituted with 1 or 2 R4; R4is halo, C1-3alkyl, -OC1-3alkyl, or 4- to 6-membered monocyclic heterocyclyl, wherein the 4- to 6-membered monocyclic heterocycly is optionally substituted with 1 or 2 halo or C1-3haloalkyl.

110. The method of claim 109, wherein111. The method of claim 109 or 110, wherein each R4is independently –F, -CH3, - OCH(CH3)2, or-OC(CH3)3, or R4is represented by the following structural formula: . 229 ME150647165v.1130090-01720 112. The method of any one of claims 1-68, wherein the DHX9 inhibitor is N-(3-chloro-5-(methylsulfonamido)phenyl)-4-(3-methylpyridin-2-yl)thiophene-2- carboxamide, or N-(3-chloro-5-(methylsulfonamido)phenyl)-5-(3,5-difluoropyridin-2-yl)-1-methyl- 1H-pyrrole-3-carboxamide, or a pharmaceutically acceptable salt thereof. 230 ME150647165v.1

Images